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CHAPTER ONE
INTRODUCTION
Inflammatory bowel diseases (IBD) affect a large number of individuals around the
world. This group of diseases is largely composed of two types: Chron’s disease (CD) and
ulcerative colitis (UC). CD and UC are characterized by inflammation that can occur anywhere
in the gastrointestinal tract or the colon, respectively. The immediate cause of these diseases is
not defined but research implicates a combination of genetics, the environment, and the intestinal
microbiome. Upon development of IBD, patients experience cyclical episodes of inflammation,
known as flares. Just like the etiology of IBD, flare induction appears to arise from multiple
factors, which can also vary on a person-to-person basis. Since no cure is available, current
treatments are aimed at alleviating symptoms and limiting flares in the disease. Commonly, after
careful observation, components of one’s diet may be recognized as flare inducing, which leads
to avoidance of that food in the future. One food that physicians frequently recommend that IBD
patients avoid is alcohol, despite our limited understanding of the mechanism by which alcohol
affects IBD.
Alcohol consumption is ubiquitous in today’s society. Whether consumed moderately or
chronically and in small or large amounts, alcohol can induce a variety of physiological effects
that have direct implications on an individual’s health. Many of these involve changes in the
major organ of alcohol metabolism, the liver, like fat deposition and fibrosis which can
eventually progress to cancer. In addition, alcohol consumption has been linked to a variety of
malignancies in the upper and lower gastrointestinal tract. Of particular importance is how
alcohol modifies the intestinal environment, by inducing gut leakiness, altering intestinal
1
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microbial populations, and producing reactive substances. These changes induced by alcohol
consumption parallel many of the changes seen during the active disease state of IBD. Therefore,
we can anticipate that the combination of alcohol use in the setting of IBD can further exacerbate
the disease or promote induction of flare. To that end, studies have identified that alcohol use can
induce gastrointestinal symptoms or flare in IBD patients, however, how these changes occur are
not defined. A mechanistic understanding of these changes would contribute to the pressing need
to better understand the effects of alcohol in IBD, while providing targetable pathways to prevent
IBD flare or limit its severity. Furthermore, this would be especially important in those who
develop IBD with a concurrent alcohol use disorder, since their ability to limit alcohol
consumption may be severely impaired and thus require therapies that may work despite their
continued consumption of alcohol.
One possibility through which alcohol can affect IBD is via the changes in the intestinal
microbiome, specifically increases in proinflammatory bacteria and decreases in beneficial
bacteria. The proinflammatory bacteria can express higher amounts of endotoxin and invade into
the mucosa. Furthermore, their consumption of nutrients in the nutrient-limited environment of
the intestine prevents growth of beneficial bacteria and their metabolites key to intestinal health.
The beneficial bacteria also express lower levels of endotoxin, promote intestinal tight junction
integrity, and can also inhibit growth of the pro-inflammatory bacteria. Thus, once the
proinflammatory bacteria establish themselves, they may be active participants in the disease
cycling of IBD.
Based on this information, my central hypothesis is that alcohol enhances the symptoms
associated with colitis by altering intestinal bacterial populations. To address this hypothesis, we
constructed four aims. Aim 1 determines whether alcohol use affects clinical outcomes of
patients admitted for IBD, UC, and CD. Aim 2 examines whether there is bacterial dysbiosis
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after alcohol and DSS treatment and how this alteration occurs. Aim 3 assesses the contribution
of nitric oxide synthase 2 and nitrate utilization in relation to bacterial and pathologic changes
observed in the colitis and ethanol model. Aim 4 examines the effects of combined DSS and
alcohol administration on the liver.
Various methods were employed to ascertain alcohol’s effects on the intestinal
microbiome in the setting of colitis. We first used a patient database to determine clinical,
diagnostic, and therapeutic outcomes of patients admitted for IBD that had a history of alcohol
use compared to patients admitted for IBD without a history of alcohol use. Previously, our lab
identified that alcohol can exacerbate a flare period in a mouse model of colitis, which we used
in the subsequent studies. Cecal and fecal pellets were collected from mice, processed for DNA,
then assessed for bacteria by quantitative polymerase chain reaction (qPCR). Mucin staining and
fluorescent in situ hybridization were used to characterize the mucin barrier and bacterial
infiltration of the mucosa. Isolated intestinal epithelial cells (IECs) were examined for tight
junction, mucin, bacterial pathogen associated molecular pattern receptors, and antimicrobial
peptide expression via qPCR. IEC expression of reactive oxygen producing enzymes and Nos2
was evaluated, with additional examination of Nos2 protein levels by Western blot and
immunohistochemistry (IHC). Tungstate (W) and L-N6-(1-Iminoethyl)-lysine (L-NIL) treatments
were given to mice to prevent nitrate utilization and inhibit nitrate production, respectively.
Global microbiome assessment occurred via 16S rRNA sequencing of DNA isolated from cecal
contents. Sections of the colon were assessed for histopathology. Livers were examined for cell
infiltration, fat deposition, inflammatory gene expression, and activation of inflammatory
signaling pathways.
Our findings identify that the exacerbated symptoms associated with alcohol in IBD
patients and our mouse model of colitis may occur by compounding an already perturbed
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intestinal microbiome, leading to overgrowth of the pro-inflammatory Enterobacteriaceae and
limiting growth of healthy bacteria like the Lactobacillus. Inhibition of nitrate production and
nitrate utilization limited Enterobacteriaceae growth in colitis, but when alcohol was
administered after colitis, the rise in Enterobacteriaceae was only slightly depressed. This
suggests that nitrate may only partially explain the overgrowth of Enterobacteriaceae when
alcohol use and colitis are co-occurring. Meanwhile, the liver experiences downregulation of
inflammatory processes in the combined administration of colitis and alcohol compared to colitis
alone. The results of these studies have implications for limiting the exacerbation of colitis flares
and possibly the induction of flare through the promotion of a healthy intestinal microbiome and
discontinuation of alcohol use.

CHAPTER TWO
REVIEW OF RELATED LITERATURE
Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) are extremely prevalent within the United States,
affecting 1.5 million individuals, while in other countries the incidence of IBD is increasing
rapidly(1). The economic burden of IBD patients on the healthcare system is quite high due to
the lifelong nature of the disease, ineffective treatments, complex therapeutic regimens that are
difficult to maintain, and the increased likelihood of colorectal cancer development (2-4).There
are two forms of IBD: Crohn’s disease (CD), which produces discontinuous lesions throughout
the gastrointestinal tract and ulcerative colitis (UC), which produces a continuous mucosal lesion
that is localized to the colon. The disease onset of both CD and UC follows a similar course
whereby patients develop marked changes in bowel habits, often including intense abdominal
pain, diarrhea, and bloody stools. The diagnosis is often made upon endoscopy and biopsy of the
intestine, with the combined perspective of the patient’s clinical history. After the initial
diagnosis, both CD and UC begin a cyclical pattern of disease quiescence and reactivation. The
etiology of IBD is not known but is thought to be due to a combination of genetic(5-7),
microbial(8), and environmental/lifestyle factors(9).
Genetics of Inflammatory Bowel Disease
Genome wide studies of IBD patients have identified 163 loci associated with the
disease(7). Of these loci, 110 are associated with both UC and CD, 30 are specific to CD, and 23
are specific to UC. The genes where these loci are found are quite diverse in their functionality,
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being involved with immune response, inflammation, mucus formation, intestinal barrier
integrity, and autophagy, among other functions.
The most well studied gene in IBD is that of the Nucleotide-binding oligomerization
domain-containing protein 2 (NOD2). Mutations within NOD2 are strongly correlated with the
development of CD(5, 10, 11). Normally, NOD2 detects a fragment of bacterial peptidoglycan,
muramyl dipeptide, leading to downstream activation of the nuclear factor kappa-light-chainenhancer of activated B cells (NF-kB)(12). Many of the CD related NOD2 mutations are
localized to the muramyl dipeptide binding site, a leucine rich repeat domain(10, 11). Cells
transfected with the NOD2 mutants exhibit decreased immune activation in response to treatment
with bacteria(11), which appears contrary to the observed increased inflammatory response in
these patients. However, it is proposed that the loss of function of NOD2 may impose deficits on
macrophage and/or intestinal epithelial cell recognition of pathogenic bacteria, leading to
initially dampened immune responses that proceed to persistent infections, which culminate in
the manifestation of CD(13, 14). For individuals that are homozygous for NOD2 mutations, their
relative risk of developing CD increases greatly, but possessing these mutations is not sufficient
for development of CD, suggesting that factors outside genetics are necessary for CD
development(14, 15). This is strengthened by research examining NOD2 deficient mice, which
do not develop any overt signs of intestinal inflammation unless a second stimulus is applied(16,
17). To initiate disease, the NOD2 deficient mice require pretreatment with inflammatory agents
or reactive T cells, which only then produce disease that is exacerbated relative to wild type
mice.
Other mutations implicated in IBD appear to follow a trend similar to that of NOD2
mutations in that they do not guarantee IBD development but only increase the relative risk.
Thus, there appears to be non-genetic components that promote the actual manifestation of the
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disease. One such component that has been thoroughly examined in the context of IBD is the
intestinal microbiome.
The Microbiome
A microbiome consists of a complex diverse community of organisms, encompassing
bacteria, fungi, viruses, and bacteriophages. Every multicellular organism is colonized in one
way or another by a microbiome, be it flies(18), termites(19), whales(20), or plants(21).
Furthermore, it appears that nearly every anatomical site has its own distinct microbiome(22).
Human microbiome research has focused on bacteria, particularly those residing within the large
intestine. Of the roughly 1014 bacteria within the adult human large intestine(23), 2,172 species
have been identified. Most of the intestinal bacteria fall under five phyla: Firmicutes,
Bacteroidetes, Proteobacteria, Actinobacteria, and Verrucomicrobia (24-27). In the healthy adult
human gut, the Firmicutes and Bacteroidetes phyla account for greater than 90% of all bacteria
(27, 28). These bacteria are capable of encoding 9,879,896 genes(24), about 400 times that of the
~22,500 human genes(29). In addition, unlike human genes, many of the downstream functions
of the proteins generated from these bacterial genes remain unknown(30). Moreover, these
microbiomes are dynamic, exhibiting rhythmic changes that mimic our own biological
cycles(31). Initially, these microbiomes were largely considered to be commensal and possibly
even parasitic, but our current understanding indicates that more so than not, the relationship
between a host and its microbiome is symbiotic. In fact, many times over, researchers have
shown that microbiomes are essential to health and development.
The Developing Intestinal Microbiome
Immediately after birth, human bodies are exposed to a variety of microbial organisms,
with the intestine being a primary site of this interaction. During the first three years of life, there
are dynamic fluctuations in the species of bacteria that colonize the intestine, after which the
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microbial community begins to exhibit a stability, diversity, and relative abundance similar to
that of the adult intestinal flora(32, 33). The early shifts in the infant intestinal microbiome can
be related to the infant intestinal nutrient profile, which promotes or inhibits the growth of
certain bacteria depending on their metabolic capacities.
Compared to the adult microbiome, the newborn microbiome is characterized by a high
proportion of Proteobacteria and Actinobacteria, and a lower proportion of Firmicutes and
Bacteroidetes(34). The oxygen rich environment promotes the growth of Proteobacteria which
can proficiently use oxygen as an energy source and also withstand the oxidative effects of
oxygenated environments. As the oxygen is consumed, Proteobacterial oxidative
phosphorylation decreases, necessitating a shift to less energetically favorable metabolic
pathways, like fermentation. Furthermore, compared to other intestinal bacteria, the
Proteobacteria are less efficient fermenters putting them at a competitive disadvantage(35). With
the decreased oxygen concentration and the advantage of efficient fermentation pathways, the
largely oxygen intolerant Firmicutes and Bacteroidetes begin to increase in number. The
importance of oxygen depletion in allowing growth of obligate anaerobes has been observed in
germ free mice where colonization of anaerobic bacteria was only achieved by a select group of
obligate anaerobes(36) or by co-administration with E. coli(37). Importantly, beside bacterial
consumption, other processes, like endogenous lipid oxidation, appear to play a role in intestinal
oxygen depletion, since adult germ free mice have the same partial pressure of oxygen within
their intestines as conventional adult mice(38).
Infant intestinal Actinobacteria, Bifidobacteria in particular, are heavily linked to a
vaginal birth and breastfeeding(39). Specifically, there is direct vertical transmission of these
bacteria from the mother to the infant, as studies have identified the same exact strains of
Bifidobacteria in infant intestinal contents which are also observed in the mother’s feces(40, 41),
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breast milk(42), or both the feces and milk(43, 44). In addition, the maintenance of these bacteria
within the intestine ishighly dependent on breast milk, since it contains complex
oligosaccharides which the infant cannot break down and are only be utilized by select
Bifidobacteria(45, 46). Weaning and the introduction of solid foods leads to decreased
Actinobacteria(47, 48), and an increase in the bacterial diversity(49) which begins to mirror that
of the adult intestinal microbiome(50, 51).
During this initial time period of microbiome development, numerous additional factors
can influence the microbiome. For example, immediately after birth newborns delivered by
cesarean exhibit intestinal bacteria similar to the mother’s skin microbiome, while those
delivered vaginally exhibit a microbiome similar to that of the mother’s vagina(51, 52). Cesarean
section newborns have decreased intestinal Bacteroides and Bifidobacterium; they also exhibit
an adult-like microbiome sooner than that of vaginal births(50, 53). Interestingly, applying
vaginal fluid to neonates born by cesarean section can help in promoting their microbiome to
resemble that of a vaginal birth(54). Other alterations in the developing infant microbiome have
be attributed to antibiotic use(33) and formula feeding versus breast feeding (33, 50). It should
be noted, the trajectories of bacterial changes in a developing infant are not absolute, with
numerous studies showing variation, some of which may be attributed to the methods used and
selected study population (34, 49-51, 55). Furthermore, we lack the understanding of how or
even if the early intestinal microbiome changes can produce long lasting effects on the infants
later in life. Despite this, there is a clear role in health that the intestinal microbiota plays, since
animals that develop in the absence of any microbial interaction, identified as germ-free(GF) or
gnotobiotic exhibit deficiencies in variety of health and physiological parameters(56).
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Intestinal Microbiome and Immune System Development
GF animals were noted to have profound histologic and morphologic differences in their
small intestine compared to conventionally raised animals. In the GF mice, the small intestine
villi appear more uniform, the crypts are not as deep, and there is decreased turnover of epithelial
cells(57). From an immunological perspective, the lamina propria and the mucus layer are
thinner(37, 57, 58). The thinned lamina propria, which contains the bulk of intestinal immune
cells that normally sample the luminal environment of the intestine, is due to decreased immune
cell number and activity(57, 59). Furthermore, the decreased presence and activation of immune
cells coincides with depressed levels of circulating serum immunoglobulin, meanwhile, this
dampened immune response can be rescued by the inoculation of bacteria(58, 59). The various
products of the bacteria, like their surface molecules, lipopolysaccharide (LPS) and muramyl
dipeptide, and their metabolites, like short chain fatty acids (SCFAs), are key in promoting the
proper development of the systemic and intestinal immune system.
Intestinal Microbiome Metabolite Production
Studies have identified that microbiome also plays a major role in host metabolism.
When the microbiome is absent such as in GF animals, metabolism and nutrient absorption are
severely disrupted. For example, compared to conventional mice, GF mice have decreased
circulating levels of vitamin D(60) and become more moribund when administered vitamin
deficient diets(61, 62). In addition, GF mice are susceptible to Vitamin K deficiency, because a
portion of Vitamin K is derived from intestinal bacterial metabolism(63-65). This same
deficiency can even manifest in humans after taking broad spectrum antibiotics(66). Bacteria are
capable of synthesizing a wide array of vitamins and metabolites(67), which some researchers
are beginning to explore in a probiotic context. For example, studies have identified that
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administration of folate synthesizing bacteria, are capable of increasing concentrations of folate
in the feces(68) and in the serum(69).
One group of essential bacterial metabolites is the SCFAs, which are the product of
bacterial fermentation derived from dietary fibers. The SCFAs are widely recognized as
important for the maintenance of intestinal health and health of the host. When the microbiome is
absent, the cecum of mice greatly expanded as a result of accumulated mucin and dietary
fibers(70), which is associated with SCFA depletion(71). The intestinal SCFAs are largely
composed of butyrate, propionate, acetate. Butyrate is of particular importance within the
intestine, as it produces a variety of signaling and metabolic effects, most of them localized
directly to the intestine. Butyrate is the preferred energy source for intestinal epithelial cells(7274), and nearly all of the intestinal butyrate is absorbed by these cells. In the intestines of GF
mice, where bacterial production of butyrate is absent, there is selective deprivation of energy
limited to the colonocytes, which can be rescued by the administration of butyrate producing
bacteria(75). Aside from its role as an energy source, upon entering certain cell types, butyrate
can act also act as a histone deacetylase inhibitor(76, 77) and promote the induction of T
regulatory cells(78). Butyrate can also exert its effect through activation of G-protein coupled
receptors, which produce intracellular signaling that regulate fatty acid and glucose
metabolism(79). On its own, butyrate has been implicated in a variety of defense mechanisms by
increasing production of intestinal mucins (80-82) increasing antimicrobial peptide
production(83), and inhibiting the upregulation of pathogenicity islands in Salmonella(84).
Numerous bacteria are capable of producing butyrate directly (Prevotellaceae,
Clostridiaceae, Ruminococcaceae, and Lactobacillaceae) but there are also large numbers of
bacteria that promote production of butyrate indirectly via cross feeding of substrates, like
acetate (Ruminococcaceae and Actinomycetaceae), lactate
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(Ruminococcaceae and Lactobacillaceae), and succinate (Actinomycetaceae), which other
bacteria can convert to butyrate(85, 86). While most of butyrate is consumed by the colonic
mucosa(87), the bulk of intestinally derived acetate and propionate enter the portal venous
system and where they are eventually absorbed by the liver for use as an energy source or as
substrates for synthesis of other molecules(79).
Intestinal Host Defense Mediated by the Microbiome
A healthy intestinal flora can act to prevent intestinal infection by way of niche
occupation. This can be understood in the context of Clostridum difficle, a toxin producing
bacterium that can manifest devastating disease when microbiomes are disrupted. This bacterium
exists as either a spore, where it is inactive, or as a vegetative bacterium, where it is active and
produces disease. Around 3% of adult humans carry this pathogen in their intestines, yet very
few exhibit any symptoms of disease(88). The colonization and manifestation of disease in GF
animals proceeds unimpeded, due to the lack of a microbiome(89), however, the presence of an
intestinal microbiome readily suppresses C. difficile growth and disease(90). When antibiotics
are administered, the spores of C. difficile have an opportunity to geminate and cause disease.
While possibly being effective in removing bacteria responsible for the underlying infection, the
antibiotics also non-selectively eliminate healthy bacteria and their metabolic capacities, one of
which is the transformation of bile acid(91). Animal studies have identified that antibiotics can
lead to an increases in intestinal primary bile acids, like taurocholate, among other metabolites,
which promote the germination of C. difficile spores(92, 93). To clear the C. difficile infection,
the antibiotics metronidazole and/or vancomycin are typically given, but their non-selective
nature also limits the reestablishment of the healthy intestinal flora, which may account for the
high recurrence of C. difficile, around 15-30%(94). In these cases, a fecal microbial transplant
(FMT), sourced from the feces of a healthy human donor and administered as a pill or via
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endoscopy, is often the next step of treatment. This treatment leads to cures in roughly 90% of
cases(95, 96). Furthermore, in a study of patients with recurrent C. difficile infection treated with
FMT, 11 of 12 patients exhibited clinical recovery which was associated with an increase in the
diversity of the intestinal microbiome and decrease in the intestinal concentrations of primary
bile acids(97).
Similar niche occupation is seen in mouse models of Salmonella infection, where bacteria
from the Enterobacteriaceae family, which includes the Salmonella genus, impede infection
unless extremely high doses of Salmonella are administered(98). This may be explained in part
by the consumption of oxygen and other electron acceptors by the endogenous
Enterobacteriaceae(99-101).
Co-culturing of bacteria to identify their potential to inhibit the growth of other bacteria
has also provided some insight into maintenance of a healthy intestinal microbiome. Lactobacilli
are a generally safe genus of bacteria, often used probiotics, and have been utilized in a variety
of settings to ameliorate intestinal diseases. Various studies have examined its co-culture with
pathogenic bacteria or Enterobacteriaceae and have largely found that the Lactobacillus can exert
anti-proliferative effects on these bacteria(102-106). The ability by which Lactobacillus
accomplishes this is thought to occur by production of SCFAs and lactic acid that alter the pH of
the culture, which the Lactobacillus can tolerate but the other bacteria cannot(107).
Defense against invading organisms can also be accomplished by the maintenance of
acidic intestinal pH and the production of SCFAs. Neither of which are mutually exclusive. An
optimal pH promotes SCFA production from SCFA-producing bacteria while also favoring their
growth, and then the SCFAs themselves influence intestinal pH because they are mildly
acidic(79, 108). As would be expected a strong correlation exists between lower pH and high
SCFA concentrations in the intestine(87). Culturing of intestinal contents with varied pHs
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demonstrated that, butyrate production is particularly favored at lower pH (~5.5), while actetate
and propionate are favored at slightly higher pH (~6.5)(109). Numerous studies have identified
that lower pHs, increased SCFAs, or both can inhibit the growth of Enterobacteriaceae (110112).
Microbiome in IBD
In the setting of IBD, an intestinal dysbiosis is observed, wherein the intestinal bacterial
communities are altered relative to healthy individuals. The IBD dysbiosis is characterized by
marked increases in the Proteobacteria phyla(113-115), which are normally maintained at low
levels in the intestine(27), and decreases in bacteria from the Firmicutes and Bacteroidetes
phyla(116). The increase in Proteobacteria is most often due to an expansion of bacteria from the
Enterobacteriaceae family, which is composed of gram negative facultative anaerobic
bacilli(117). Whether these bacteria instigate, participate, or are a mere consequence of the
disease process of IBD is not entirely defined.
Various studies examining mice with NOD2 deficiency, identified alterations in the
intestinal microbiota(16, 118-120), increased susceptibility to bacterial infection(121), or
both(122). However, transplantation of the intestinal microbiota from NOD2 deficient mice to
healthy mice gave mixed results, with one study showing that colitis and colorectal cancer were
transmissible(118), while another study did not reproduce this finding(16). In a separate study,
no difference in relative abundance of various intestinal bacteria was observed in NOD2deficient mice(123). In humans with IBD, NOD2 mutations exhibit a positive correlation
between intestinal Enterobacteriaceae load and the pressence of one or more NOD2 mutations,
although this occurs irrespective of whether the patient has CD or UC(124).
As mentioned earlier, butyrate is an essential energy source for colonocytes, and thus
changes in intestinal butyrate concentration can lead to a dysfunctional shift in colonocyte
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metabolism. Such a change is observed in UC patient colonocytes, which utilize less butyrate
than colonocytes from control patients, with the energy deficit being compensated by the
utilization of glucose(125). Similar effects on colonocyte butyrate utilization are observed in
colonocytes isolated from a mouse model of colitis(126). Furthermore, antibiotic treatment that
eliminates butyrate producing bacteria, promotes Enterobacteriaceae overgrowth in part due to
increased luminal oxygen concentrations that would normally be used by the intestinal
epithelium to oxidize butyrate(127). In the healthy colon, butyrate utilization is highly favored in
the distal colon portion compared to the proximal portion(74). This has led to the hypothesis that,
at least in UC, which manifests initially at the rectum and proceeds proximally, the more distal
portion of the intestine may be energy starved(125). Due to this, the distal portion of the colon
cannot maintain its integrity, leading to inflammation and disease. Furthermore, treatments to
increase intestinal butyrate, directly via enema(128) or indirectly, by either administering
butyrate producing bacteria(129, 130) or increasing consumption of fibers that enhance bacterial
production of butyrate(131), have produced some favorable outcomes in murine models of IBD
and IBD patients.
Apart from the noted increase in Enterobacteriaceae during colitis, there are noted
reductions in beneficial bacteria, such as Lactobacillus, which has been observed in UC
patients(132). Thus, researchers have attempted to reintroduce these bacteria, which has largely
been met with favorable outcomes(133-135). Furthermore, the probiotic VSL#3, which has been
used to successfully maintain UC patients in remission(136) and even promote entrance into
remission from active UC(137), actually contains four different strains of Lactobacillus, among
strains of Bifidobacteria and Stretptococcus.
Aside from identifying differences in individual bacteria, assessment of the overall
bacterial diversity revealed that IBD patients have a decreased diversity relative to healthy
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controls(138). Efforts to reestablish diversity through fecal microbial transplant (FMT) have
been somewhat promising. Changes in bacterial diversity and UC remission are limited when
administering a single transplant from a single donor.(139, 140). In contrast, trials that utilized
multiple transplant administrations(141, 142) or fecal samples from multiple donors(143) had
greater success in increasing microbial diversity and achieving UC remission. These recent
findings highlight the significant role played by the intestinal microbiota in UC and how their
normalization is important.
Altered Nutrient and Redox Profile in the Intestines of IBD Patients
As described earlier, the nutrients within the large intestine are a major driving force for
the selective increase in some bacteria over others. In the healthy large intestine, fermentation of
indigestible polysaccharides is the primary source of ATP generation(144). Due to their
fermentation efficiency, the Bacteroidetes and Firmicutes phyla dominate the large intestine(27,
28, 35). During flares of UC, inflammation leads to the production of free radicals mostly
derived from oxygen (i.e. superoxide anion, hydrogen peroxide, hydroxyl radical)(145, 146) and
nitrogen (i.e. nitric oxide, peroxynitrite)(147). These free radicals are produced by colonocytes
and invading immune cells with a primary purpose of killing bacteria that are invading into the
epithelium and surrounding tissue. The large proportion of intestinal bacteria that come into
contact with the free radical burst will be neutralized as the radicals induce oxidation of lipids,
proteins, and DNA(148). However, some bacteria, like the Enterobacteriaceae, have the ability to
detoxify these radicals, using enzymes like superoxide dismutase, peroxidase, catalase, and
cytochrome bd oxidase(149, 150). The Enterobacteriaceae also express siderophores that can
inhibit ROS production, which can also enhance Enterobacteriaceae virulence(151-153).
In addition, the Enterobacteriaceae are capable of using downstream products of
inflammation as substrates for ATP generation(154). One of these substrates include nitrate,
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which is increased during an active UC flare(147). Enterobacteriaceae, can utilize nitrates as the
terminal electron acceptor during the process of anaerobic respiration(155), while the
Bacteroidetes and Firmicutes cannot or are extremely inefficient(156). Furthermore, the
reduction of nitrate during anaerobic respiration and oxygen during oxidative phosphorylation is
much more energetically favorable than polysaccharide fermentation(155), and thus may allow
for the observed overgrowth of Enterobacteriaceae(157).
The intestinal inflammation during IBD flare may also affect the pathogenicity and
fitness of Enterobacteriaceae, as inflammation promotes horizontal gene transfer between
Enterobacteriaceae(158). Furthermore, in both UC and CD, select variants of Escherichia coli
are increased relative controls(159), particularly those with enteroadhesive properties(160).
The alteration in the oxidative potential within the intestine during IBD has been
proposed to play a role in the dysbiosis of the intestine(161). This hypothesis is based on the
decrease of viable obligate anaerobes and the overgrowth of facultative anaerobes and aerobes in
the intestines of IBD patients. This could account for the decreased diversity in IBD intestinal
bacteria. Furthermore, when UC patients enter into a remission period their intestines exhibit
increases in the obligate anaerobe and butyrate producer Faecalibacterium prausnitzii(162, 163).
This study also found that UC patients who eventually had a relapse were likely to have a
decreased abundance of this bacterium(162).
The change in intestinal oxygenation could also lead to a shift in the mutualism of
bacteria. In the healthy intestine, a cross-talk exists between the bacterial communities in which
there is cross-feeding of metabolites, where bacterial fermentation of one substrate leads to the
formation of a product that is utilized as substrate for energy by another bacterium, such as the
conversion of acetate to butyrate(164). In an in vitro system, researchers modeled bacterial
interactions through co-culture under anoxic or normoxic conditions. Surprisingly, bacteria that
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were normally mutualistic in an anoxic environment, became parasitic in a normoxic
environment(165).
Mucus Defects in IBD
In the healthy large intestine, epithelial cell interaction with the bacterial populations is
buffered by a coating of mucus. The mucus is composed of two layers. The first layer is
normally nonpermeable and lies immediately adjancent to the intestinal epithelial cells. The
second layer is considered semipermeable and resides between the first layer and the lumen of
the intestine(166). Intestinal bacteria can be classified based on their localization to this mucus.
The Firmicutes reside further from the mucus in the lumen of the intestine, while the
Proteobacteria are enriched in the semipermeable mucus layer(167, 168). This distribution is
likley related to the preferred habitat of these organisms, where the Firmicutes grow optimally in
the anoxic environment of the lumen while the Protebacteria prefer growth near the slighlthy
more oxygenated mucosal tissue, which allows them to use oxygen that has diffused from the
bloodsteam into the mucus.
Changes in the intesitnal mucus barrier of IBD patients, particularly those with UC, leads
to a differential distribution of the intestinal micorbiota. In UC a variety of deleterious changes
occur to the mucus layer, like decreased thickness(169), altered composition(170, 171), and
decreased mucin producing goblet cells(172). Exhausiton of the goblet cells, as measuered by a
decreased release of mucin in response to a bacterial ligand, has also been observed in biospies
from patients with active UC(171). These changes in the mucus layer allow for increased
interaction of bacteria with the epithelium, which can lead to an inflammatry response. The
Enterobacteriaceae are known to penetrate the mucus layer of UC patient intestines(113, 114,
173) and studies carried out in UC disease models show that the bacterial penetration of the
mucus layer occurs before the onset of intestinal tissue damage(174, 175). Even during UC
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remission, bacteria can still be localized to the intestinal epithelium as well as the lamina
propria(173). This may be explained by these patients having increases in the semipermeable
mucus layer compared to healthy controls and deficeits in the chloride-bicarbonate exchanger,
SLC26A3, which is important for proper mucin secertion(171).
Current Understanding of IBD and Alcohol
Upon development of IBD, individuals experience cyclical periods of disease remission
and reactivation. The triggers of reactivation appear to be multifactorial but can be precipitated
by certain foods (176). Though physicians caution IBD patients against alcohol consumption,
sparse and conflicting studies have been published on the topic. Focusing specifically on UC,
studies have shown that alcohol can affect reactivation (177, 178). However, the few studies
examining the effects of alcohol use on UC onset have been inconsistent with studies showing
positive correlation (179), negative correlation(180), or no correlation(181). Thus, our
understanding of alcohol’s ultimate effects in this disease remains unclear.
On its own, alcohol intake, particularly the binge drinking variety, imposes a heavy
burden on society. According to a 2015 survey of United States individuals 18 and older, 56%
reported drinking in the past month(182), and 26.9% reported binge drinking in the past
month(183). Economically, misuse of alcohol has cost nearly 249 billion dollars(184). Based on
its societal impact, it’s important to understand how alcohol may be contributing to the disease
state of IBD. Use of alcohol has been associated with altered metabolism(185), immune
function(186), gut barrier integrity(187, 188), and an intestinal dysbiosis (189-192), which
exhibits a similarity to that of the dysbiosis in observed in UC(115, 193).
Effects of Alcohol on the Intestinal Microbiome
Individuals with chronic overconsumption of alcohol are noted to have increased
Enterobacteriaceae populations(194, 195). The changes related to Lactobacillus are less clear, as

20
studies have identified alcoholics as having decreased intestinal Lactobacillus(195), while others
identify increased intestinal Lactobacillus(194). Methodological differences in determining
Lactobacillus may account for some of these changes, as the former study used quantification of
live bacterial colonies and the latter used sequencing. Studies of the oral microbiome identified
that compared to non-drinkers, moderate alcohol consumers display increased
Enterobacteriaceae and decreased Lactobacillus, which is more pronounced in heavy
drinkers(196). Despite these differential changes in Lactobacillus, administration of
Lactobacillus in the individuals with alcohol use and models of alcohol consumption are broadly
beneficial(191, 195, 197, 198).
Similar to humans, alcohol intake in murine models can cause perturbations of the
intestinal microbiome with increases in Proteobacteria/Enterobacteriaceae(191, 199, 200).
However, just as in humans, the proportion of Lactobacillus can either increase(199) or decrease
in such models(200, 201).
After alcohol intake, the concentration of alcohol observed in the bloodstream mirrors
that seen along the lower gastrointestinal(202), while the alcohol metabolite, acetaldehyde, is
produced in appreciable amounts within the intestine(203, 204). This increase in acetaldehyde is
attributed to metabolism that occurs by the IECs and the intestinal bacteria(203, 204).
Furthermore, treatment with metronidazole, boosts intestinal acetaldehyde concentrations, which
is attributed to a decrease of intestinal anaerobic bacteria and increase in aerobic bacteria,
particularly the Enterobacteriaceae(204). Meanwhile, the metronidazole treatment does not
induce any effect on blood levels of ethanol(204). Select strains of intestinally derived E. coli are
able to oxidize ethanol to acetaldehyde under conditions similar to that found within the
intestine(205).
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The relevance of having increased intestinal acetaldehyde concentrations derives from its
reactive nature (206, 207), which is implicated in cancer(208, 209), and its ability to disrupt
intestinal tight junctions(210-212) leading to intestinal permeability(197). In addition, a single
binge of alcohol(197) or chronic administration(213), can produce decreased expression of tight
junction proteins which likely contribute to the increased permeability. The increased
permeability leads to increased circulating endotoxin which is eventually trafficked to the liver
inducing inflammation(197, 214).
Alcohol also influences handling of iron, a limiting micronutrient essential for bacterial
growth. Consumption of alcohol downregulates expression of hepcidin, which normally
functions to inhibit intestinal iron absorption or inhibit release of iron stored in macrophages, and
therefore increases circulating levels of iron(215). In a study, individuals consuming more than
two alcoholic drinks a day were found to be at significant risk of iron overload(216). These
changes in iron are relevant to the Enterobacteriaceae since they express siderophores with a
high affinity for iron, while numerous studies have shown that additional iron enhances the
virulence of the Enterobacteriaceae(217).
Conclusions
A variety of mechanisms appear to play a role in pathogenesis of IBD flare and onset,
with particular influences derived from the intestinal microbiome. A healthy microbiome
consists of a complex network of diverse bacteria that directly interface with the intestinal
mucosa to provide essential nutrients to the epithelial cells and underlying immune cell
populations. These bacteria also serve in a defensive capacity by preventing the growth or
colonization of potentially pathogenic bacteria. During IBD flare, there are significant shifts in
the intestinal bacterial populations with increases in pro-inflammatory bacteria and decreases in
beneficial bacteria. The infiltrative nature of these pro-inflammatory bacteria and concomitant
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changes in the intestinal mucosa, such as decreased mucin expression, allows for the direct
interaction of these bacteria with the intestinal mucosa. In mouse models of colitis, penetration of
these bacteria precedes the onset of intestinal inflammation. Alcohol consumption leads to
changes within the intestinal environment that are similar to those observed in IBD, chiefly
increased pro-inflammatory bacteria and decreased beneficial bacteria, as well as alterations in
the mucosa, such as tight junction protein disruption. There are tentative associations between
alcohol consumption and the disease process of IBD, however, how these two factors converge
in terms of microbial changes has not been defined. First, using a database analysis, we seek to
expand the clinical effects of alcohol consumption on patients with IBD. Second, using a model
of ethanol consumption in the setting of colitis developed by our lab, we aim to identify the
intestinal microbial changes and how they may participate in the exacerbation of a flare period.

CHAPTER THREE
DOCUMENTED HISTORY OF ALCOHOL USE ENHANCES SYMPTOMS AND
PROPENSITY FOR INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS
Abstract
Alcohol consumption is prevalent in the United States and has been linked to the onset
and exacerbation of numerous diseases. Alcohol has particularly potent effects on the
gastrointestinal tract related to leakiness, bacterial dysbiosis, and colorectal cancer. However,
there is a limited understanding of how alcohol can affect the outcomes of patients hospitalized
for IBD in the context of alcohol use. Due to this, we used inpatient databases from New York
and Florida to stratify patients into cohorts based on their first admission UC or CD. Studies also
examined the UC and CD patients as a whole in the IBD cohort. These cohorts were then
separated based on their history of alcohol use as determined by diagnosis codes. The patients
were matched for various commodities to isolate the effect of alcohol on IBD. We concluded that
alcohol negatively impacts patients admitted for IBD leading to increased intestinal infections,
antibiotic injections, and diagnostic procedures.
Introduction
Alcohol consumption can promote inflammation and directly harm the intestinal barrier
leading to intestinal permeability (192, 218-220). Alcohol induced intestinal permeability, allows
for increased interaction of luminal bacteria with epithelial cells and the underlying gut
associated lymphoid tissue. This enhanced interaction leads to activation of the immune system
while simultaneously releasing bacteria and their products into the bloodstream(200, 220, 221).
Despite this, only a handful of studies have explored the impact of alcohol in the setting of IBD.
23
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In studies of UC patients, those with higher daily alcohol consumption were more likely
to have a UC flare(178) and those that drank alcohol had worsening of their gastrointestinal
symptoms(177). In addition, a self-reported survey identified that alcohol use could worsen IBD
symptoms(222). In terms of onset of disease, one study identified that intoxication by alcohol
promotes disease onset(179), while another study describes that alcohol has no effect in the onset
of UC(181). The limited evidence in supporting or contradicting alcohol's role in IBD flares
and/or onset prompted us first to elucidate whether alcohol is a contributing factor in UC and CD
research.
To address this question, we conducted a retrospective analysis of inpatient databases of
two states (New York and Florida) to assess clinical outcomes of patients admitted with
diagnoses for IBD, UC, and CD that either have or do not have documented history of alcohol
use. The results of this analysis suggested that patients with documented history of alcohol use
have an increased risk of infections as well as require more diagnostic and therapeutic
procedures.
Methods
Data was obtained from the Healthcare Cost and Utilization Project (HCUP) State in
Patient Databases (SID) for New York and Florida from 2009–2013. Using the International
Classification of Diseases, Ninth Revision, Clinical Modification, (ICD‐9‐CM) diagnosis codes,
three study groups were defined: IBD, UC, and CD. All patient admission data was retained if
the patient had a primary diagnosis of IBD. All of the ICD‐9‐CM codes used in this study can be
found in Table 1. In addition, we utilized the HCUP cost‐to‐charge ratio files,
which provide a ratio of the actual cost relative to the total amount charged to insurance for each
separate hospital. These files are used to estimate the actual cost for individual patient
admissions.
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Comorbidities were assigned to patients on the basis of the Agency for Healthcare
Research and Quality (AHRQ) comorbidity measures. For each individual patient, if the
presence of a comorbidity was indicated, then the comorbidity was applied to all of that patient's
admissions. Patients were classified as smokers based on whether any admission contained ICD‐
9‐CM codes for tobacco use disorder or personal history of tobacco use. To evaluate the impact
of alcohol on outcomes in IBD, patients were identified as having a documented history of
alcohol use (+A) based on whether any admission contained ICD‐9‐CM codes relating to alcohol
use or the AHRQ comorbidity measure for alcohol abuse, otherwise the patients were classified
as not having a documented history of alcohol use (-A).
Table 1. ICD9 Codes Used to Identify Diagnoses, Patients and Procedures
Admitting diagnosis
IBD
556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9, 555.0, 555.1, 555.2, 555.9
UC
556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9
CD
555.0, 555.1, 555.2, 555.9
Patients
Smoker
Documented history of alcohol use

305.1, V15.82
291.81, 291.82, 291.89, 291.9, 303.00, 30.301, 303.02, 303.03, 303.90, 303.91, 303.92, 303.93,
305.00, 305.01, 305.02, 305.03, V11.3, AHRQ comorbidity measure for alcohol abuse

Secondary diagnoses during admission
Clostridium difficle infection
Poorly defined intestinal infection
All other intestinal infections (inclusive of
C. difficle and poorly defined intestinal
infection)

008.45
009.0, 009.1, 009.2, 009.3
008.00, 008.01, 008.02, 008.03, 008.04, 008.09, 008.1, 008.2, 008.3, 008.41, 008.42, 008.43,
008.44, 008.45, 008.46, 008.47, 008.49, 008.5, 008.61, 008.62, 008.63, 008.64, 008.65, 008.66,
008.67, 008.69, 008.8, 009.0, 009.1, 009.2, 009.3

Procedures
CT scan of abdomen
Small intestine biopsy
Small intestine resection
Colectomy
Large intestine biopsy
Rectal biopsy
Antibiotic injection

88.01
45.14, 45.15, 45.16, 45.19
45.33, 45.61, 45.62, 45.63
45.81, 45.82, 45.83
45.25, 45.26
48.24, 48.25
99.21

Following this, only admissions for which the primary cause was IBD, UC, or CD were
retained, and all other admissions were excluded. Patients aged 18–90 years of age were included
for study. Admissions missing data elements for the median household income national quartile
for patient ZIP code, unique VisitLink patient identifier, age, length of stay, total charges, and
patient race, were excluded. The -A and +A patients from each respective study group of IBD,
UC or CD, were propensity score matched 1:1 at their first admission based on age, sex, race,
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primary expected payer, median household income national quartile for patient ZIP code,
smoking status, and various comorbidities (AIDS, congestive heart failure, chronic pulmonary
disease, coagulopathy, depression, diabetes mellitus, drug abuse, hypertension (combined
complicated and uncomplicated), neurological disorders, obesity, psychoses, and renal failure).
Subsequent admissions of propensity matched patients following their first recorded hospital
admission were collected. The complete admission history of matched patients within each study
group was used for data analysis, allowing for a 5-year perspective of what occurs when -A and
+A patients are admitted for IBD, UC, or CD. Patient selection workflow is detailed in Figure 1.
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New York (2009-2013)
Total admissions: 12,801,935
12,307,601
New York admissions excluded

Florida (2009-2013)
Total admissions: 12,166,880

Exclude patients without a history of primary diagnosis of IBD

11,218,604
Florida admissions excluded

Assign procedure variables separately for states

Merge New York and Florida Datasets

Assign comorbidities, smoking status, documented alcohol use to patients

1,368,025
Admissions excluded

Exclude admissions where IBD is not
primary cause of admission

Exclude admissions where UC is not
primary cause of admission

1,414,040
Admissions excluded

Exclude admissions where CD is not
primary cause of admission

1,396,595
Admissions excluded

7,425
Admissions excluded

Exclude patients if age<18 or age>90
Exclude admissions with missing data

Exclude patients if age<18 or age>90
Exclude admissions with missing data

3,116
Admissions excluded

Exclude patients if age<18 or age>90
Exclude admissions with missing data

4,028
Admissions excluded

Perform propensity matching

Perform propensity matching

Perform propensity matching

Obtain 2,021 matched patients in each
IBD-A and IBD+A

Obtain 992matched patients in each
UC-A and UC+A

Obtain 1,083 matched patients in each
CD-A and CD+A

Total # of admissions for
IBD-A = 4,965; IBD+A = 4,013

Total # of admissions for
UC-A = 1,602; UC+A = 1,437

Total # of admissions for
CD-A = 3,089; CD+A = 2,548

Figure 1. Patient Data Collection Workflow.
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Results
Within the patient database study groups, there were 41,810 IBD patients, 18,695 UC
patients, and 24,059 CD patients that met the inclusion criteria. The baseline demographics of
these groups are shown in Tables 2, 3 and 4, respectively. Additional demographics are shown
in Table 5. Before matching, the age, race, primary expected payer, and median household
income, were nearly all significantly different between the -A and +A patients, notwithstanding
the age of patients in the UC study group. Males, African Americans, and smokers were
overrepresented within the +A patients. With regard to the primary expected payer, the +A
patients were more likely to carry Medicaid and self‐pay, while being less likely to carry private
insurance. The lowest quartile for median household income contains more +A patients then -A
patients, while the inverse can be seen for the highest income quartile. The +A patients had
significantly increased comorbidities across all measures compared to the -A patients (Table 5).
Table 2. IBD Patient Demographics and Commoribidites Pre and Post Match
Pre match
Post match
IBD-A (n=39,730) IBD+A (n=2,080)
p value
IBD-A (n=2,021) IBD+A (n=2,021)
Mean Age
47.05
48.21
0.0009
48.19
48.3
Sex
Male
Female
Race
White
African American
Hispanic
Asian or Pacific
Islander
Native American
Other

< 0.001
17,658 (44.4%)
22,072 (55.6%)

1,343 (64.6%)
737 (35.4%)

28,440 (71.6%)
4,112 (10.3%)
4,715 (11.9%)

0.948
1,289 (63.8%)
732 (36.2%)

1,287 (63.7%)
734 (36.3%)

1,435 (69.0%)
315 (15.1%)
221 (10.6%)

1,409 (69.7%)
302 (14.9%)
218 (10.8%)

1,398 (69.2%)
303 (15.0%)
214 (10.6%)

518 (1.3%)

19 (0.9%)

12 (0.6%)

19 (0.9%)

74 (0.2%)
1,871 (4.7%)

<10 (%)*
87 (4.2%)

<10 (%)*
79 (3.9%)

<10 (%)*
84 (4.2%)

427 (21.1%)
1,594 (78.9%)

466 (23.1%)
1,555 (76.9%)

< 0.001

Smoking Status
Non smoker
26,956 (67.8%)
466 (22.4%)
Smoker
12,774 (32.2%)
1,614 (77.6%)
*AHRQ restricts reporting of values when n<10

p value
0.8251

0.728

< 0.001

0.139
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Table 3. UC Patient Demographics and Commoribidites Pre and Post Match
Pre match
Post match
UC-A (n=17,653)
UC+A (n=1,042)
p value
UC-A (n=992)
UC+A (n=992)
Mean Age
50.48
50.45
0.9519
50.68
50.72
Sex
Male
Female

p value
0.9515

< 0.001

Race
White
African American
Hispanic
Asian or Pacific
Islander
Native American
Other

7,712 (43.7%)
9,941 (56.3%)

706 (67.8%)
336 (32.2%)

12,039 (68.2%)
1,926 (10.9%)
2,443 (13.8%)

0.569
649 (65.4%)
343 (34.6%)

661 (66.6%)
331 (33.4%)

665 (63.8%)
172 (16.5%)
136 (13.1%)

647 (65.2%)
152 (15.3%)
143 (14.4%)

636 (64.1%)
162 (16.3%)
130 (13.1%)

293 (1.7%)

11 (1.1%)

10 (1.0%)

11 (1.1%)

40 (0.2%)
912 (5.2%)

<10 (%)*
56 (5.4%)

<10 (%)*
39 (3.9%)

<10 (%)*
51 (5.1%)

245 (24.7%)
747 (75.3%)

258 (26.0%)
734 (74.0%)

< 0.001

Smoking Status
Non smoker
12,546 (71.1%)
258 (24.8%)
Smoker
5107 (28.9%)
784 (75.2%)
*AHRQ restricts reporting of values when n<10

0.698

< 0.001

0.502

Table 4. CD Patient Demographics and Commoribidites Pre and Post Match
Pre match
Post match
CD-A (n=22,956)
CD+A (n=1,103)
p value
CD-A (n=1,083) CD+A (n=1,083)
Mean Age
44.26
45.88
0.0005
45.35
45.82
Sex
Male
Female

p value
0.4906

< 0.001

Race
White
African American
Hispanic
Asian or Pacific
Islander
Native American
Other

10,332 (45.0%)
12,624 (55.0%)

682 (61.8%)
421 (38.2%)

16,994 (74.0%)
2,298 (10.0%)
2,392 (10.4%)

0.826
657 (60.7%)
426 (39.3%)

662 (61.1%)
421 (38.9%)

804 (72.9%)
163 (14.8%)
91 (8.3%)

792 (73.1%)
166 (15.3%)
94 (8.7%)

790 (72.9%)
159 (14.7%)
89 (8.2%)

236 (1.0%)

<10 (%)*

<10 (%)*

<10 (%)*

35 (0.2%)
1,001 (4.4%)

<10 (%)*
36 (3.3%)

<10 (%)*
23 (2.1%)

<10 (%)*
36 (3.3%)

207 (19.1%)
876 (80.9%)

215 (19.9%)
868 (80.1%)

< 0.001

Smoking Status
Non smoker
14,935 (65.1%)
215 (19.5%)
Smoker
8,021 (34.9%)
888 (80.5%)
*AHRQ restricts reporting of values when n<10

0.666

< 0.001

0.664

Post propensity matching, the differences observed for age, sex, race, smoker status,
primary expected payer, median household income, and comorbidities between the -A and +A
patients within the three study groups were no longer statistically significant (Table 2, 3, 4, 5).
For the IBD study group, there were 2,021 matched patients (Table 2), that encompassed 4,965
IBD-A admissions and 4,013 IBD+A admissions (Table 6). For the UC study group, there were
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992 matched patients (Table 3), that encompassed 1,602 UC-A admissions and 1,437 UC+A
admissions (Table 6). For the CD study group, there were 1,083 matched patients (Table 4), that
encompassed 3,089 CD-A admissions and 2,548 CD+A admissions (Table 6).
Examination of intestinal infection diagnoses during the admission for either the IBD,
UC, or CD study groups revealed that +A patients had significantly increased intestinal
infections (Table 6). The IBD+A patients had increased Clostridium difficile intestinal infection
(2% vs. 2.6%, p < 0.05), poorly defined intestinal infection (0.4% vs. 0.8%, p < 0.01), and
overall intestinal infections (2.6% vs. 3.9%, p < 0.01). The UC+A patients had increased poorly
defined intestinal infections (0.6% vs. 1.5%, p < 0.05), while the CD+A patients had increased
intestinal infections of all types (2.1% vs. 3.1%, p < 0.05).
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Table 5. Additional Patient Demographics and Commoribidites Pre and Post Match
Pre match
IBD-A
IBD-A
IBD+A
(n=39,730)
(n=2,080)
(n=2,021)
p value
Primary Expected Payer
Medicare
Medicaid
Private inusrance
Self-pay
No charge
Other

10,499 (26.4%)
5,255 (13.2%)
19,324 (48.6%)
2,754 (6.9%)
670 (1.7%)
1,228 (3.1%)

598 (28.8%)
530 (25.5%)
524 (25.2%)
262 (12.6%)
77 (3.7%)
89 (4.3%)

Median household income for patient's
ZIP Code
0-25th percentile
26th to 50th percentile (median)
51st to 75th percentile
76th to 100th percentile

8,832 (22.2%)
10,065 (25.3%)
10,131 (25.5%)
10,702 (26.9%)

665 (32.0%)
580 (27.9%)
460 (22.1%)
375 (18.0%)

103 (0.3%)
2,399 (6.0%)
7,326 (18.4%)
2,882 (7.3%)
7,870 (19.8%)
5,542 (13.9%)
2,638 (6.6%)

19 (0.9%)
246 (11.8%)
770 (37.0%)
487 (23.4%)
936 (45.0%)
434 (20.9%)
833 (40.0%)

14,616 (36.8%)
2,915 (7.3%)
4,445 (11.2%)
2,632 (6.6%)
3,021 (7.6%)

1,243 (59.8%)
425 (20.4%)
319 (15.3%)
611 (29.4%)
251 (12.1%)

Comorbidities
AIDS
Congestive heart failure
Chronic Pulmonary Disease
Coagulopathy
Depression
Diabettus mellitus
Drug use
Hypertension: Uncomplicated and
Complicated
Neurological disorders
Obese
Psychiatric disorders
Renal Failure

Post match
IBD+A (n=2,021) p value

< 0.001

Pre match
UC+A
(n=1,042)

UC-A (n=17,653)

0.863
580 (28.7%)
479 (23.7%)
548 (27.1%)
265 (13.1%)
63 (3.1%)
86 (4.3%)

588 (29.1%)
494 (24.4%)
524 (25.9%)
255 (12.6%)
74 (3.7%)
86 (4.3%)

606 (30.0%)
613 (30.3%)
472 (23.4%)
330 (16.3%)

632 (31.3%)
568 (28.1%)
454 (22.5%)
367 (18.2%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

15 (0.7%)
225 (11.1%)
755 (37.4%)
435 (21.5%)
863 (42.7%)
382 (18.9%)
757 (37.5%)

18 (0.9%)
235 (11.6%)
733 (36.3%)
435 (21.5%)
884 (43.7%)
415 (20.5%)
774 (38.3%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

1,178 (58.3%)
381 (18.9%)
289 (14.3%)
531 (26.3%)
245 (12.1%)

1,189 (58.8%)
386 (19.1%)
312 (15.4%)
559 (27.7%)
242 (12.0%)

< 0.001

Post match
p value

UC-A (n=992) UC+A (n=992) p value

< 0.001
5,504 (31.2%)
2,188 (12.4%)
7,919 (44.9%)
1,185 (6.7%)
309 (1.8%)
548 (3.1%)

322 (30.9%)
282 (27.1%)
235 (22.6%)
132 (12.7%)
36 (3.5%)
35 (3.4%)

4,047 (22.9%)
4,383 (24.8%)
4,544 (25.7%)
4,680 (26.5%)

362 (34.7%)
266 (25.5%)
212 (20.3%)
202 (19.4%)

0.6
0.62
0.473
1
0.505
0.192
0.581

67 (0.4%)
1,415 (8.0%)
3,500 (19.8%)
1,514 (8.6%)
3,476 (19.7%)
3,092 (17.5%)
884 (5.0%)

17 (1.6%)
140 (13.4%)
395 (37.9%)
299 (28.7%)
452 (43.4%)
259 (24.9%)
377 (36.2%)

0.725
0.841
0.309
0.321
0.885

7,488 (42.4%)
1,549 (8.8%)
2,106 (11.9%)
1,221 (6.9%)
1,602 (9.1%)

670 (64.3%)
221 (21.2%)
174 (16.7%)
288 (27.6%)
148 (14.2%)

0.206

CD-A
(n=22,956)

Pre match
CD+A
(n=1,103)

0.772
313 (31.6%)
256 (25.8%)
218 (22.0%)
138 (13.9%)
27 (2.7%)
40 (4.0%)

315 (31.8%)
251 (25.3%)
235 (23.7%)
124 (12.5%)
33 (3.3%)
34 (3.4%)

316 (31.9%)
257 (25.9%)
239 (24.1%)
180 (18.1%)

331 (33.4%)
260 (26.2%)
206 (20.8%)
195 (19.7%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

<10 (%)*
123 (12.4%)
358 (36.1%)
266 (26.8%)
414 (41.7%)
246 (24.8%)
316 (31.9%)

<10 (%)*
132 (13.3%)
368 (37.1%)
252 (25.4%)
411 (41.4%)
243 (24.5%)
328 (33.1%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

627 (63.2%)
197 (19.9%)
162 (16.3%)
248 (25.0%)
153 (15.4%)

623 (62.8%)
187 (18.9%)
166 (16.7%)
250 (25.2%)
139 (14.0%)

< 0.001

p value

CD-A
(n=1,083)

Post match
CD+A
(n=1,083)

284 (26.2%)
256 (23.6%)
309 (28.5%)
129 (11.9%)
42 (3.9%)
63 (5.8%)

295 (27.2%)
254 (23.5%)
308 (28.4%)
133 (12.3%)
42 (3.9%)
51 (4.7%)

323 (29.8%)
327 (30.2%)
258 (23.8%)
175 (16.2%)

318 (29.4%)
325 (30.0%)
258 (23.8%)
182 (16.8%)

< 0.001

p value
0.908

5,188 (22.6%)
3,257 (14.2%)
11,784 (51.3%)
1,645 (7.2%)
377 (1.6%)
705 (3.1%)

298 (27.0%)
267 (24.2%)
308 (27.9%)
133 (12.1%)
42 (3.8%)
55 (5.0%)

4,999 (21.8%)
5,904 (25.7%)
5,812 (25.3%)
6,241 (27.2%)

326 (29.6%)
334 (30.3%)
260 (23.6%)
183 (16.6%)

0.502
0.546
0.641
0.474
0.891
0.876
0.565

39 (0.2%)
1,040 (4.5%)
4,039 (17.6%)
1,485 (6.5%)
4,702 (20.5%)
2,582 (11.2%)
1,909 (8.3%)

<10 (%)*
113 (10.2%)
403 (36.5%)
204 (18.5%)
524 (47.5%)
192 (17.4%)
491 (44.5%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

<10 (%)*
101 (9.3%)
403 (37.2%)
186 (17.2%)
511 (47.2%)
163 (15.1%)
469 (43.3%)

<10 (%)*
106 (9.8%)
386 (35.6%)
190 (17.5%)
507 (46.8%)
186 (17.2%)
471 (43.5%)

0.654
0.715
0.448
0.82
0.863
0.179
0.931

0.852
0.57
0.809
0.918
0.375

7,442 (32.4%)
1,460 (6.4%)
2,478 (10.8%)
1,530 (6.7%)
1,491 (6.5%)

615 (55.8%)
224 (20.3%)
161 (14.6%)
352 (31.9%)
115 (10.4%)

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001

584 (53.9%)
202 (18.7%)
147 (13.6%)
320 (29.5%)
98 (9.0%)

596 (55.0%)
211 (19.5%)
158 (14.6%)
334 (30.8%)
110 (10.2%)

0.605
0.623
0.497
0.512
0.382

0.332

< 0.001

0.98

*AHRQ restricts reporting of values when n<10
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With regard to procedures during the admission (Table 6), all +A patients had significant
increases of abdominal CT scans (IBD: 6.8% vs. 9.6%, p < 0.001; UC: 6.9% vs. 9.0%, p < 0.05;
CD: 7.3% vs. 9.9%, p < 0.01) and antibiotic injections (IBD: 3.1% vs. 5.8%, p < 0.001; UC:
3.8% vs. 5.5%, p < 0.05; CD: 3.4% vs. 5.8%, p < 0.001). Large intestine and rectal biopsies were
significantly increased in +A patients compared to -A patients within the IBD study group
(18.1% vs. 21.7%, p < 0.001; 3.1% vs. 4.3%, p < 0.01). Within the UC and CD study group,
large intestine and rectal biopsies were not significantly different between the -A and +A
patients, although UC+A patients did have a trend toward increased large intestine biopsies
(30.7% vs. 32.6%, p = 0.272). Small intestine biopsies were unchanged between the -A and +A
patients. Resection of the small intestine was significantly increased in -A patients with IBD
(1.9% vs. 1.1%, p < 0.01) and CD (2.4% vs. 1.5%, p < 0.05). For the UC study group, -A
patients displayed a trend toward increased colectomy (4.7% vs. 3.4%, p = 0.077). The
differences in percentages of colectomy and small intestine resection procedures for the UC and
CD study groups support the appropriate separation of these patients into their respective groups.
The median length of stay was unchanged between -A and +A patients in all study groups (4
days), however the IQR was significantly increased for the -A patients in the IBD (2–7 days vs.
2–6 days, p < 0.01) and CD (2–7 days vs. 2–6 days, p < 0.05) study groups. In terms of total
cost, the -A patients had increased total cost during hospitalization for all study groups compared
to the +A patients (IBD: $13,880.65 vs. $12,262.51, p < 0.0001; UC: $14,564.63 vs.
$13,217.54, p < 0.05; CD: $13,480.92 vs. $11,794.42, p < 0.001) (Table 6).

33

Table 6. Outcomes of Patients During IBD, UC, or CD Admission
IBD admissions
IBD-A
IBD+A
(n=4,965)
(n=4,013)
Diagnoses during admission
C. difficile intestinal infection
98 (2.0%)
105 (2.6%)
Poorly defined intestinal infection
18 (0.4%)
31 (0.8%)
All intestinal infection
131 (2.6%)
158 (3.9%)

p value
0.042
0.009
0.001

UC-A
(n=1,602)

UC admissions
UC+A
(n=1,437)

p value

CD-A
(n=3,089)

CD admissions
CD+A
(n=2,548)

61 (3.8%)
10 (0.6%
75 (4.7%)

47 (3.3%)
21 (1.5%)
79 (5.5%)

0.427
0.022
0.304

52 (1.7%)
<10 (%)*
65 (2.1%)

57 (2.2%)
10 (0.4%)
78 (3.1%)

110 (6.9%)
158 (9.9%)
12 (0.7%)
492 (30.7%)
75 (4.7%)
133 (8.3%)
61 (3.8%)

130 (9.0%)
134 (9.3%)
5 (0.3%)
468 (32.6%)
49 (3.4%)
125 (8.7%)
79 (5.5%)

0.026
0.616
0.139
0.272
0.077
0.695
0.027

226 (7.3%)
306 (9.9%)
73 (2.4%)
475 (15.4%)
11 (0.4%)
59 (1.9%)
105 (3.4%)

252 (9.9%)
246 (9.7%)
39 (1.5%)
399 (15.7%)
13 (0.5%)
46 (1.8%)
148 (5.8%)

p value
0.133
0.514
0.023

Procedures/Surgery
Abdomen CT Scan
Biopsy Small Intestine
Resection Small Intestine
Biopsy large intestine
Colectomy
Biopsy Rectum
Antibiotic injection

338 (6.8%)
432 (8.7%)
92 (1.9%)
897 (18.1%)
79 (1.6%)
156 (3.1%)
154 (3.1%)

386 (9.6%)
384 (9.6%)
44 (1.1%)
872 (21.7%)
62 (1.5%)
173 (4.3%)
234 (5.8%)

Mean Length of Stay (Days)

6.08

5.47

< 0.0001

6.3

5.84

0.0547

5.87

5.26

0.0002

37743.97

< 0.0001

45817.08

40657.12

0.0058

41881.23

36215.62

0.0001

Mean Total Charge
43538.74
*AHRQ restricts reporting of values when n<10

< 0.001
0.155
0.004
< 0.001
0.861
0.003
< 0.001

0.001
0.752
0.026
0.771
0.376
0.772
< 0.001
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Summary
Alcohol is known to have numerous deleterious effects in a variety of settings, yet its
effects in IBD are not well understood. In this study, we described a potential role for alcohol
affecting the inpatient care of IBD patients. Patients admitted for IBD, and its subsets, UC and
CD, that had a documented history of alcohol use were more likely to experience increased
intestinal infections, increased diagnostic procedures, and required more antibiotic injections.
Based on these results, we concluded that alcohol consumption does impact the clinical
outcomes of patients admitted for IBD. The observed increase in intestinal infections and
antibiotic administration seems to suggest that the intestinal microbiomes of IBD patients with a
documented history of alcohol use might more disrupted than those without a documented
history of alcohol use. Knowing this, we wanted to examine how the intestinal microbiome is
affected by the concomitant use of alcohol in the setting of colitis. Therefore, we turned to a
mouse model of colitis and combined ethanol administration that our lab developed.

CHAPTER FOUR
ALCOHOL ALTERS RATIO OF LACTOBACILLUS TO ENTEROBACTERIACEAE IN
MOUSE MODEL OF COLITIS
Abstract
The intestinal microbiome plays a pivotal role in gut health through processes like
essential metabolite production and defending against invading pathogens. Any disruptions in the
microbiome can negatively impact the intestinal health as well as the overall health of the host.
Pronounced gut microbial changes, characterized by increased Enterobacteriaceae and decreased
Lactobacillus, have been observed in individuals who have IBD or consume alcohol. These
bacterial changes are relevant since the Enterobacteriaceae can infiltrate the intestinal mucosa
and promote inflammation, while the Lactobacillus help prevent inflammation. We anticipate
that alcohol consumption in the setting of colitis may further alter the intestinal microbiome to
exacerbate a colitis flare. To assess this, we used a mouse model of dextran sodium sulfate (DSS)
colitis in conjunction with a binge alcohol regimen. We determined that the intestinal contents of
DSS+ethanol mice exhibit a 1 log increase in Enterobacteriaceae (p<0.05) and a 0.5 log decrease
in Lactobacillus compared to DSS+vehicle mice. These bacterial shifts correlate with shorter
colons and more weight loss. Trends for the microbial changes induced by alcohol in the DSS
mice could be observed after a single gavage of alcohol, while significant effects manifested
after three gavages of alcohol. DSS administration decreased intestinal epithelial cell (IEC) tight
junction and mucin expression compared to control groups, but no additional changes were
observed in the DSS+ethanol group. Similarly, mice receiving DSS had increased bacterial
penetration of the intestinal mucosa compared to control groups, but alcohol did not appear to
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enhance this effect. However, the increased intestinal burden of the pro-inflammatory
Enterobacteriaceae and their propensity to infiltrate the mucosa, may increase intestinal
inflammation in the DSS+ethanol mice, exacerbating a flare.
Introduction
Once an individual develops IBD, they will experience episodes of recurring disease,
known as flares, which are characterized by bloody stools, abdominal discomfort, and weight
loss. These flares in the disease are frequent, with only 20% of patients with the UC subtype of
IBD, being flare free after two years(223). Studies examining IBD patients have found that
alcohol consumption is associated with induction of flare(178), as well as worsening of
gastrointestinal symptoms(177, 222) and increased intestinal infections(224). These effects may
arise from alcohol’s ability to alter the intestinal microbiota (189-192, 194), which would
negatively impact the already altered intestinal microbiome of IBD patients(113-115). In
particular, both alcohol consumption and IBD are independently characterized by a decrease in
the Lactobacillus genus(132, 195) and an increase in the Enterobacteriaceae family(113-115,
194, 195). The observed increase in Enterobacteriaceae is relevant because they can penetrate the
mucus layer of intestines in patients suffering from ulcerative colitis(113, 114, 173). Studies
carried out in mouse model of colitis show that this penetration occurs before the onset of
intestinal tissue damage(174, 175). The decrease in Lactobacillus may further compound this
effect since it is a beneficial bacterium that promotes intestinal health and also checks the growth
of Enterobacteriaceae(102-106). Furthermore, studies have determined that the intestinal ratio of
these two bacteria can be an indicator of gut health(225, 226). Using a mouse model of DSS
induced colitis and alcohol, we explored whether alcohol has any effect on Enterobacteriaceae
and Lactobacillus populations in mice treated with DSS and whether changes in these bacteria
has any relationships with colitis flare.
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Materials and Methods
Murine Model of Alcohol and Colitis.
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles
River Laboratories (Wilmington, MA). The mouse model used in this study was previously
described(224). Briefly, mice were randomly assigned to four experimental groups:
Control+vehicle (Ctrl+V), Control+ethanol (Ctrl+E), Dextran sodium sulfate+vehicle (DSS+V),
Dextran sodium sulfate+ethanol (DSS+E). As seen in Figure 2, mice were administered either
normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000 molecular weight; MP
Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS was stopped and mice
received a gavage of either 3g/kg ethanol or water per day until day 7. Mice were euthanized
three hours after the last gavage. Mice were weighed each day to determine percent weight
change relative to day 0. Following euthanasia, the large intestine was excised and its length
determined.

3g/kg EtOH or H2O gavage
Day 0

5
2% DSS or H2O

6
H2O

Experimental groups
Control+Vehicle (Ctrl+V)

DSS+V

Control+EtOH (Ctrl+E)

DSS+E

Figure 2. Mouse Model Timeline of DSS-colitis and Alcohol Gavage with
Experimental Groups.
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Blood Alcohol Level Quantification.
Plasma samples were assayed on an Analox-GL5 machine (Stourbridge, England) to
detect alcohol according to manufacturer’s guidelines. The apparatus uses the reaction of alcohol
and oxygen catalyzed by alcohol oxidase to determined alcohol levels.
Bacterial DNA Isolation.
Bacterial DNA was isolated from fecal pellets, large intestine contents, and cecal contents
using the QIAamp PowerFecal DNA Kit (Qiagen) according manufacturer’s guidelines. The
optional 5 minute incubation at 2-8°C was not used. Isolated DNA was quantified using a
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Due to noted PCR inhibition in
the DNA from the day 5 fecal pellets of the DSS mice, all day 5 fecal pellet DNA samples were
further purified using the DNeasy PowerClean Pro Cleanup Kit (Qiagen).
Bacterial DNA qPCR.
Primers for bacterial community(227) quantification were as follows: Total bacteriaUniF340 (ACTCCTACGGGAGGCAGCAGT) and UniR514 (ATTACCGCGGCTGCTGGC),
annealing temperature 63°C; Enterobacteriaceae- Uni515F (GTGCCAGCAGCCGCGGTAA)
Ent826R (GCCTCAAGGGCACAACCTCCAAG), annealing temperature 67°C; LactobacillusLabF362 (AGCAGTAGGGAATCTTCCA) and LabR677 (CACCGCTACACATGGAG),
annealing temperature 56°C. 6 uL of of DNA (0.7ng/uL for fecal pellets and large intestine
contents, or 7 ng/uL cecal contents) was mixed with 2 uL of each forward and reverse primer and
10 uL of iTaq Universal SYBR Green supermix (Bio-Rad) for a total reaction volume of 20 uL.
Reactions were performed on a Step One Plus qPCR instrument (Applied Biosystems) and run as
follows: 95°C for 3 min, 40 cycles of 95°C for 15s, followed by data collection at the annealing
temperature for 1 min. This was followed by a melt-curve analysis. To interpret bacterial DNA
relative quantity, Ct values from target bacteria (Enterobacteriaceae or Lactobacillus) were
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subtracted from total bacteria Ct values to obtain a ΔCt, this was used for the 2^(-ΔCt)
calculation. The 2^(-ΔCt) value was then log10 transformed. For ratio assessment the
Lactobacillus 2^(-ΔCt) value was divided by the Enterobacteriaceae value, the result was then
log10 transformed.
IEC Isolation.
Isolation of IECs was performed as described previously (228). The large intestine was
opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum
(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The
isolated epithelial cells were washed twice in PBS.
IEC RNA Isolation, cDNA Synthesis, and Gene Expression.
RNA was isolated from large IECs using the RNeasy Mini Kit (Qiagen) according to
manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with
the RNA isolation kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast
Thermocycler (Life Technologies).
Expression of mucins and tight junction proteins were assessed by qPCR using TaqMan
primer probes and TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions
were performed on a Step One Plus qPCR instrument (Applied Biosystems). Endogenous
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controls for the targets are as listed on the y-axis of the figure. Targets were assessed using the
2^(-ΔCt) method and expressed as fold change relative to control+vehicle.
Large Intestine Mucin Staining.
A 1 cm portion of the distal large intestine was removed, fixed in Carnoy’s solution, and
submitted to AML. Samples were embedded in paraffin and sectioned at 5μm onto glass slides.
Slides were stained with Periodic acid-Schiff and Alcian blue, to detect neutral and acidic
mucins. Images were taken on an Olympus BX43 Microscope using an Olympus DP26 camera.
Fluorescent in situ Hybridization.
Hybridization of distal large intestine sections with bacterial probes was completed as
described previously(229). Briefly, unstained slides containing colon sections were
deparaffinized in 3 washes with xylene followed by 3 washes in ethanol. Slides were dried in an
incubator for 50° C for 25 minutes. Slides were incubated overnight at 50° C with 1 ng/uL of
probe targeting all bacteria (EUB338: Alexa 555 5’-GCTGCCTCCCGTAGGAGT -3’) in a
buffer (0.9M NaCl, 20mMTris-HCL, pH 7.5, 0.1% SDS). Slides were washed 3 times in the
buffer (0.9M NaCl, 20mMTris-HCL, pH 7.5, 0.1% SDS) with 15-minute incubations. Slides
were then air dried, mounted, and counterstained with ProLong Gold Antifade Mountant with
DAPI (Thermo Fisher Scientific). Slides were then imaged on a Zeiss Axiovert 200m fluorescent
microscope and processed by the Axiovision software. A histogram stretch was employed for the
blue and red channels to spread the image intensities across the entire intensity display range.
Statistics.
Linear regression and One-way ANOVA followed by Tukey post-hoc test and Student’s
t-test were performed using GraphPad Prism software (Version 8.1.2).
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Results
Pathology and Blood Alcohol Concentration.
Consistent with our previous observations(224), mice gavaged with alcohol after DSS
treatment show more pronounced weight loss and shorter colon lengths (Figure 3A, B). Blood
alcohol concentrations are also increased in mice receiving ethanol gavage, with a significant
increase observed between control+ethanol and the DSS+ethanol (Figure 3C).
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Increased Enterobacteriaceae and Decreased Lactobacillus in Colon and Cecal Contents.
To assess intestinal bacterial changes, cecal contents and large intestine contents were
harvested from mice euthanized on day seven, three hours after final gavage. DNA was isolated
from the large intestine and cecal contents followed by qPCR to detect levels of
Enterobacteriaceae and Lactobacillus. Both the colon and cecal contents of the DSS mice had
significantly increased Enterobacteriaceae compared to the control mice (p < 0.05; Figure 4A).
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Furthermore, between the DSS mice, ethanol administration produced a 1 log increase (p < 0.05)
in the Enterobacteriaceae compared to vehicle administration. Lactobacillus levels were
decreased 0.5log in DSS+ethanol mice compared to all other experimental groups, which was
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not significant, but a trend for significance was observed in the cecal contents (Figure 4B).
Ratios of Lactobacillus to Enterobacteriaceae have been used as determinants of intestinal
health(225, 226). This ratio is significantly depressed (> 1.5 log) in DSS administered mice
compared to control mice (p < 0.05; Figure 4C). Meanwhile between the DSS mice, ethanol
gavage significantly decreases the Lactobacillus:Enterobacteriaceae ratio in colon (~1 log, p <
0.05) and cecal (~1.5 log, p<0.05) contents compared vehicle (Figure 4C).
Longitudinal Assessment of Enterobacteriaceae and Lactobacillus in Fecal Pellets.
To define the longitudinal changes of the Enterobacteriaceae and Lactobacillus, we
collected fecal pellets from the mice after weighing and before gavaging with vehicle or ethanol
on days 5 and 6. Unfortunately, some mice did not produce a pellet, hindering continuous
sampling from the same mouse, and so data are presented as a summary of each experimental
group. Despite this, the effect of ethanol on bacterial populations in mice receiving combined
DSS+ethanol can begin to be appreciated on day 6, one day after the first administration of
alcohol. From day 5 to day 6, there is a 0.9 log increase in the Enterobacteriaceae from
DSS+ethanol mice compared to a 0.7 log increase from the DSS+vehicle mice (Figure 5A).
During this same time period, the Lactobacillus decreases by 0.2 log in the DSS+ethanol mice,
while there is a slight increase (0.1 log) in the DSS+vehicle mice (Figure 5B). Altogether these
changes culminate in a ~1 log decrease in the day 5 to day 6 Lactobacillus:Enterobacteriaceae
ratio of DSS+ethanol mice, whereas this ratio that decreases ~0.5 log compared to DSS+vehicle
mice (Figure 5C).
These results suggest that the alcohol treatment elicits an effect on the intestinal
microbiota after colitis leading to increases in Enterobacteriaceae and decreases in Lactobacillus
culminating in a decreased Lactobacillus:Enterobacteriaceae ratio. The higher level of
Enterobacteriaceae and lower level of Lactobacillus may contribute to flare induction.
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Correlation of Enterobacteriaceae and Lactobacillus to Disease State.
To further assess how the disease state of the mouse relates to the intestinal bacteria, we
performed a linear regression of the cecal contents bacteria in relation to the mouse colon length.
The colon length is a macroscopic indicator of the inflammatory status of the colon, where
longer colons are healthier and shorter colons are more inflamed. In our experiment, the colon
length is inversely correlated to cecal content of Enterobacteriaceae (Figure 6A) and directly
correlated to cecal content of Lactobacillus (Figure 6B). On the scatter plot of the linear
regression, we observe that the samples from the DSS+ethanol mice have shorter colons in
conjunction with increased Enterobacteriaceae (Figure 6A) and decreased Lactobacillus (Figure
6B). In addition, combining data from all four experimental groups, we examined the correlation
of colon length, day 7 % weight change, and cecal contents bacteria using a Pearson correlation
(Figure 6C). This revealed that the colon length, and day 7 % weight change are positively
correlated with Lactobacillus while being inversely correlated with Enterobacteriaceae.
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Meanwhile, the relationship of Enterobacteriaceae and Lactobacillus are inversely correlated,
although this result was not significant.
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Mucin Alterations After DSS Colitis and Ethanol.
The healthy large intestine is covered by mucins which act as a barrier to limit bacterial
interaction with the intestinal epithelium, while in IBD there are marked disruptions of the
intestinal mucin. This allows for increased interaction of the bacteria with the intestinal
epithelium and may induce a flare. In our model, we first assessed mucin changes using a PASAlcian blue stain of intestinal sections. We observed that mucin staining was unaffected in the
control mice but severely decreased in the DSS mice (Figure 7A). The decreased intestinal
mucin levels in the DSS mice suggests that bacteria interaction with the epithelium is
uninhibited. We isolated IECs and assessed their expression of mucins and trefoil factor, a
marker of intestinal health. Mucin 4, mucin 2, intestinal trefoil factor 3 were all significantly
decreased ~2-fold in the DSS mice and compared to the control mice (p<0.05) (Figure 7B). This
mirrors the histologic changes observed in Figure 7A. These data suggest that DSS induces a
primary effect on intestinal mucin depletion, while alcohol has no additive effect.
Bacterial Infiltration of the Mucosa and Tight Junction Protein Expression.
To determine bacterial proximity to the epithelial lining, we used fluorescent in situ
hybridization with a probe targeting all bacteria. We detected an increased presence of bacteria
in the mucosa of DSS mice, meanwhile bacteria were largely relegated to the intestinal lumen in
control mice (Figure 8A). IEC RNA expression of tight junction proteins revealed that DSS
administration led to ~2-fold decrease in ZO-1, Occludin, and Claudin-4 compared to the
control+vehicle (p<0.05) (Figure 8B). Some direct effects of ethanol appear to also occur as
there was a significant decrease in Occludin expression in the control+ethanol mice compared to
the control+vehicle mice, which is not significant between the mice receiving DSS. The
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combined observations of decreased tight junction expression and increased mucosal infiltration
suggest that there is increased bacterial translocation, which may further contribute to flare.
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Summary
The results presented here suggest that in the setting of colitis, alcohol induces additional
bacterial changes compared to colitis alone. These changes can be seen 24 hours after a single
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gavage of ethanol as determined by bacterial qPCR of DNA isoalted from fecal pellets on day 6.
The primary observations were increases in the pro-inflammatory Enterobacteriaceae and
decreases in the beneficial Lactobacillus. At sacrfice on day seven, after three gavages of ethanol
have been administered, the changes in Enterobacteriaceae and Lactobacillus are more
pronounced. Furthermore, the changes in these bacteria directly correlate with weight loss and
colon length. While changes in IEC RNA expression of mucin and tight junction proteins did not
differ between the DSS+vehicle and DSS+ethanol mice, the heightened load of
Enterobacteriaceae suggests that there would be a relative increase in the translocation of this
bacteria and their products in the DSS+ethanol mice.

CHAPTER FIVE
ALCOHOL INCREASES IEC NOS2 EXPRESSION AFTER COLITIS INDUCTION
Abstract
During flares of IBD, the intestine exhibits increased inflammatory metabolites and
breakdown products. One metabolite particularly enriched during flares of IBD is nitrate. This
metabolite arises from the reaction of nitric oxide, derived from nitric oxide synthase 2 (Nos2),
and oxygen radicals generated by various inflammatory processes. The Enterobacteriaceae can
use nitrate as an energy source while other intestinal bacteria are unable or have a limited
capacity to do so. Using the mouse model of colitis and alcohol we assessed expression and
localization of Nos2 as well as the expression of enzymes that may contribute to the pool of
reactive oxygen in the intestine. After colitis induction, we observed that the DSS+ethanol mice
had a 1.5-fold increase in IEC expression of Nos2 compared to DSS+vehicle (p<0.05), which
was also verified by western blot. Immunostaining of intestinal swiss rolls revealed increased
Nos2 localization to the apical surface of the intestinal epithelium from DSS+ethanol mice
compared to DSS+vehicle mice. Colitis also induced the expression of IEC dual oxidase 2
(Duox2), which can contribute to nitrate production via generation of reactive oxygen species.
We further observed that after colitis induction, mice receiving a single gavage of ethanol
exhibited a trend for increased IEC Nos2 expression. These results suggest that in the setting
colitis, ethanol can have a potentiating effect on the expression of IEC Nos2.
Introduction
Bacteria are capable of using a number of substrates for energy production and,
depending on the surrounding environment, can switch their metabolism to utilize the substrate
50
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most advantageous to their growth. In the healthy large intestine, fermentation of indigestible
polysaccharides is the primary source of ATP generation(144). Due to their fermentation
efficiency, the Bacteroidetes and Firmicutes phyla dominate the large intestine, comprising at
least 90% of all bacterial populations(27, 35). However, during flares of UC, these is
upregulation of the intestinal enzyme Nos2 and its product nitric oxide, which can eventually
promote the production of a non-fermentable energy source, nitrate(147).
There are three nitric oxide synthase isozymes, each of which catalyze the reaction of Larginine and oxygen to form L-citrulline and nitric oxide. Nos1 and Nos3 are constitutively
expressed in neuronal tissue and endothelial tissue, respectively, while Nos2 is inducible and can
be expressed in a variety of cells. Aside from expression differences, these enzymes also differ in
the regulation of their activity. Nos1 and Nos3 activity is regulated by calcium fluxes and can
produce nanomolar concentrations of nitric oxide for brief periods of time. In contrast, Nos2 is
not regulated by calcium and thus, once expressed, can produce micromolar concentrations of
nitric oxide for long durations(230). Nos2 can be induced by a variety of factors including LPS,
tumor necrosis α, interleukin 1β, and interferon γ(231).
In the oxidative environment of an IBD flare, the nitric oxide reacts with reactive oxygen
species leading to the formation of peroxynitrite, which can oxidize numerous biological
components and nitrosylate protein tyrosine residues(232). In fact, models of colitis have been
generated simply by administering peroxynitrite(233) and a study found increased concentrations
of peroxynitrite in the intestine of UC patients(234). However, peroxynitrite can also
spontaneously degrade into nitrate(232), which can be used by facultative anaerobic bacteria,
like the Enterobacteriaceae, as a terminal electron acceptor in the process of anaerobic
respiration(155, 235), while the Bacteroidetes and Firmicutes cannot(156). Furthermore, the
reduction of nitrate during anaerobic respiration is much more energetically favorable than
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polysaccharide fermentation(155), which allows for Enterobacteriaceae overgrowth(157). To
facilitate the utilization of this precious energy source, the Enterobacteriaceae encode a
chemoreceptor that detects nitrates and initiates subsequent chemotaxis toward the nitrate
source(236, 237).
In the previous chapter, we identified that the combined effect of colitis and alcohol
administration led to increased intestinal Enterobacteriaceae. As the Nos2 metabolite nitrate has
been linked to the growth of Enterobacteriaceae, we studied the expression of intestinal Nos2 in
our model. We observed that at the RNA and protein level Nos2 IEC expression was
significantly increased in the combined DSS+ethanol compared to the DSS+vehicle. Nos2
immunohistochemistry of intestinal swiss rolls, revealed a similar result, with enhanced Nos2
staining localized to the apical surface of the intestinal epithelium in the DSS+ethanol relative to
DSS+vehicle. This suggests that alcohol may contribute to the expansion of Enterobacteriaceae
by increasing the expression of epithelial Nos2 and thus an increase in intestinal nitrate.
Materials and Methods
Murine Model of Alcohol and Colitis.
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles
River Laboratories (Wilmington, MA). The mouse model used in this study was previously
described(224). Briefly, mice were randomly assigned to four experimental groups:
Control+Vehicle (Ctrl+V), Control+Ethanol (Ctrl+E), Dextran sodium sulfate+Vehicle
(DSS+V), Dextran sodium sulfate+Ethanol (DSS+E). As seen in Figure 2, mice were
administered either normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000
molecular weight; MP Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS
was stopped and mice received a gavage of either 3g/kg ethanol or water per day until day 7.
Mice were euthanized three hours after the last gavage. Blood was collected via cardiac puncture
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and processed for plasma. Mice were weighed each day to determine percent weight change
relative to day 0. Following euthanasia, the large intestine was excised and its length determined.
For the single gavage experiment, the model proceeded as described above, however,
mice were only given one gavage of alcohol or vehicle on day 5, followed by euthanasia 3 hours
after the gavage.
IEC Isolation.
Isolation of large IECs was performed as described previously (228). The large intestine
was opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum
(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The
isolated epithelial cells were washed twice in PBS.
RNA Isolation, cDNA Synthesis, and Gene Expression.
RNA was isolated from large IECs or total tissue using the RNeasy Mini Kit (Qiagen)
according to manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in
conjunction with the RNA isolation kit to remove genomic DNA. RNA was quantified using a
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti
96-well Fast Thermocycler (Life Technologies).
Expression of targets was assessed by qPCR using TaqMan primer probes and TaqMan
Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions were performed on a Step One
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Plus qPCR instrument (Applied Biosystems). Endogenous controls for the targets are as listed on
the y-axis of the figure. Targets were assessed using the 2^(-ΔCt) method and expressed as fold
change relative to Control+Vehicle.
Protein Quantification and Western Blot of Nos2.
IECs were homogenized in 1x Cell Lysis Buffer (Cell Signaling Technologies) supplemented
with 1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Protein was
quantified using the DC Protein Assay (Bio-Rad). Protein was separated using SDS-PAGE using
Bolt Bis-Tris gels (Thermo Fisher Scientific) and then transferred to a PVDF Membrane using a wet
transfer method. Membrane was blocked with milk, washed with TBS, then incubated overnight with
Nos2 antibody (Cell Signaling Technology). After washing with TBST, the membrane was incubated
with HRP-linked secondary antibody (Cell Signaling Technology) and developed using Western
Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer). Membrane was
imaged on a ChemiDoc (Bio-Rad) and densitometry analysis performed using ImageLab software
(Bio-Rad). Afterwards the blot was stripped using Restore Plus Stripping Buffer (Thermo Fisher
Scientific) and then probed for β-actin (Cell Signaling Technologies), which was used for band
normalization.
Plasma Nitrate+Nitrite Assessment.
Amicon Ultra-0.5 mL Centrifugal Filters were first rinsed with molecular grade water. After
rinsing, plasma was applied to the column and centrifuged. The filtrate was used to asses total nitric
oxide metabolites (nitrate+nitrite) using a Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical)
according to manufacturer’s guidelines.
Immunohistochemistry of Large Intestine Swiss Rolls.
After sacrifice, the large intestine of the mouse was excised, opened longitudinally, and
cleared of any fecal matter. The intestine was rolled from the distal end to the proximal, stabilized
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with a syringe needle, placed in a cassette, and then fixed in 10% neutral buffered formalin. Tissues
were embedded in paraffin and sectioned at 5 uM onto glass slides. Slides were deparaffinized by
incubating in graded washes of xylene and then ethanol. Deparaffinized slides were incubated in
0.2% triton X-100 PBS for 10 minutes, followed by boiling in sodium citrate buffer (Abcam) for 30
minutes, then removed from heat and allowed to cool for 45 minutes. Slides were then incubated at
room temperature for 2 hours with Nos2 antibody (Cell Signaling Technologies, 1:400) or Nos2
antibody and Anti-neutrophil antibody (Abcam, 1:50). Slides were washed three times with PBS and
then incubated with goat anti-rabbit AlexaFlour555 (Thermo Fisher Scientific, 1:200) or goat antirabbit AlexaFlour488 (Thermo Fisher Scientific, 1:200) and goat anti-rat AlexFlour555 (Thermo
Fisher Scientific, 1:200). Slides were then counterstained and mounted with ProLong Gold
Antifade Mountant with DAPI (Thermo Fisher Scientific). Slides were then imaged on a Zeiss
Axiovert 200m fluorescent microscope and processed by the Axiovision software. For Nos2
swiss roll staining, in order to capture the entire swiss roll multiple images were taken at 25x and
then Adobe Photoshop was used to merge images together. For all flourescence images, a
histogram stretch was employed in Adobe Photoshop for the blue, red, and green channels to
spread the image intensities across the entire intensity display range.
Statistics.
One way ANOVA followed by Tukey post-hoc test was used for significance analysis
using GraphPad Prism software (Version 8.1.2).
Results
Increased Intestinal Expression of Reactive Oxygen Generating Enzymes After DSS.
The production of nitrate within the intestine requires both the presence of oxygen radicals
and nitric oxide(35). These components can react, producing peroxynitrite, which can spontaneously

56
degrade into nitrate(232), a substrate that facultative anaerobic bacteria, like the
Enterobacteriaceae, can use as an energy source(235).
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We first examined IEC RNA expression of Nicotinamide adenine dinucleotide phosphate
oxidase 1 (Nox1) and Duox2, both of which can lead to the production of reactive oxygen species.
No significant changes were observed in the expression of Nox1 (Figure 9A). Duox2 expression was
significantly increased in the mice receiving DSS compared to control but not significantly altered
after alcohol gavage (Figure 9B).
After consuming alcohol, bloodstream levels of alcohol can mirror those seen along the
gastrointestinal tract(202), while the alcohol metabolite, acetaldehyde, is produced in appreciable
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amounts within the intestine(203, 204). This increase in acetaldehyde is attributed to metabolism
that occurs by the IECs and the intestinal bacteria(203, 204). As the process of alcohol
metabolism through its endogenous reactions and acetaldehyde production can participate in
reactive oxygen generation(207) we examined IEC RNA expression of alcohol metabolizing
enzymes. Alcohol dehydrogenase (Adh1), the enzyme responsible for the bulk of ethanol metabolism
in the human body, was significantly decreased in mice receiving DSS compared to control mice,
with no significant difference observed between DSS+vehicle and DSS+ethanol (Figure 9C).
Ethanol can also be metabolized by catalase and cytochrome P450 2E1. Catalase RNA expression
was unchanged (Figure 9D), while Cytochrome P450 2E1 RNA levels were undetectable (data not
shown).
Increased IEC Expression of Nos2 in DSS+ethanol.
The other component of nitrate generation is nitric oxide, which is produced by Nos2. We
examined RNA expression of Nos2 in both total large intestine tissue homogenates and IECs. While
Nos2 RNA expression was observed to be increased in total tissue from DSS mice compared to
control (Figure 10A), examination of IECs provided a clearer picture of the Nos2 changes between
groups, displaying a significant 1.5-fold increase in DSS+ethanol compared to DSS+vehicle (Figure
10B). This increase was confirmed by assessment of IEC Nos2 protein levels (Figure 10C),
followed by densitometry (Figure 10D). We attempted to assess nitrate levels in cecal scrapings
however no nitrates were detectable (data not shown). This may be due to either our sample
preparation or the kit we used may have lacked the sensitivity to detect nitrates. Increases in serum
nitrate concentration has been observed in active IBD(238), thus we examined plasma nitrate levels
in mice from our model. Although nitrates were increased in both DSS+vehicle and DSS+ethanol,
these results were not significant between any of the experimental groups (Figure 10E). These data
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indicate that DSS+ethanol IECs significantly upregulate Nos2 expression relative to the other
experimental groups.
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Figure 10. DSS+ethanol Increases IEC Nos2 Expression. (A) Total tissue Nos2 RNA
expression. (B). IEC Nos2 RNA expression. (C) IEC Nos2 Western blot. (D)
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Increased Localization of Nos2 to the Intestinal Epithelium in DSS+ethanol.
We next wanted to determine the localization of Nos2 within the intestine. In control mice
there was no detectable staining of Nos2 (Figure 11). In the DSS mice, Nos2 was observed and
primarily localized to the apical surface of the epithelium (Figure 11). This coincides with the
localization of Nos2 observed in histological samples from IBD patients(234). Nos2 staining in
the DSS+ethanol mice appeared to be increased in terms of intensity, and distribution along the
length of the intestine as well as the intestinal crypt.
Since neutrophils are a potential source of Nos2 and their invasion into the intestine is
well documented in both UC(239) and mouse models of colitis(240), we wanted to identify
whether neutrophils were potentially contributing to nitric oxide generation. To accomplish this,
we used antibodies specific to Nos2 and neutrophils to detect colocalization of Nos2 with
neutrophils in our model. While we were able to identify neutrophils in the intestines of mice
receiving DSS, we did not observe colocalization of Nos2 with the neutrophil marker. This
suggests that the IECs are the primary source of Nos2 and thus the major contributor to nitric
oxide for generation of nitrate (Figure 12).
Single Gavage of Ethanol has Slight Potentiating Effect on Nos2 IEC RNA Expression.
The effect of a single dose of ethanol was assessed in our model by sacrificing mice on
day five, three hours after gavage, as observed in (Figure 13A). The colon lengths of the DSS
mice were shorter compared to the control mice, but only significant between control+ethanol
mice (Figure 13B). No significant % weight change observed on day five between all
experimental groups (Figure 13C). Similar to the results presented in Figure 9B, IEC Duox2
RNA expression was significantly increased in the mice receiving DSS compared to control mice
(Figure 13D). DSS also increased epithelial expression of Nos2 compared to control mice
(Figure 13E). While the Nos2 RNA expression was increased in mice receiving a single gavage
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of alcohol following DSS compared to DSS+control mice, the increase in Nos2 was not found to
be significant. This seems to indicate that in the setting of DSS-induced colitis, a single gavage
may also augment Nos2 expression but is limited compared to the effect by three gavages.

Ctrl+V

Ctrl+E

DSS+V

DSS+E, No 10

DSS+E

Nuclei = DAPI
Nos2 = Red

Figure 11. DSS+ethanol Increases Nos2 Immunostaining which is Localized to the
Intestinal Epithelium. Square images consist of separate images taken at 25x and
merged together. Insert images for DSS+V and DSS+E taken at 200x. Ctrl images
representative of 2 animals per group. DSS images are of three animals per group.
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Figure 12. Nos2 does Not Colocalize with Infiltrating Neutrophils After DSS
Treatment. All images are at 200x, unless noted otherwise. Images representative of 1-2
animals per group.
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Summary
The results indicate that in the setting of colitis, alcohol may promote the growth of
Enterobacteriaceae by increasing the expression of Nos2. The increased expression of Nos2 likely
contributes to increased intestinal nitrate, a favorable energy source for the Enterobacteriaceae. The
expression of Nos2 in the intestine was localized to the epithelial layer specifically the apical surface,
suggesting that nitric oxide is being released directly into the intestinal lumen. While neutrophils
were present infiltrating into the intestinal crypts, Nos2 was not detected within the neutrophils, thus
IECs may be a primary source of nitric oxide in the intestine. Upon release, nitric oxide can react
with the reactive oxygen substances produced from Duox2 or other reactive processes. Interestingly,
IEC RNA expression of alcohol dehydrogenase was decreased in DSS, suggesting that ethanol may
be present in larger quantities in the intestine and thereby contribute to a more reactive environment.
Furthermore, in DSS mice, ethanol’s potentiating effect on IEC Nos2 expression could be observed
even after a single dose compared to DSS mice receiving vehicle.

CHAPTER SIX
ENTEROBACTERIACEAE PERSIST AFTER ALCOHOL ADMINISTRATION DESPITE
INHIBITION OF NOS2 ACTIVITY AND NITRATE UTILIZATION
Abstract
We observed that the combination of colitis and alcohol increased IEC expression of
Nos2 compared to colitis and a vehicle. This suggests that the intestines of DSS+ethanol mice
exhibit increased levels of intestinal nitric oxide, which in turn can lead to increased nitrates, and
a bloom in Enterobacteriaceae. To mitigate the expansion of Enterobacteriaceae, we employed
two treatments, L-N6-(1-iminoethyl)-L-lysine dihydrochloride (L-NIL), which inhibits Nos2
activity, and tungstate (W), which inhibits nitrate utilization. Global assessment of the
microbiome via 16S sequencing, indicated that all mice receiving DSS had decreased alpha
diversity compared to the controls. The DSS+ethanol mice had significantly decreased bacterial
community evenness compared to DSS+vehicle mice, yet no significant change in bacterial
community richness was observed between the DSS mice. In addition, DSS altered beta
diversity, with notable differences being observed between the DSS+vehicle groups and the
DSS+ethanol groups. In depth examination of bacteria at the phylum and family levels revealed
additional changes between groups. The DSS+vehicle mice that received either of the L-NIL or
Tungstate treatment exhibited decreased Enterobacteriaceae. However, the DSS+ethanol group
that received these treatments exhibited levels of Enterobacteriaceae that appeared to be
intermediate to the mice receiving either DSS+vehicle and DSS+ethanol. Each of the
experimental groups was also characterized by increases in select taxa of bacteria. Due to the
intermediate changes in the Enterobacteriaceae of the DSS+ethanol mice that received treatment,
64
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we examined IEC RNA expression of Nos2 and unexpectedly found its expression was
decreased in DSS+ethanol compared to DSS+vehicle. Examination of prior Nos2 expression
data in relation to weight loss indicated that once a certain weight loss threshold was met, Nos2
expression began to decrease rather than increase. The treatments had some benefit by
preventing weight loss, increasing colon length, and limiting intestinal damage. In a separate set
of experiments, we assessed nitrate dependent growth in the DSS+vehicle and DSS+ethanol
experimental groups using nitrate reductase proficient or deficient bacteria. While there appeared
to be a small benefit to nitrate dependent growth, differences between DSS+ethanol and
DSS+vehicle appeared either negligible or slightly favoring nitrate dependent growth in
DSS+ethanol. Limited colonization of these bacteria in the mice may have played a role in this
result. Combined treatment with both L-NIL and tungstate to target the respective nitrate
production and utilization pathways, led to decreased Enterobacteriaceae growth in both
DSS+vehicle and DSS+ethanol but the effect of ethanol in reducing Lactobacillus persisted.
Lastly, alterations in the cecal content SCFAs were assessed, revealing a strong effect of DSS in
reducing SCFAs, with smaller effects attributable to ethanol administration.
Introduction
In mouse models, Nos2 inhibition or Nos2 deficiency decreases susceptibility to
colitis(241). Initial studies attributed this beneficial effect largely relied on limitation of general
oxidative stress, however, more recent studies have proposed that this effect may be mediated in
part by decreased growth of the pro-inflammatory bacteria like Enterobacteriaceae(242). In order
to use nitrates as an energy source, the Enterobacteriaceae encode three nitrate reductases: two
membrane bound nitrate reductases (NarZ, NarG), and one periplasmic nitrate reductase (NapA)
(155). Deleting these genes in E. coli, a representative Enterobacteriaceae bacterium, inhibits
growth in inflammatory situations relative to wild-type E. coli(243, 244). The nitrate reductase
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enzymes require a molybdenum containing molybdopterin cofactor, which catalyzes the
reduction of nitrate(245). Molybdenum can be replaced with tungstate, which inactivates the
molybdopterin cofactor and prevents bacterial utilization of nitrates as an energy source(246). A
previous study has demonstrated that tungstate treatment inhibited the growth of
Enterobacteriaceae as well as reduced the severity of intestinal damage in a mouse model of
colitis, suggesting a role of Enterobacteriaceae in the disease pathogenesis of colitis(247).
To examine whether decreased nitrates or decreased nitrate utilization could ameliorate
the bacterial changes induced by the combined insult of alcohol and colitis, we treated the mice
with L-NIL and tungstate. As has been shown previously the dysbiosis induced by DSS was
limited by L-NIL and tungstate, however, this effect appeared to be blunted when these
treatments were administered in the combined setting of alcohol and colitis. This suggests that
other effects induced by ethanol aside from nitrate and nitrate utilization may play a role in the
bacterial changes elicited by ethanol and colitis.
Materials and Methods
Murine Model of Alcohol and Colitis with Either L-NIL or Tungstate Treatment and
Combined L-NIL and Tungstate Treatment.
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles
River Laboratories (Wilmington, MA). The mouse model used in this study was previously
described(224). Briefly, mice were randomly assigned to eight experimental groups:
control+vehicle (Ctrl+V), control+ethanol (Ctrl+E), dextran sodium sulfate+vehicle (DSS+V),
dextran sodium sulfate+ethanol (DSS+E), DSS+vehicle+L-NIL (DSS+V+L), DSS+ethanol+LNIL (DSS+E+L), DSS+vehicle+tungstate (DSS+V+W), and DSS+ethanol+tungstate
(DSS+E+W). As seen in Figure 14, mice were administered either normal drinking water or a
2% (w/v) solution of DSS (36,000-50,000 molecular weight; MP Biomedicals) ad libitum,
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starting on day 0 and until day 5. On day 4 mice in the L-NIL and tungstate treatment groups had
their water bottle replaced with either 2% DSS with 1mg/mL L-NIL or 2% DSS with 0.2%
tungstate. On day 5, DSS was stopped and water bottle solutions were replaced with either LNIL, Tungstate, or normal drinking water. Mice then received a gavage of either 3g/kg ethanol or
water per day until day 7. Mice were euthanized three hours after the last gavage. Mice were
weighed each day to determine percent weight change relative to day 0. Following euthanasia,
the large intestine was excised and its length determined.
3g/kg EtOH or H2O gavage
Day 0

4

5

2% DSS or H2O

6

7

H2O

L-NIL (1mg/mL)
or W (0.2%)

Experimental groups
Ctrl+V

DSS+V

DSS+V+L

DSS+V+W

Ctrl+E

DSS+E

DSS+E+L

DSS+E+W

Figure 14. Colitis and Alcohol Model with L-NIL and Tungstate Treatment
Using only DSS+vehicle and DSS+ethanol, the treatment paradigm proceeded as shown
in Figure 6.1 and described as above, except the water bottles contained both L-NIL and
Tungstate. This led to the formation of 2 groups: DSS+V+L-NIL+Tungstate (DSS+V+L+W) and
DSS+E+L-NIL+Tungstate (DSS+E+L+W). DNA was isolated from cecal contents for bacterial
qPCR.
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Bacterial DNA Isolation.
Bacterial DNA was isolated from fecal pellets, large intestine contents, and cecal contents
using the QIAamp PowerFecal DNA Kit (Qiagen) according manufacturer’s guidelines. The
optional 5 minute incubation at 2-8°C was not used. Isolated DNA was quantified using a
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).
Microbial Community Characterization Using Deep Sequencing of 16S rRNA Gene
Amplicons.
Genomic DNA extracted from soil was PCR amplified with primers CS1_515Fb and
CS2_806Rb (modified from the primer set employed by the Earth Microbiome Project (EMP;
GTGYCAGCMGCCGCGGTAA and GGACTACNVGGGTWTCTAAT) targeting the V4
regions of microbial small subunit ribosomal RNA genes. Amplicons were generated using a
two-stage “targeted amplicon sequencing (TAS)” protocol (248, 249). The primers contained 5’
common sequence tags (known as common sequence 1 and 2, CS1 and CS2) as described
previously (250, 251). First stage PCR amplifications were performed in 10 microliter reactions
in 96-well plates, using the MyTaq HS 2X mastermix. PCR conditions were 95°C for 5 minutes,
followed by 28 cycles of 95°C for 30”, 55°C for 45” and 72°C for 60”.
Subsequently, a second PCR amplification was performed in 10 microliter reactions in
96-well plates. A mastermix for the entire plate was made using the MyTaq HS 2X mastermix.
Each well received a separate primer pair with a unique 10-base barcode, obtained from the
Access Array Barcode Library for Illumina (Fluidigm, South San Francisco, CA; Item# 1004876). These AccessArray primers contained the CS1 and CS2 linkers at the 3’ ends of the
oligonucleotides. Cycling conditions were as follows: 95°C for 5 minutes, followed by 8 cycles
of 95°C for 30”, 60°C for 30” and 72°C for 30”. A final, 7 minute elongation step was performed
at 72°C. Samples were pooled in equal volume using an EpMotion5075 liquid handling robot
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(Eppendorf, Hamburg, Germany). The pooled library was purified using an AMPure XP cleanup
protocol (0.6X, vol/vol; Agencourt, Beckmann-Coulter) to remove fragments smaller than 300
bp. The pooled libraries, with a 20% phiX spike-in, were loaded onto an Illumina MiniSeq midoutput flow cell (2x153 paired-end reads). Fluidigm sequencing primers, targeting the CS1 and
CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads was performed on
instrument. Library preparation, pooling, and sequencing were performed at the University of
Illinois at Chicago Sequencing Core (UICSQC).
Sequencing Data Processing and Analysis.
Raw data was demultiplexed, filtered on quality, and merged using dada2 v1.12
(https://benjjneb.github.io/dada2) run on R version 3.5.2. Afterwards data was imported into
Quantitative Insights into Microbial Ecology 2 (QIIME2) v2019.1 ((https://qiime2.org/) to align
sequences and identity amplicon sequence variants (ASVs) against a Naive Bayes classifier
trained on Silva 132 99% OTUs from 515F/806R region of sequences
(https://docs.qiime2.org/2019.1/data-resources/). Alpha and beta diversity analysis was
performed using the QIIME2 program. Alpha diversity analysis was performed after rarefying to
59,000 reads. No rarefication was performed for beta diversity analysis. Alpha diversity
significance was assessed using a Kruskal-Wallis pairwise analysis followed by Benjamini &
Hochberg correction, while beta diversity was assessed using PERMANOVA, followed by
Benjamini & Hochberg correction. * q < 0.05. 2-D PCoA plots were also generated using the
QIIME2 program.
To identify differentially abundant bacteria, the sequencing data taxonomy was collapsed
to the family level then applied to the Linear discriminant analysis (LDA) Effect Size (LEfSe)
method was used from the Galaxy website (http://huttenhower.sph.harvard.edu/galaxy/) with the
following parameters: Kruskal-Wallis test alpha value of 0.05; Logarithmic LDA score for
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discriminative features of 2.0; All-against-all strategy for multi-class analysis. LDA plot and
cladograms were edited in Adobe Illustrator.
Bacterial DNA qPCR.
Primers for bacterial community(227) quantification were as follows: Total bacteriaUniF340 (ACTCCTACGGGAGGCAGCAGT) and UniR514 (ATTACCGCGGCTGCTGGC),
annealing temperature 63°C; Enterobacteriaceae- Uni515F (GTGCCAGCAGCCGCGGTAA)
Ent826R (GCCTCAAGGGCACAACCTCCAAG), annealing temperature 67°C; LactobacillusLabF362 (AGCAGTAGGGAATCTTCCA) and LabR677 (CACCGCTACACATGGAG),
annealing temperature 56°C. 6 uL of of DNA (0.7ng/uL for fecal pellets and large intestine
contents, or 7 ng/uL cecal contents) was mixed with 2 uL of each forward and reverse primer and
10 uL of iTaq Universal SYBR Green supermix (Bio-Rad) for a total reaction volume of 20 uL.
Reactions were performed on a Step One Plus qPCR instrument (Applied Biosystems) and run as
follows: 95°C for 3 min, 40 cycles of 95°C for 15s, followed by data collection at the annealing
temperature for 1 min. This was followed by a melt-curve analysis. To interpret bacterial DNA
relative quantity, Ct values from target bacteria (Enterobacteriaceae or Lactobacillus) were
subtracted from total bacteria Ct values to obtain a ΔCt, this was used for the 2^(-ΔCt)
calculation. The 2^(-ΔCt) value was then log10 transformed. For ratio assessment the
Lactobacillus 2^(-ΔCt) value was divided by the Enterobacteriaceae value, the result was then
log10 transformed.
IEC Isolation.
Isolation of large IECs was performed as described previously (228). The large intestine
was opened longitudinally and placed in cold PBS containing a 1% penicillin/streptomycin
(pen/strep) cocktail. The tissues were washed twice with PBS+pen/strep, then place in a
digestion solution (prewarmed to 37°C) containing 5% heat-inactivated fetal bovine serum
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(FBS), 1% HEPES, 1% pen/strep, 0.5% gentamicin, 5mM EDTA, and 1mM dithiothreitol in
Hank’s Balanced Salt Solution. The tissues were then placed in a 37°C shaking incubator (250
rpm) for 20 minutes, then vortexed to dissociate epithelial cells and passed through a 100μm
filter set in a tube on ice. The prior step was repeated with additional digestion solution. The
isolated epithelial cells were washed twice in PBS.
RNA Isolation, cDNA Synthesis, and Gene Expression.
RNA was isolated from large IECs or total tissue using the RNeasy Mini Kit (Qiagen) or
the mirVana miRNA Isolation Kit (Thermo Fisher Scientific) according to manufacturer’s
guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with the RNeasy Mini
Kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific). cDNA was synthesized using the High Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast Thermocycler (Life
Technologies).
Histology and Histopathology.
A 1 cm portion of the distal large intestine was removed, fixed in Carnoy’s solution, and
submitted to AML. Samples were embedded in paraffin and sectioned at 5μm onto glass slides,
followed by H&E stain. These sections were then scored based on a 0-4 point scale examining
exudate, epithelial damage, polymorphonuclear leukocyte invasion, submucosal edema, and
necrosis. The values from each of these categories were summed to produce the combined
histopathology score.
Competitive Index Experiments.
Studies assessing the competitive advantage of nitrate utilization in the intestine have knocked
out the three nitrate reductase enzymes from Escherichia coli, a representative bacterium of the
Enterobacteriaceae(242, 243). This knockout bacterium (ΔNR) and wildtype with nitrate
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reductases intact (WT) have been provided to us by Dr. Tyrrell Conway of Oklahoma State
University. The bacteria are derived from the E. coli MG1655 K-12 strain. The WT has a
genomic integrated antibiotic resistance to both streptomycin (Str) and nalidixic acid (Nal), while
the ΔNR has genomic integrated resistance to both Str and chloramphenicol (Cat). The
experiment was conducted as described earlier in Figure 4.1 with modifications. Instead of using
Charles River mice, male 8-9 week old (∼23–25 g body weight) C57BL/6 were obtained from
Jackson Labs. In addition, on day 4 of the mice received a 5 x 108 CFU gavage of each WT and
ΔNR in 0.1 mL of LB media generating two experimental groups: DSS+V+E. coli (DSS+V+E),
and DSS+E+E. coli (DSS+E+E). Fresh fecal pellets were collected on ice on day 5, 6, and 7,
weighed, then processed immediately by homogenizing in 1 mL sterile PBS and plating in serial
10-fold dilutions on selective MacConkey agar plates. The plates contained either Str(50 µg/mL)
and Nal(50 µg/mL) or Str(50 µg/mL) and Cat(30 µg/mL) for selection of the WT and ΔNR
bacteria, respectively. This same process was used for intestinal contents removed from the mice
after euthanasia on day 7. After overnight incubation at 37°C overnight, colony forming units
(CFUs) were counted and normalized to gram feces. A bacterial competitive index for each
mouse will be determined by dividing the WT CFUs over the ΔNR CFUs.
SCFA Analysis.
Cecal contents of control+vehicle, control+ethanol, DSS+vehicle, DSS+ethanol were
weighed and submitted to the UIC mass spectrometry core for quantification of the short chain
fatty acids, acetic acid, propionic acid, and butyric acid. Cecal contents and standards of the three
short chain fatty acids were derivatized with 3-nitrophenylhydrazine hydrochloride and 3ethylcarbodiimide. Samples were analyzed on an AB Sciex Qtrap 5500 coupled to Agilent
UPLC/HPLC system. Concentrations of cecal content short chain fatty acids were normalized to
the input weight of the cecal content sample.
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Blood Alcohol Level Quantification.
Plasma samples were assayed on an Analox-GL5 machine (Stourbridge, England) to
detect alcohol according to manufacturer’s guidelines. The apparatus uses the reaction of alcohol
and oxygen catalyzed by alcohol oxidase to determined alcohol levels.
Statistics.
Linear regression, One-way ANOVA followed by Tukey post-hoc test, and Student’s ttest were performed using GraphPad Prism software (Version 8.1.2). Statistics related to
sequencing data can be found in preceding Materials and Methods section titled Sequencing Data
Processing and Analysis.
Results
DSS+ethanol Cecal Contents Exhibit Global and Specific Changes in Microbial
Populations.
The microbiomes of the mice were examined by 16S rRNA sequencing. Global
differences in the microbiomes of the mice were assessed by alpha and beta diversity. Different
alpha diversity assessments can identify the richness and the evenness in a sample. Richness is
defined as how many different species can be identified in a sample, while evenness determines
whether there is an equal proportion of bacteria in a sample or does any one type of bacteria
predominate. Alpha diversity evenness was assessed by two tests, Pielou’s Evenness Index and
Shannon Index (Figure 15A, B), while alpha diversity richness was assessed by the number of
observed operational taxonomic units (OTUs) and Faith’s phylogenetic diversity index (Figure
15C, D). Global changes in alpha diversity were significant for all assessments except for Faith’s
phylogenetic diversity, which did exhibit a trend for significance. In pairwise assessments of
evenness, all experimental groups that received DSS+ethanol had significant decreases (or trends
for significance) in evenness compared to the Control and DSS+vehicle groups. In pairwise
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assessment of richness, no significance difference was obtained, however, its apparent that all the
DSS experimental groups exhibited decreased richness relative to the control experimental
groups.
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Figure 15. Combined DSS and Ethanol Administration Decreases Cecal Bacterial
Alpha Diversity, with Targeted Effects on the Species Evenness. (A) Pielou’s
evenness, measurement of evenness. (B) Shannon index, measurement of evenness. (C)
Observed OTUs, measurement of richness. (D) Faith’s phylogenetic diversity. * q < 0.05
by Kruskal-Wallis pairwise analysis followed by Benjamini & Hochberg correction.
Samples with horizontal lines above are being used compared to samples with vertical
lines.
Beta diversity assesses differences in microbial composition between different samples.
This was assessed using both unweighted and weighted UniFrac, which incorporates
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phylogenetic distances between samples to determine differences(252). Unweighted UniFrac is a
qualitative measure taking into account whether a bacterial species is present or absent.
Weighted UniFrac is a quantitative measure taking into account the abundance of the bacterial
species. In the PCoA plot output for Weighted UniFrac, we can observe a clear separation
between the control groups, the DSS+vehicle groups, and the DSS+ethanol groups (Figure
16A). The Unweighted Unifrac PCoA plot identifies shows that the control groups are clustering
more closely together, while the DSS groups irrespective of ethanol are clustering more closely
together (Figure 16B). Despite the closer clustering of the DSS groups in the Unweighted
UniFrac, there were globally significant differences in both the Weighted and Unweighted
UniFrac analyses. In addition, during pairwise comparison, all control groups were significantly
altered compared to the DSS experimental groups (Table 7 and 8). In comparing between the
DSS experimental groups, there was either significance or a trend for significance between all
groups using both the weighted and unweighted UniFrac. The only comparison that did not meet
these criteria was the comparison of the weighted UniFrac result between the DSS+vehicle and
the DSS+vehicle+L-NIL (q = 0.556).
Summary of the bacterial phylum level changes can be seen in Figure 17A. Compared to
control mice, the DSS groups exhibit an increased abundance of Proteobacteria, with the largest
increase seen in the DSS+ethanol groups (Figure 17B). The Firmicutes are decreased in the DSS
groups compared to control groups, with the most significant changes seen in the DSS+ethanol
groups, irrespective of whether they received the L-NIL and Tungstate treatment (Figure 17C).
Levels of Bacteroidetes were unchanged (Figure 17D). Verrucomicrobia were increased in the
DSS and combined ethanol administration groups (Figure 17E), however, we anticipate that this
effect may be related to a cage effect, related to endogenous bacterial populations. The four
animals in the DSS+ethanol group with the highest load of Verrucomicrobia, were all housed in
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Figure 16. Combined DSS and Ethanol Administration Alters β-diversity
Compared to Other Experimental Groups. (A) Weighted UniFrac. (B) Unweighted
Unifrac.
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Table 7. Weighted UniFrac Significance by PERMANOVA with Benjamini-Hochberg
Correction
Group 1
Group 2
pseudo-F
p-value
q-value
Ctrl+V
Ctrl+E
1.06413995
0.365 0.37851852
Ctrl+V
DSS+V
7.1098051
0.001
0.0028
Ctrl+V
DSS+E
8.2439773
0.002 0.00430769
Ctrl+V
DSS+V+L
5.79170171
0.001
0.0028
Ctrl+V
DSS+E+L
13.2497898
0.001
0.0028
Ctrl+V
DSS+V+W 7.33154927
0.001
0.0028
Ctrl+V
DSS+E+W
15.4220541
0.003
0.0056
Ctrl+E
DSS+V
4.58379519
0.006
0.0105
Ctrl+E
DSS+E
5.65522158
0.001
0.0028
Ctrl+E
DSS+V+L
3.79275075
0.012 0.01768421
Ctrl+E
DSS+E+L
9.65103133
0.002 0.00430769
Ctrl+E
DSS+V+W 5.25031447
0.001
0.0028
Ctrl+E
DSS+E+W
10.2677725
0.001
0.0028
DSS+V
DSS+E
1.70381303
0.125
0.14
DSS+V
DSS+V+L
0.7168567
0.556
0.556
DSS+V
DSS+E+L
4.94793215
0.009 0.01482353
DSS+V
DSS+V+W 2.05708161
0.06
0.08
DSS+V
DSS+E+W
7.18746828
0.001
0.0028
DSS+E
DSS+V+L
2.97536786
0.019
0.0266
DSS+E
DSS+E+L
1.34893144
0.219 0.23584615
DSS+E
DSS+V+W 3.35594319
0.012 0.01768421
DSS+E
DSS+E+W
2.32037951
0.085 0.10818182
DSS+V+L DSS+E+L
6.5408668
0.003
0.0056
DSS+V+L DSS+V+W 1.86027851
0.105
0.1225
DSS+V+L DSS+E+W
9.4881251
0.001
0.0028
DSS+E+L
DSS+V+W 6.02937922
0.001
0.0028
DSS+E+L
DSS+E+W
1.88168896
0.091 0.11078261
DSS+E+W DSS+V+W 8.83009182
0.002 0.00430769
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Table 8: Unweighted UniFrac Significance by PERMANOVA with Benjamini-Hochberg Correction

Group 1

Group 2

pseudo-F

p-value

q-value

Ctrl+V

Ctrl+E

0.67353202

0.754

0.754

Ctrl+V

DSS+V

6.180945

0.001

0.00254545

Ctrl+V

DSS+E

5.68654357

0.001

0.00254545

Ctrl+V

DSS+V+L

5.86499438

0.002

0.00373333

Ctrl+V

DSS+E+L

5.40726477

0.001

0.00254545

Ctrl+V

DSS+V+W

5.69089887

0.001

0.00254545

Ctrl+V

DSS+E+W

4.59543277

0.001

0.00254545

Ctrl+E

DSS+V

5.13493122

0.001

0.00254545

Ctrl+E

DSS+E

4.75869829

0.002

0.00373333

Ctrl+E

DSS+V+L

4.73661691

0.002

0.00373333

Ctrl+E

DSS+E+L

4.35830195

0.001

0.00254545

Ctrl+E

DSS+V+W

4.77868705

0.001

0.00254545

Ctrl+E

DSS+E+W

3.792031

0.001

0.00254545

DSS+V

DSS+E

1.30654212

0.122

0.12651852

DSS+V

DSS+V+L

1.45674726

0.047

0.06266667

DSS+V

DSS+E+L

1.33988359

0.064

0.07791304

DSS+V

DSS+V+W

1.72898591

0.002

0.00373333

DSS+V

DSS+E+W

1.91200777

0.062

0.07791304

DSS+E

DSS+V+L

2.0091022

0.001

0.00254545

DSS+E

DSS+E+L

1.29902295

0.074

0.08633333

DSS+E

DSS+V+W

1.61228206

0.033

0.04863158

DSS+E

DSS+E+W

1.77111506

0.086

0.09632

DSS+V+L

DSS+E+L

1.78340984

0.001

0.00254545

DSS+V+L

DSS+V+W

1.85143848

0.003

0.00494118

DSS+V+L

DSS+E+W

2.39889417

0.003

0.00494118

DSS+E+L

DSS+V+W

1.61696638

0.009

0.014

DSS+E+L

DSS+E+W

1.47426941

0.099

0.10661538

DSS+V+W

DSS+E+W

1.98833174

0.043

0.0602
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Figure 17. Combined DSS and Ethanol Administration Alters Bacterial Populations
at the Phylum Level. (A) Summary of phylum level changes. (B) Proteobacteria. (C)
Firmicutes. (D) Bacteroidetes. (E) Verrucomicrobia. Values are mean ± SEM. * p<0.05
by One-Way ANOVA with Tukey post-hoc test. n= 6-8 per group.

80
a single cage, while the other four with the lowest levels of Verrucomicrobia were housed in a
separate cage. Meanwhile, we can see that for the DSS+vehicle+tungstate mice, there are four
animals with slight increases of the Verrucomicrobia, these four mice were also housed in a
single cage. The primary constituents of the Verrucomicrobia in these mice was Akkermansia
muciniphila (determined by sequencing and qPCR, data not shown), which can be increased in a
number of inflammatory settings, with studies identifying roles that are pathogenic(253) and
beneficial(254). Examination of day 0 fecal pellets for A. muciniphila revealed little observable
difference in the presence of this bacteria in the mice from the various experimental groups (data
not shown), although studies have noted that the fecal pellet is not the best representative sample
of the intestinal microbiome(255-257). Furthermore, we do not anticipate that these changes in
A. muciniphila are due to differences in cecal content sampling since the bacterial load of A.
muciniphila is roughly consistent on a cage to cage basis.
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Figure 18. Summary of Family Level Bacterial Changes. n=6-8 per group.
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Analysis of the microbial constituents at the family level provided more detailed changes
between the various experimental groups (Figure 18). The results seen for the
Enterobacteriaceae (Figure 19A) and Lactobacillaceae (Figure 19B) mimic those previously
observed in Figure 4A and Figure 4B, respectively. Changes were also observed in the
Ruminococcaceae (Figure 19C) and Lachnospiraceae (Figure 19D) families of bacteria, which
include a large proportion of bacteria capable of producing butyrate(127). Compared to the
Control groups, DSS administration groups appeared to increase populations of
Ruminococcaceae while decreasing Lachnospiraceae. Adding together the reads for the
Lachnospiraceae and Ruminococcaceae (Figure 19E) displayed an overall decrease in these
bacteria after DSS administration in comparison to controls which is more pronounced in the
combination of DSS+ethanol, irrespective of L-NIL and Tungstate treatment. Another family of
bacteria that we observed to change was that of the Bacteroideaceae (Figure 19F), which, when
compared to the Control groups, were increased in all the DSS+vehicle groups and significantly
increased in all the DSS+ethanol groups. Coinfection of Bacteroideaceae and Enterobacteriaceae
is a common finding in patients with perforated appendicitis(258), meanwhile numerous studies
have identified that bacteria within these 2 families, chiefly the Bacteroides and Escherichia,
exhibit synergistic growth which can potentiate disease(259). Furthermore, Bacteroides and
Escherichia are commonly found in the intestinal mucosa of patients with IBD(260, 261).
Knowing this, we examined the relationship of Enterobacteriaceae and Bacteroideaceae using
linear regression and found pronounced correlations of the two bacteria in all DSS receiving
groups, except the DSS+V+W (Figure 20). Furthermore, the slope of the line for the
DSS+ethanol mice was nearly equal to 1, indicating that in the setting of DSS+ethanol increases
in Enterobacteriaceae are met with equal increases in Bacteroidaceae.
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Figure 19. Combined DSS and Ethanol Administration Alters Bacterial
Populations at the Family Level. (A) Enterobacteriaceae. (B) Lactobacillaceae.
(C) Ruminococcaceae. (D) Lachnospiraceae. (E) Lachnospiraceae+
Ruminococcaceae. (F) Bacteroidaceae. Values are mean ± SEM. * p<0.05 by OneWay ANOVA with Tukey post-hoc test.
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The observed results of the Enterobacteriaceae and Lactobacillaceae from the sequencing data
were confirmed using qPCR of the Enterobacteriaceae and Lactobacillus (the underlying genus
of the Lactobacillaceae family; Figure 21). The results of this qPCR were very similar to that
seen in the sequencing data as well as our prior experiment (Figure 4).
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To define significant bacterial changes between experimental groups we used the linear
discriminant analysis Effect Size (LEfSe) method(262). After collapsing the sequencing data to
the to the family taxonomic level and performing the LEfSe method, we observe that each
experimental group exhibits some significant increase in particular bacteria (Figure 22).
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Figure 22. Each Experimental Group Exhibits Differentially Expressed Bacteria at
the Family Level Identified using the LEfSe Method.
The Enterobacteriaceae are significantly increased in the DSS+ethanol group, meanwhile
Lactobacillaceae are most abundant in the control+vehicle group, which has been suggested by
our prior results. The output of the LEfSe was then plotted on a cladogram, allowing for
visualization of the different bacterial changes for each experimental group relative to the
taxonomic level (Figure 23). The center of this graph represents the highest taxonomic level, the
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kingdom, which in this case is bacteria. Moving outward from the center of the graph to the first
ring, we observe nine nodes, which represent the nine phyla in our analysis. These nodes then
branch to give rise to the class, and so on until we reach the outermost set of circles which
represent the family taxonomic level. We can observe that while some experimental groups are
enriched in bacteria from the phylum level down to family level, such as the Actinobacteria to
the Coriobacteriales in the control+vehicle group. In other cases, for example the Firmicutes
phylum is primarily enriched in the control+vehicle mice, however, examination of the family
level reveals differential enrichment in of these bacteria in other experimental groups, such as the
Peptococcaceae in the DSS+ethanol.

Figure 23. Cladogram of Differentially Expressed Bacteria at the Family Level
Identified using the LEfSe method. The presence of an experimental group color at
one of the taxonomic levels indicates that at the bacteria within that taxonomic level are
enriched in that particular experimental group.
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Nos2 Expression Decrease Associated with Exacerbated Weight Loss.
Upon seeing that the L-NIL and tungstate treatments induced a decrease in the
Enterobacteriaceae when administered with DSS+vehicle but not with DSS+ethanol, we
examined RNA expression of Nos2 in the large IECs of these mice. We found that Nos2
expression was increased in all the DSS experimental groups, but unlike the changes seen prior
in Figure 10B, we did not observe that the DSS+E mice had increased levels of Nos2, compared
to the DSS+vehicle mice (Figure 24A). We also examined Nos2 expression within the cecum
and found that while all mice receiving DSS had increased Nos2 cecal expression, there were no
significant differences (Figure 24B). One possibility which may have limited the ability to
identify the change in Nos2, could be related to the severity of the colitis in this experiment,
which was increased relative to our previous published experiment(224), as assessed by the day
7% weight change, colon length, and colon combined histopathology score (Figure 25).
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Figure 24. IEC and Cecum Nos2 RNA Expression Not Different Between DSS
Groups. (A) IEC RNA expression of Nos2. (B) Cecum RNA expression of Nos2. n=4
Values are mean ± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test.
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Figure 25. Increased Weight Loss Observed in DSS+ethanol Groups. (A) Day 7%
weight change. (B) Colon length. (C) Combined histopathology score. Values are mean
± SEM. * p<0.05 by One-Way ANOVA with Tukey post-hoc test. (D). Linear
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We compared experiments in which we assessed Nos2 IEC expression and found that in the
setting of increasing weight loss, alcohol administration led to decreased Nos2 expression
(Figure 26). In comparing all the data points for Nos2 IEC expression and day 7 % weight loss
from DSS mice on a scatter plot followed by a linear regression, we can that a slight correlation
exists between weight loss and Nos2 expression, where mice with less weight loss have
increased Nos2 expression (Figure 26B). There appeared to be threshold of around 10% weight
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Figure 26. Passing a Weight Loss Threshold Leads to Decreased Expression of Nos2
Rather than Increased Expression of Nos2. (A) Composite of different experiments in
which either IECs were assessed for Nos2 RNA expression or swiss rolls were used for
Nos2 immunostaining. Different groups of experiments are separated by vertical dashed
line. For fold change determination, all control+vehicle sample Nos2 values were pooled
together from which was then used the determination of Nos2 fold change. Select
experiemnts that were used as data are delineated. Nos2 Blot, Nos2 qPCR: Figure 10;
Nos2 Swiss Roll staining: Figure 11. Values are mean ± SEM. (B) Scatter plot of day 7%
weight change and Nos2 fold change expression for data presented in (A), with linear
regression. (C) Scatter plot examining IEC Nos2 expression when weight loss is less than
10% with linear regression line. (D) Scatter plot examining IEC Nos2 expression when
weight loss is greater than 10% with linear regression line. n=62.
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loss where the directionality shifts. Mice that received DSS and had less than 10% weight loss
had increased expression of Nos2 (Figure 26C), however, weight loss greater than 10% leads to
decreased expression of Nos2 (Figure 26D). Further corroborating this effect, the mice from
which the intestinal swiss rolls were produced, exhibited a more moderate weight loss, which
coincided with the pronounced increase in Nos2 epithelial staining from that experiment (Figure
11).
To further determine the role of nitrates in the expansion of the Enterobacteriaceae during
combined DSS and ethanol administration, we gavaged mice with equal amounts of E. coli that
were either nitrate reductase proficient (WT) or deficient (DNR) and assessed their growth
relative to each other (competitive index). This experiment was first attempted with Charles
River mice, which contain endogenous Enterobacteriaceae(127), and we did not observe any
viable E. coli (data not shown). The experiment was repeated with Jackson Laboratories mice,
which do not harbor any endogenous Enterobacteriaceae(127), and we observed viable E. coli on
day 5 and 6 (Figure 27). On day 7 samples began to no longer exhibit viable E. coli and thus this
day was excluded from analysis. On day 5, prior to the gavage of either vehicle or ethanol a
slight competitive advantage appeared to be conferred to the WT bacteria (Figure 27A). On day
6, the competitive advantage increased for the WT bacteria but no significant difference was
observed between the DSS+vehicle and DSS+ethanol mice, each of which had received a single
gavage at this time point when fecal pellets were collected (Figure 27A). In examining the
samples individually, one from the DSS+vehicle and one from the DSS+ethanol appeared to be
outliers (shown in dashed lines in Figure 27B). With these outliers removed, the increase in the
competitive index in the DSS+ethanol group from day 5 to day 6 trended toward significance,
while no change was observed in DSS+vehicle (Figure Figure 27C, D). In addition, no
significant change was observed in the competitive index on day 5 or day 6 between the
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DSS+vehicle and DSS+ethanol, though there was a slight increase in the competitive index for
DSS+ethanol on day 6 compared to DSS+vehicle (Figure 27C).
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To further elucidate the effects of nitrate production and nitrate utilization in our model,
we combined both L-NIL and tungstate treatment with either DSS+vehicle or DSS+ethanol.
Between these two groups, Enterobacteriaceae were unchanged (Figure 28A) while a significant
decrease in Lactobacillus was observed (Figure 28B). A slight decrease in the
Lactobacillus:Enterobacteriaceae ratio was observed in the mice receiving the ethanol gavage,
however, it was not significant (Figure 28C).
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DSS Severely Disrupts Cecal Content SCFAs with Differential Effects Mediated by
DSS+ethanol.
Bacterial metabolites, particularly the SCFAs, play an important role in the health of the
intestine. Prior work has demonstrated the intestinal SCFAs are depleted and intestinal pH is
disturbed in IBD patients, while alcohol administration in a mouse model has been demonstrated
to increase intestinal pH(191). Therefore, we examined levels of the cecal contents SCFAs acetic
acid, propionic acid, and butyric acid (Figure 29). We observe a significant decrease in the total
SCFAs concentration after DSS administration (Figure 29A). Individual examination of each
SCFA respective to the experimental groups revealed a similar trend where each individual
SCFA is decreased after DSS (Figure 29B). In the healthy intestine, acetic acid, propionic acid,
and butyric acid, exist in ratio of 60:20:20. The ratio of acetic acid in cecal contents
progressively increases from control+vehicle to DSS+ethanol (Figure 29C). Relative to
control+vehicle and DSS+vehicle, ethanol administration in control and DSS reduced the ratio of
propionic acid, although this result was only significant for the control+ethanol group. The ratio
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of butyric acid was significantly decreased in the DSS groups relative to the control groups. The
observed increase in the ratio of acetic acid for the mice that received ethanol gavage may be
related to the presence of alcohol and/or acetaldehyde in the cecum, which are eventually
metabolized to acetic acid. Interestingly, DSS administration with vehicle gavage is able to
induce an increase in the ratio of acetic acid compared to the control+vehicle and
control+ethanol, but only significantly increased with respect to control+vehicle. This suggests
that colitis itself induces altered metabolism of acetic acid, that becomes further perturbed by
ethanol. In addition, we observe that the blood alcohol content of mice receiving DSS and the
ethanol gavage, irrespective of the L-NIL or tungstate treatment, is increased relative to mice
simply receiving the ethanol gavage (Figure 29D). The increased circulating ethanol may play a
role in increasing cecal acetic acid by providing sustained amounts of ethanol to the intestine that
may be used a as substrate for eventual acetic acid production.
Summary
Overall, bacterial shifts are noted between each of the DSS groups and the control groups.
Inhibition of nitrate production by L-NIL and nitrate utilization by Tungstate, prevented the
overgrowth of Enterobacteriaceae in DSS+vehicle mice, but this effect was not observed in
DSS+ethanol mice. Ethanol administration after DSS appears to have a very strong effect on
alpha diversity evenness indicating that certain bacterial populations are being enriched. While
initially we observed Nos2 expression to be increased in the combination of alcohol and colitis
relative to colitis alone, this did not appear to be the case in the this set of experiments, likely due
to an enhanced weight loss response in these mice. This exacerbated body weight may allow for
sustained LPS signaling within the intestinal epithelium. Examination of tolerance induction
pathways in the IECs between the DSS+vehicle and DSS+ethanol in this experiment and
experiments where weight loss was not as severe may further elucidate the observed changes in
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IEC Nos2 expression. Nitrate reductase proficiency appeared to confer a slight competitive
advantage in mice experiencing colitis that was slightly improved with ethanol administration.
Simultaneous inhibition of both nitrate production and nitrate utilization abrogated the effects of
ethanol on increasing Enterobacteriaceae growth but Lactobacillus remained decreased. SCFAs
are severely dysregulated in DSS colitis. Ethanol administration appears to contribute to this
dysregulation by increasing the SCFA ratio of acetic acid. These results suggest that while nitrate
contributes to intestinal dysbiosis during colitis, ethanol may be inducing alternative pathways
promoting dysbiosis.

CHAPTER SEVEN
ALCOHOL ATTEUNATES LIVER INFLAMMATION IN SETTING OF COLITIS
Abstract
The portal venous system carries deoxygenated blood from the intestine to the liver.
Therefore, the liver becomes the point of first contact for any translocated bacteria, bacterial
components, or bacterial metabolites. Using our mouse model of alcohol and colitis, we
examined the inflammatory markers and inflammatory signaling pathways in the liver. High
power magnification of H&E stained sections, revealed a significant increase in mononuclear
cell counts in liver samples from DSS+ethanol compared to all other groups (p<0.05). Between
control+ethanol and DSS+vehicle livers, mononuclear cell numbers were unchanged, but both
groups exhibited significant increases in mononuclear cells compared to control+vehicle livers.
RNA expression of CXCL1 in DSS+ethanol livers was significantly increased (27-fold)
compared to control+vehicle and control+ethanol livers. Interestingly, DSS+ethanol CXCL1
liver expression was significantly lower (2-fold) compared to DSS+vehicle livers. The liver
RNA expression results of CXCL1 mirrored those at the protein level. Similar results were
obtained for other inflammatory or inflammatory signaling molecules, except for Lipocalin-2
(Lcn2). Liver RNA expression of Lcn2 was significantly increased in DSS mice groups
compared to the control mice, but no difference was observed between DSS+vehicle and
DSS+ethanol. Western blot analysis of DSS+vehicle liver homogenates revealed increased
NFkB and STAT1 phosphorylation, while their phosphorylation was undetectable in
DSS+ethanol liver homogenates. We examined the RNA expression of the inflammatory liver
markers 24 hours post gavage and found that, compared to three hours post gavage, there was no
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difference in expression between the DSS+vehicle and DSS+ethanol. These findings suggest that
while there is an increase in liver mononuclear cells in DSS+ethanol mice, their ability to
produce inflammatory mediators is compromised shortly after the gavage, due to either direct or
indirect effects of ethanol.
Introduction
The portal vein accounts for approximately 75% of the total blood flow into the liver with
the mesenteric veins of the gastrointestinal tract being one of its primary tributaries(263). All the
nutrients ingested by an organism will eventually flow into this system and become filtered by
the sinusoids of the liver. To this end, the liver will also be the first point of contact for any
translocated bacteria and their products. Within the sinusoids, resident macrophages, known as
Kupffer cells, continuously sample the blood and are poised to initiate a primary inflammatory
response should they encounter a translocated bacterial organism or its component(264). LPS is
the most well studied and understood bacterial component in this respect.
Increased circulating LPS is a common finding in IBD patients(265). IBD patients also
experience increased liver enlargement and steatosis(266). Altered liver enzymes have been
noted in IBD patients as well, though they have not been directly linked with IBD disease
activity(267). Furthermore, IBD patients are also particularly susceptible to development of
primary sclerosing cholangitis, a disease that leads to fibrosis of the bile ducts(268, 269). These
liver changes observed in IBD may partially result from the persistent circulating LPS in the
host.
Increases in circulating LPS can also be induced with alcohol consumption, acute and
chronic(188, 270). Meanwhile, various studies have shown that the co-administration of
antibiotics during alcohol consumption can attenuate the liver inflammatory response induced by
endotoxin, (214, 270, 271). In addition, since alcohol is primarily metabolized within the liver,
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we anticipated that this added stressor may exacerbate a liver inflammatory response in our
mouse model of colitis.
In our mouse model of colitis, we assessed the liver inflammatory status. We observed a
decreased inflammatory response in the livers of mice receiving DSS+ethanol compared to
DSS+vehicle, that coincided with decreased activation of pro-inflammatory transcription factors.
Therefore, the livers of DSS+ethanol mice exhibited a tolerant phenotype. RNA expression of
inflammatory genes after a one day recovery from the ethanol or vehicle gavage, were not
significantly different, indicating a temporal role for alcohol induced liver tolerance in our
model.
Materials and Methods
Mouse Model of Alcohol and DSS-induced Colitis.
Male 8-9 week old (∼23–25 g body weight) C57BL/6 mice were obtained from Charles
River Laboratories (Wilmington, MA). The mouse model used in this study was previously
described(224). Briefly, mice were randomly assigned to four experimental groups:
Control+Vehicle (Ctrl+V), Control+Ethanol (Ctrl+E), Dextran sodium sulfate+Vehicle
(DSS+V), Dextran sodium sulfate+Ethanol (DSS+E). As seen in Figure 2, mice were
administered either normal drinking water or a 2% (w/v) solution of DSS (36,000-50,000
molecular weight; MP Biomedicals) ad libitum, starting on day 0 and until day 5. On day 5, DSS
was stopped and mice received a gavage of either 3g/kg ethanol or water per day until day 7.
Mice were euthanized three hours after the last gavage. Mice were weighed each day to
determine percent weight change relative to day 0. After euthanasia livers were removed, a
portion cut and embedded in optimal cutting temperature media for frozen sectioning and the
remainder stored at -80° C until processed.
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For the one day recovery experiment, a similar setup was used as in Figure 2, except that
instead of sacrificing mice on day seven, mice were allowed to recover from ethanol gavage and
sacrificed on day eight. Only two groups were generated: DSS+Vehicle+1 Day (DSS+V+1) and
DSS+Ethanol+1 Day (DSS+E+1). After euthanasia livers were removed and stored at -80° C
until processed.
Liver Histology and Oil Red O Staining.
Livers were fixed in 10% neutral buffered formalin and submitted to AML labs
(Jacksonville, FL) for processing, embedding, and H&E staining. For mononuclear cell
quantification of H&E stained liver slides, a single area at 400x was counted by a blinded
technician.
Livers embedded in optimal cutting temperature media were cut into 5 um sections in a
cryostat. Followed by staining at Sections were stained with Oil Red O at the Loyola Histology
Core.
Liver RNA Expression.
RNA was isolated from liver using the RNeasy Mini Kit (Qiagen) according to
manufacturer’s guidelines. The RNase-free-DNase Set (Qiagen) was used in conjunction with
the RNA isolation kit to remove genomic DNA. RNA was quantified using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and run on a Veriti 96-well Fast
Thermocycler (Life Technologies).
Expression of targets was assessed by qPCR using TaqMan primer probes and TaqMan
Fast Advanced Master Mix (Thermo Fisher Scientific). Reactions were performed on a Step One
Plus qPCR instrument (Applied Biosystems). Endogenous controls for the targets are as listed on
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the y-axis of the figure. Targets were assessed using the 2^(-ΔCt) method and expressed as fold
change relative to Control+vehicle.
Liver Enzyme Linked Immunosorbent Assay.
CXCL1 ELISA (R&D Systems) of liver homogenates was performed according to
manufacturer’s instructions.
Liver Western Blot.
Thirty mg of liver were homogenized in 1x Cell Lysis Buffer (Cell Signaling Technologies)
supplemented with 1x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific).
Protein was quantified using the DC Protein Assay (Bio-Rad). Protein was separated using SDSPAGE using Bolt Bis-Tris gels (Thermo Fisher Scientific) and then transferred to a PVDF Membrane
using a wet transfer method. Membrane was blocked with milk, washed with TBS, then incubated
overnight with respective antibodies (pNFkB, Cell Signaling Technologies; NFkB Cell Signaling
Technologies; pSTAT1 Abcam; STAT1 Abcam; β-actin Cell Signaling Technologies). After washing
with TBST, the membrane was incubated with HRP-linked secondary antibody (Cell Signaling
Technology) and developed using Western Lightning Plus-ECL, Enhanced Chemiluminescence
Substrate (Perkin Elmer). Membrane was imaged on a ChemiDoc (Bio-Rad) and densitometry
analysis performed using ImageLab software (Bio-Rad). Afterwards the blot was stripped using
Restore Plus Stripping Buffer (Thermo Fisher Scientific) and then reprobed with a different antibody.
Densitometry analysis examined the ratio of the specific phosphorylated protein to the total
unphosphorylated protein.
Statistics: One way ANOVA followed by Tukey post-hoc test was used for significance
analysis using GraphPad Prism software (Version 8.1.2). For densitometric analysis between the
DSS+vehicle and the DSS+ethanol, a student’s t-test was performed.
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Results
Increased Liver Mononuclear Cells and Lipid Deposition in Livers of DSS+ethanol Mice.
Bacteria and bacterial products that translocate from the colon, enter into the mesenteric
circulation and eventually arrive in the liver. Within the liver these translocated elements can
induce inflammation and accumulation of inflammatory cells. To assess liver inflammation in
our model, we counted the number of mononuclear cells located around the central vein of H&E
stained liver sections (Figure 30A). The mean number of mononuclear cells in control+vehicle
was significantly increased compared to control+ethanol, DSS+vehicle, and DSS+ethanol
(Figure 30C). No difference in mononuclear cell number was observed between control+ethanol
and DSS+vehicle, however, DSS+ethanol did exhibit a significant increase compared to these
two groups. These data suggest that when administered separately, ethanol and DSS induce
similar mononuclear cell recruitment to the liver, but the combination of ethanol and DSS
induces an additive effect to enhance the recruitment of mononuclear cells to the liver.
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Accumulation of lipids within the liver is a marker of metabolic dysfunction and can be a
consequence of alcohol consumption. We examined liver fatty deposition using Oil Red O with
representative images shown in Figure 31. Overall, we observed that the livers of mice receiving
DSS exhibited increased lipid accumulation with livers from the DSS+ethanol mice having more
diffuse fat accumulation along with slightly larger droplets. These results indicate that while DSS
induces liver lipid deposition, the combination of DSS and ethanol further increases that effect.

Ctrl+V
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Figure 31. Increased Lipid Deposition in DSS+ethanol Livers. Oil Red O stain of
frozen liver sections. Taken at 400x total magnification. Representative images of n=6-8
per group
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DSS+ethanol Livers Display Decreased Inflammatory Gene Expression.
To assess liver inflammation, we examined liver RNA expression of various
inflammatory markers. We observed that the DSS+vehicle livers had consistent significant
increases of chemokine (CXC) ligand 1 (CXCL1), tumor necrosis factor alpha, toll-like receptor
4 (TLR4), and S100 calcium binding protein A9 (S100A9) compared to the liver of control as
well as DSS+ethanol (Figure 32A-D). The liver RNA expression of these genes in the
DSS+ethanol group were always significantly lower than the DSS+vehicle group, while also
often being significantly higher than the control groups. The RNA expression results of CXCL1
were found to be consistent at the protein level as determined by ELISA (Figure 32E). This
trend, however, did not persist for Lcn2, which instead was observed to be increased to the same
degree in both DSS+vehicle and DSS+ethanol (Figure 32F). Upon observing these differential
effects, we sought to assess whether these changes were associated with changes in activation of
proinflammatory pathways.
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DSS+ethanol Livers Display Decreased Activation of Proinflammatory Transcription
Factors.
Liver homogenates were assessed for activation of pNFkB and STAT1. Control+vehicle
had no detectable phosphorylated NFkB, while a strong increase in NFkB phosphorylation was
observed in control+ethanol (Figure 33A). This effect is likely a result of increased endotoxin
leakage from the intestine reaching the liver. All DSS+vehicle livers, exhibited phosphorylated
NFkB, meanwhile livers from DSS+ethanol displayed essentially no phosphorylated NFkB. This
result was significant by densitometric analysis (p<0.05; Figure 33A). The STAT1
phosphorylation changes mirrored those for NFKB, except that for the control+ethanol livers, we
did not observe STAT1 phosphorylation (Figure 33B). STAT1 phosphorylation in DSS+vehicle
was significantly increased relative to DSS+ethanol as determined by densitometry (p<0.05;
Figure 33B).

C

Total NFkB

pSTAT1

β-ACTIN

Total STAT1

+E

DSS+V

DSS+E

0.4

1.5

*

1.0
0.5

pSTAT1 / Total STAT1

2.0

*

0.3
0.2
0.1

SS
+E
D

E

SS
+V
D

C
trl
+

+E

E

+V

D
SS

D
SS

V

C
trl
+

C
trl
+

V

0.0

0.0

C
trl
+

pNFkB / Total NFkB

trl

+V

DSS+E

trl

DSS+V

pNFkB

C

+E

B

C
trl

C
trl

+V

A

Figure 33. Decreased Phosphorylation of Transcription Factors in DSS+ethanol Livers.
(A) Western blot of liver homogenates for pNFkB, NFkB, and b-actin. Underneath is a
densitometry plot of pNFkB/Total NFkB. (B) Western blot of liver homogenates for pSTAT1
and STAT1. Underneath is a densitometry plot of pSTAT1/Total STAT1.Values are mean ±
SEM. * p<0.05 using Student’s t-test examining DSS+vehicle vs DSS+ethanol.
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These liver expression and activated transcription factor changes observed between the
DSS+vehicle and DSS+ethanol resemble the phenomena of tolerance, wherein the normal
response of a cell to a stimulus becomes downregulated after continuous stimulation(272).
Although some genes, such as Lcn2, are characterized as non-tolerizeable, wherein expression is
sustained or even increased in situations where a cell/organism exhibits an overall picture of
tolerance(273). To assess this, we explored the ability of the DSS+ethanol liver to recover
expression of these inflammatory genes.
DSS+ethanol Liver Inflammatory Gene Expression Returns to DSS+vehicle Levels
24 Hours After Last Gavage.
After the final gavage of vehicle or ethanol on day seven, mice were allowed an
additional day to recover and sacrificed on day eight of the experiment. We observed that unlike
before, TLR4 and S100A9 were expressed to the same degree in the DSS+ethanol livers
compared to DSS+vehicle livers (Figure 34). Lcn2 was unchanged between the two groups.
These data seem to indicate that ethanol is playing some role in the mechanism of tolerance that
we are observing.
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Summary
In our model, we found that livers from DSS+vehicle mice had increased inflammatory
gene expression and activation of pro-inflammatory transcription factors, compared to the livers
from the DSS+vehicle mice. In the livers of the DSS-+ethanol mice, inflammatory gene
expression was greater than the control groups but decreased relative to DSS+vehicle.
Meanwhile, the phosphorylation of the pro-inflammatory transcription factors was entirely
absent in the livers of the DSS+ethanol mice. These results seem to suggest that the livers of the
DSS+ethanol mice are exhibiting an endotoxin-tolerant phenotype. When sacrificing the mice at
24 hours after gavage, instead of three hours of gavage, there appeared to be a recovery of the
inflammatory response in the DSS+ethanol. Further examination of the phosphorylation of
transcription factors at 24 hours might reveal more information regarding this phenotype. In
addition, identification of the cell type mediating this response would be of interest. These
findings suggest that while there is an increase in liver mononuclear cells in DSS+ethanol mice,
their ability to produce inflammatory mediators is severely compromised in the setting of colitis
followed by ethanol administration.

CHAPTER EIGHT
DISCUSSION
Contributions to the Field
The overall aims of this work were to first identify from a clinical perspective whether
there are any defined effects of alcohol consumption in the setting of IBD and then determine
how alcohol produces these effects in a mouse model. The intersection of IBD and alcohol use
has been addressed sparingly in the field, despite the plethora of commonalities that encompass
these two topics. These include effects on the intestinal microbiome, the intestinal epithelium, as
well as effects on the liver.
Using a patient database analysis, we determined that patients admitted to a hospital for
IBD with a documented history of alcohol use, had increased intestinal infections and required
more antibiotic injections than patients admitted for IBD without a documented history of
alcohol use. Based on these findings we suspected that alcohol use might further alter the
intestinal microbiome in IBD, increasing the susceptibility to these infections and therefore
necessitating antibiotic administration. We explored these potential microbial changes using a
mouse model of colitis in combination with ethanol administration, where ethanol exacerbates
the flare period of colitis.
We observed that the combined colitis and ethanol administration increased the proinflammatory bacteria, Enterobacteriaceae, and decreased the beneficial bacteria, Lactobacillus,
compared to colitis alone (Figure 35). These changes were associated with increased expression
of Nos2, which can lead to nitrate production, a favorable energy source for Enterobacteriaceae.
Blockade of either nitrate production via Nos2 inhibition or bacterial utilization of nitrate,
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prevented the overgrowth of Enterobacteriaceae during colitis but when ethanol was coadministered, Enterobacteriaceae growth was only slightly blunted. Furthermore, 16S sequencing
identified large changes in the microbiome when ethanol is administered during colitis compared
to colitis alone. These results suggested that ethanol in the setting of colitis may be potentiating
the growth of the Enterobacteriaceae via other routes. We also identified that the combined
administration of ethanol and colitis altered liver inflammatory pathways compared to the colitis
alone, indicating that this model elicits systemic effects not constrained to the intestine.
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Figure 35. Summary Figure of Effects from Combined Ethanol and Colitis
Administration. The effect of ethanol in the setting of colitis contributes to intestinal
bacterial changes. Nos2 appears to play some role in the changes of the
Enterobacteriaceae, while ethanol also contributes to decreases in Lactobacillus,
decreased bacterial diversity, and an altered SCFA ratio. These changes with addition of
ethanol ability to induce intestinal leakiness, may likely contribute to the profile of
endotoxin tolerance observed in the livers of mice receiving both the colitis and ethanol
gavage.
Taken together, we have identified ethanol as likely factor in affecting the disease process
of colitis through ethanol’s effects on the intestinal microbiome. This understanding contributes
to the pressing need to better understand the effects of ethanol in IBD while also providing
targetable pathways to prevent colitis flare or limit its severity.
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Patient Database Analysis Implicates Negative Effects of Alcohol Use in IBD
Research has shown that IBD patients and alcoholic patients carry an intestinal bacterial
dysbiosis(116, 192). A dysbiosis is believed to provide pathogens an opportunity to colonize and
proliferate(274). Indeed, studies have shown IBD patients and alcoholics are at risk for increased
infections(275, 276). Thus, we anticipated that the combination of alcohol use in a patient with
IBD would likely further increase intestinal infections, which is exactly what we observe in our
patient database analysis (Table 6). Furthermore, the patients with a documented history of
alcohol use (+A) required increased antibiotic injections as well as increased diagnostic
procedures. Despite these increases, the patients with a documented history of alcohol use (+A)
had decreased total costs compared to patients without a documented history of alcohol use (-A).
This can likely be explained by the decrease in surgical procedures (colectomy and small
intestine resection) observed in the patients with a documented history of alcohol use (+A)
patients. These patients might be less than ideal candidates for surgery, which is often more
expensive. In addition, while the median length of stay was unchanged between the patients
without a documented history of alcohol use (-A) and those that exhibited a documented history
of alcohol use (+A), the IQR for the length of stay was increased for the patients which did not
have a history of documented alcohol use (-A), which may also be related to the increase in
surgical procedures since surgical patients require longer hospitalization periods post-surgery.
How this decrease in surgical interventions affects the clinical course of IBD patients with
alcohol use remains to be further elucidated.
We would like to note that to be coded for an ICD-9 diagnosis for an alcohol related
disorder, the patient must have had some history of significant alcohol intake, thus our +A study
group likely comprises mostly heavy drinkers. Unfortunately, the databases do not contain
information regarding the amount of alcohol a patient had prior to an admission. Furthermore,
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the databases do not contain the exact cause of the IBD admission, thus we cannot discern
whether a patient was admitted for a flare or other complication of IBD. Therefore, the findings
of this analysis warrant additional research of IBD patients that could provide more detailed
information beyond what is available through ICD-9 codes. Overall, the results of our patient
database analysis further support the suggestion that alcohol has some negative impacts on the
clinical outcomes of patients with IBD(177).
An interesting hypothesis exists wherein the development of IBD and other
gastrointestinal disorders is attributed to the westernization of our diet, which no longer provides
the dietary fibers and nutrients that the healthy gut bacteria rely on for survival(277). Therefore,
the bacteria that that our intestines have evolved with over the centuries begins to decrease. This
leads to decreased production of beneficial bacterial metabolites for the intestinal epithelium,
which then results in intestinal epithelial dysfunction. Thereafter, a vicious cycle can ensue
wherein the initial disruption of the intestinal microbiome is followed by intestinal inflammation,
which then promotes the persistence of the altered bacterial populations. As the rates of overall
alcohol use, binge drinking behavior, and alcohol use disorders continue to increase at staggering
rates within the United States(278), it’s possible that alcohol consumption may also contribute to
these intestinal changes and thus contribute in part to the disease process of IBD.
Enterobacteriaceae and Lactobacillus Changes After Ethanol and Colitis
In our model, we observed that while colitis induces increases in the Enterobacteriaceae
and decreases in Lactobacillus, this effect is exacerbated when ethanol is administered in the
setting of colitis. In addition, colon lengths, an assessment of intestinal inflammatory status, were
inversely and positively correlated with the abundance of Enterobacteriaceae and Lactoabcillus,
respectively. Minimal differences were observed in terms of tight junction and mucin staining
between the DSS+vehicle and DSS+ethanol groups. However, we anticipate that the increased
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abundance of Enterobacteriaceae, with their infiltrative capacity and endotoxin, are likely
participating in the exacerbated disease process of combined ethanol and colitis(224).
Furthermore, since Lactobacillus can limit Enterobacteriaceae growth (102-106) and beneficial
effects are often associated with Lactobacillus administration in various disease states(279), their
sharp decrease in DSS+ethanol may explain the further potentiation of the flare compared to
DSS+vehicle.
Previous studies have identified that IBD patients(115, 132) and individuals with alcohol
use(189, 190) both exhibit intestinal bacterial perturbations, with notable increases in
Enterobacteriaceae, and decreases in Lactoabcillus. Changes mirroring these have also been
identified in the oral microbiome of patients with ethanol use, specifically that alcohol
consumption decrease oral Lactoabcillus and increases Proteobacteria(196). Based on these
previous studies, we anticipated that the interaction of ethanol and colitis would exacerbate the
bacterial changes, which is exactly what we observed. The mechanism by which colitis and
ethanol contribute to this change may be related to the changes in the intestinal metabolites
which favor the growth of the Enterobacteriaceae over the Lactobacillus. These substrates
include oxygen, nitrate, formate, and trimethylamine-N-oxide (TMAO) (127, 242, 280). There
are also select strains of intestinally derived E. coli that oxidize ethanol to acetaldehyde under
conditions similar to that found within the intestine(205). Meanwhile the Lactobacillus primarily
utilize fermentative pathways to generate energy(281), although select strains have been shown
to use oxygen or have genetic components that may allow them to use oxygen(282). These
substrates available for Enterobacteriaceae use are much more energetically than those available
to the Lactobacillus(155).
Another possibility is that a colitis flare and ethanol lead to increased oxidative stress
within the intestine, which the Enterobacteriaceae are adapted to tolerate(149-153) while in
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general the Lactobacillus are limited in their capacity to withstand oxidative stress(283, 284).
Alcohol metabolism may contribute to this oxidative environment, via the cytochrome P450
2E1metaboclic pathway, which generates hydrogen peroxide(285) or via the production of
acetaldehyde, which can generate harmful adducts (207). Since the metabolism of alcohol to
acetaldehyde and then acetate increases the cellular pool of NADH by two molecules, cells that
metabolize ethanol have increased resources to apply towards oxidative metabolism, which can
increase reactive oxygen species generation(286). Importantly, the alteration in nutrients and
increased oxidative environment of the intestine during colitis flare are not mutually exclusive,
since an increased oxidative environment can also facilitate the production of substrates
favorable to Enterobacteriaceae growth.
Ethanol may also induce bacterial alterations via changes in intestinal pH. Maintenance
of intestinal pH is crucial for the optimization of SCFA production and the survival of bacteria
that produce the SCFAs(87, 109). One study identified a number of relevant changes in a mouse
model fed an alcohol diet. Shortly after beginning the alcohol diet, mice developed increased
fecal pH compared to pair-fed controls(191). The increase in fecal pH persisted until the
experiment ended at eight weeks. In addition, a subset of alcohol fed mice were given a daily
gavage of Lactobacillus rhamnosus GG which significantly reduced the fecal pH compared to
mice only receiving the alcohol diet. Furthermore, these fecal pH changes coincided with
relevant changes in the intestinal microbiome as assessed by sequencing. These changes included
increased abundance of Proteobacteria and decreased Lactobacillus in the alcohol fed group,
while the alcohol fed mice that also received L. rhamnosus GG had decreased Proteobacteria
and, as would be expected, increased Lactobacillus.
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Nos2 and Reactive Oxygen Enzyme Changes
Due to the observed increase in the Enterobacteriaceae from the DSS+ethanol group, we
anticipated that there must be some change in intestinal metabolites in our model. A prior study
using the model of DSS-induced colitis, found that nitrate was of particular importance to the
overgrowth of Enterobacteriaceae during colitis, with intestinally derived Nos2 being the major
contributor to this effect(242). Therefore, we explored the possibility that the administration of
ethanol in the setting of colitis may further potentiate the expression of Nos2.
Other studies have identified that ethanol has a potentiating effect on Nos2 activation and
production of nitric oxide by treating Caco-2 cells with ethanol(287). Meanwhile, in vivo studies
have demonstrated differential effects of ethanol on Nos2 expression and activation, some
showing a potentiating effect and others showing an inhibitory effect(288). Ethanol can also
interact directly the nitric oxide metabolite, peroxynitrite, yielding ethyl nitrite(289). Ethyl nitrite
exhibits a longer half-life than that of nitric oxide and also acts as nitric oxide donor(290).
Therefore, the ethyl nitrite may prolong the persistence of nitric oxide and the generation of
nitrate within the intestine.
In our model, we observed that post DSS, ethanol was able to increase Nos2 expression.
This expression was localized to the intestinal epithelium. We also observed upregulation of the
reactive oxygen producing enzyme Duox2 after DSS with no additional effect on expression
when ethanol was added. The end products generated by these enzymes are necessary precursors
to generate nitrate. Reactive oxygen can also be generated by other pathways, such as Nox
enzymes. We examined the most highly expressed Nox enzyme in the intestinal epithelium,
Nox1, and found no difference in expression between DSS administered mice and controls.
Another source of reactive oxygen could be the invading neutrophils and their expression of
Nox2, another Nox isoenzyme, however, we did not examine Nox2 expression in our model.

114
Although Nox1 expression was unchanged, examining the localization of the cytosolic subunits
(Noxa1 and Noxo1) would indicate whether some experimental groups exhibit more Nox1 activity
compared to others, since active Nox1 would have cytosolic subunits in close proximity(291). In
contrast to this Nos2, once expressed is constitutively active(230).
Inhibition of Nitrate Production and Utilization
Having observed the relationship between the increase in Enterobacteriaceae and Nos2
expression, we decided to inhibit Nos2 activity and nitrate utilization and examine its
downstream effects on Enterobacteriaceae in our model. We employed the specific Nos2
inhibitor, L-NIL, and the nitrate reductase inhibitor, tungstate. We observed as in previously
published studies that L-NIL and tungstate were able to reduce the overgrowth of
Enterobacteriaceae after colitis. However, when these treatments were applied to mice receiving
the ethanol post DSS, the inhibition of Enterobacteriaceae growth was no longer observed. One
explanation for this effect is that when L-NIL and tungstate are administered and the
Enterobacteriaceae can no longer use nitrates, their metabolism may shift to utilize an alternative
energy source since E. coli are flexible in their metabolism and can use a variety of substrates to
produce energy.
Select strains of intestinally derived E. coli can generate ATP via the conversion of
ethanol to acetaldehyde(205). However, the more commonly used E. coli metabolic pathway is
alcoholic fermentation, which involves the reverse reaction, converting acetaldehyde to
ethanol(292-294). The increased abundance of acetaldehyde within the large intestine after
alcohol consumption(203, 204), therefore may provide yet another source of energy yielding
substrates to the Enterobacteriaceae that would not be inhibited by administration of either of our
treatments. In addition, our experiments using the nitrate reductase deficient E. coli, suggest that
in either DSS+vehicle or DSS+ethanol, nitrate may not be as advantageous to growth, which is
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in contrast to other studies(242, 247). However, the observed decrease in colonization of these
mice gavaged with the WT or ΔNR might explain the limited changes observed in this
experiment. The decrease colonization may be due to the niche which the bacteria are trying to
fill, is already being occupied by another bacterium.
Another possibility for the persistence of Enterobacteriaceae in the mice receiving
DSS+ethanol despite the treatments, may be related to differential drinking of the water in the
mice. As the mice were co-housed, accurate measuring of volume intake per mouse was not a
possibility. Future experiments may consider single housing mice, which would have the added
benefit of limiting cage effects, using an intraperitoneal injection or an oral gavage of the
treatment, and the use of metabolic cages, which would also allow us to measure other elements
like food consumption and energy expenditure of the mice. We may also consider a different
treatment regimen that would allow longer treatment with L-NIL and tungstate prior to initiating
our experimental protocol. Lastly, effects of whether mice receive enough treatment can be
mitigated by using mice that are deficient for Nos2. Care would need to taken to select strains
that exhibit endogenous Enterobacteriaceae, or either ensure colonization of the Nos2 deficient
mice via other means.
However, upon examining the sequencing data results, we can observe that there are
appreciable differences between the three groups of DSS+ethanol, DSS+ethanol+L-NIL, and
DSS+ethanol+tungstate. Trends for significance can be observed in the weighted and
unweighted UniFrac analysis. These trends persist even between the DSS+ethanol+L-NIL and
DSS+ethanol+tungstate, suggesting that in each of these groups the different treatments are
inducing differential effects on the bacterial populations. Further confirmation of this can be
observed when examining the results of the LefSe, which identifies differentially abundant
bacteria in each of the three groups.
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The observed decrease in Nos2 in the L-NIL and tungstate treatments may be related to
the severity of the colitis as determined by the weight loss observed in these experiments
compared to that observed in prior experiments (Figure 6.14). This severity of the colitis in our
model can also be observed by the histopathology score, which is much higher than in our
previous publication(224). The mechanism for the observed decrease in Nos2 could be due to an
overabundance of LPS signaling, inducing an endotoxin tolerant phenotype. Various epithelial
cells are capable of expressing a tolerant phenotype to successive administrations of LPS,
including IECs(295), intrahepatic biliary epithelial cells(296), and alveolar epithelial cells(297).
Furthermore, decreased expression of Nos2 has been previously linked to endotoxin tolerance in
IECs(298) and macrophages(299).
While endogenous tolerance of IECs might constitute one mechanism of this tolerance,
tolerance of the immune cell populations present within the large intestine may trickle down to
affect IEC expression of Nos2. This may occur via altered secretion of tumor necrosis factor α,
interleukin 1β, and interferon γ(231), which are potent activators of Nos2 expression. In fact in
the DSS-colitis model, antibody mediated depletion of interferon γ and tumor necrosis factor α,
was able to reduce increases in Nos2 expression(300). Macrophages can stimulate interferon γ
secretion from T cells and NK cells, while endotoxin tolerant macrophages are attenuated in this
capacity(301). It’s possible that in our experiment a similar situation is occurring leading to
depression of Nos2 expression in IECs.
When L-NIL and tungstate were used in conjunction to treat mice receiving DSS there
was no observed increase of Enterobacteriaceae due to ethanol gavage compared to vehicle
gavage. However, the effect of ethanol on Lactobacillus persisted. This observed effect seems to
suggest that ethanol mediates direct effects on Lactobacillus. With regard to Enterobacteriaceae
it’s possible that the L-NIL and tungstate may somehow act synergistically to reduce any effects
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ethanol may confer to the Enterobacteriaceae. Alternatively, due to the small sample size, we
may have been unable to observe the effects of ethanol on the Enterobacteriaceae.
SCFAs are essential to the health of the intestine. We observed that the total
concentration of cecal SCFAs are decreased after DSS colitis, while the ratios of these SCFAs
are also disturbed when comparing between the four groups (control+vehicle, control+ethanol,
DSS+vehicle, DSS+ethanol). Two research studies on murine models fed alcohol diets,
identified that alcohol can induce increases in acetic acid, and decreases in propionic acid, and
butyric acid(302, 303). In our model, the cecal SCFAs between the control+vehicle and
control+ethanol largely recapitulate these findings, though the effect on butyric acid was not
observed in our model. This may be due to the more acute nature of our ethanol regimen than
those from the other studies. The DSS experimental groups, compared to control groups,
exhibited an overall decrease in the total concentration of SCFAs, while also exhibiting
decreases in each individual SCFA. Examination of the SCFA revealed that on their own,
ethanol or DSS increases the SCFA ratio of acetic acid, while the combination of DSS+ethanol
leads to an even higher ratio of acetic acid. The increases of acetic acid in the ethanol
administered groups is likely due to the metabolism of ethanol to acetate.
The observed shifts in the total SCFA and SCFA ratios, may also have a differential
effect on the inhibition of pro-inflammatory bacteria. Butyrate is the primary energy source of
IECs, as well as serves as modulator of immune function. Butyrate has also been determined to
be a ligand that activates the transcription factor peroxisome proliferator-activated receptor γ,
which can inhibit the expression of Nos2(127, 304). Inhibition of Enterobacteriaceae growth has
been ascribed to the SCFAs acetic acid and butyric acid(111), as well as propionic acid(305).
Therefore, the sharp decrease in these SCFAs and the alteration of the ratios seen in DSS
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administered mice likely also play a part in the overgrowth of the Enterobacteriaceae observed in
our model.
DSS+ethanol Induced Liver Endotoxin Tolerance
In our model, we observed that the livers of control+ethanol and DSS+vehicle had
similarly increased numbers of mononuclear cells compared to livers of control+vehicle.
DSS+ethanol livers exhibited the most mononuclear cells of all experimental groups. This initial
finding seemed to suggest that the livers of the DSS+ethanol mice may be experiencing more
inflammation. However, RNA expression of inflammatory genes revealed that the DSS+vehicle
livers had the highest expression, the control groups exhibited minimal expression, and the
DSS+ethanol had an intermediate expression. This seemed to indicate that the livers of
DSS+ethanol mice were exhibiting a tolerant phenotype. We also observed sustained expression
of Lcn2 in the DSS experimental groups, which is non-tolerizeable. Observation of increased
activation of proinflammatory transcription factors in DSS+vehicle mice livers, while decreased
activation is observed in the DSS+ethanol mice livers, further supporting the conclusion that the
DSS+ethanol livers are tolerant.
The induction of tolerance in part relies on the increased expression of IRAK-M, which
has been identified as a negative regulator of TLR signaling(306). In contrast, the persistent
expression of Lcn2 was described in kidney fibroblasts to occur via a biphasic mechanism
wherein LPS activates TLR4, leading to early phase activation of c-Jun, followed by late phase
and sustained activation of C/EBPδ(307).
Within the acute setting of alcohol intake, temporal regulation governs the inflammatory
response of Kupffer cells. LPS treatment of Kupffer cells isolated from rats two hours after
alcohol administration exhibit a decreased inflammatory response, while Kupffer isolated 24
hours after alcohol administration exhibit an increased inflammatory response(214). To examine
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whether a similar effect occurs in our model, we assessed liver inflammatory gene expression 24
hours after the last ethanol gavage, instead of the usual three hours. We found that the
inflammatory gene expression in the liver did not differ between the mice that received ethanol
or a vehicle 24 hours prior to sacrifice. In addition, there may have even been an increase in the
expression of these genes in the DSS+ethanol+1 mouse livers, however, this experiment will
need to be repeated in order to sufficiently determine this effect.
Inflammation of the liver and mononuclear cell infiltrate has been previously observed in
various mouse models of colitis, including DSS(308). When GF mice were administered DSS,
they developed colitis but the numbers of liver mononuclear cells were unchanged from that of
germ free mice receiving water(308). Other effects of DSS administration include alteration of
liver metabolism leading to increased lipoprotein lipase(309) and increased circulating
lipids(310), alanine aminotransferase, and aspartate aminotransferase(311).
The fact that IBD patients have increased circulating levels of endotoxin indicates that
their livers are exposed to more than normal levels of endotoxin and thus might be stressed(265).
In this regard, studies have found that some IBD patients have increased hepatic steatosis, liver
enlargement(266), and elevated liver enzymes(267). The addition of alcohol in our model could
lead to indirect effects on the liver by increasing the intestinal permeability, increasing the
abundance of endotoxin expressing bacteria, and/or directly by the added stress on the liver to
metabolize circulating alcohol. The presence of increased circulating alcohol relative to the
control+ethanol mice, seems to suggest that there is some dysfunction of alcohol metabolism in
the DSS+ethanol mice that is still observed when L-NIL or tungstate is administered.

REFERENCE LIST
1.

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nature reviews
Gastroenterology & hepatology. 2015;12(4):205-17.

2.

Gisbert J, Marín A, McNicholl A, Chaparro M. Systematic review with meta‐analysis:
the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose
previous anti‐TNF treatment has failed. Alimentary pharmacology & therapeutics.
2015;41(7):613-23.

3.

Choi P, Zelig M. Similarity of colorectal cancer in Crohn9s disease and ulcerative colitis:
implications for carcinogenesis and prevention. Gut. 1994;35(7):950-4.

4.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and
out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national
survey. Digestive diseases and sciences. 2012;57(12):3080-91.

5.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited
determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association
study. The Lancet. 2016;387(10014):156-67.

6.

Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, et al.
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci
implicated in Crohn's disease. Nature genetics. 2008;40(6):710.

7.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host–
microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
Nature. 2012;491(7422):119.

8.

Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology.
2008;134(2):577-94.

9.

Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease.
Gastroenterology & hepatology. 2010;6(5):339.

10.

Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cézard J-P, Belaiche J, et al. Association
of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature.
2001;411(6837):599.

11.

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift
mutation in NOD2 associated with susceptibility to Crohn's disease. Nature.
2001;411(6837):603.

120

12.

121
Al Nabhani Z, Dietrich G, Hugot J-P, Barreau F. Nod2: The intestinal gate keeper. PLoS
pathogens. 2017;13(3):e1006177.

13.

Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel
disease. Nature reviews immunology. 2003;3(7):521.

14.

Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications
for clinicians. Current gastroenterology reports. 2002;4(6):481-9.

15.

Van Der Linde K, Boor PP, Houwing-Duistermaat JJ, Kuipers EJ, Wilson JP, De Rooij
FW. CARD15 and Crohn's disease: healthy homozygous carriers of the 3020insC
frameshift mutation. The American journal of gastroenterology. 2003;98(3):613.

16.

Udden SN, Peng L, Gan J-L, Shelton JM, Malter JS, Hooper LV, et al. NOD2 suppresses
colorectal tumorigenesis via downregulation of the TLR pathways. Cell reports.
2017;19(13):2756-70.

17.

Strober W, Kitani A, Fuss I, Asano N, Watanabe T. The molecular basis of NOD2
susceptibility mutations in Crohn's disease. Mucosal immunology. 2008;1(1s):S5.

18.

Cox CR, Gilmore MS. Native microbial colonization of Drosophila melanogaster and its
use as a model of Enterococcus faecalis pathogenesis. Infection and immunity.
2007;75(4):1565-76.

19.

Waidele L, Korb J, Voolstra CR, Künzel S, Dedeine F, Staubach F. Differential
ecological specificity of protist and bacterial microbiomes across a set of termite species.
Frontiers in microbiology. 2017;8:2518.

20.

Sanders JG, Beichman AC, Roman J, Scott JJ, Emerson D, McCarthy JJ, et al. Baleen
whales host a unique gut microbiome with similarities to both carnivores and herbivores.
Nature communications. 2015;6:8285.

21.

Edwards J, Johnson C, Santos-Medellín C, Lurie E, Podishetty NK, Bhatnagar S, et al.
Structure, variation, and assembly of the root-associated microbiomes of rice.
Proceedings of the National Academy of Sciences. 2015;112(8):E911-E20.

22.

Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature
Reviews Genetics. 2012;13(4):260.

23.

Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells
in the body. PLoS biology. 2016;14(8):e1002533.

24.

Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An integrated catalog of
reference genes in the human gut microbiome. Nature biotechnology. 2014;32(8):834.

25.

Hugon P, Dufour J-C, Colson P, Fournier P-E, Sallah K, Raoult D. A comprehensive
repertoire of prokaryotic species identified in human beings. The Lancet Infectious
Diseases. 2015;15(10):1211-9.

122
26.

Thursby E, Juge N. Introduction to the human gut microbiota. Biochemical Journal.
2017;474(11):1823-36.

27.

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity
of the human intestinal microbial flora. science. 2005;308(5728):1635-8.

28.

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut
microbial gene catalogue established by metagenomic sequencing. nature.
2010;464(7285):59.

29.

Consortium IHGS. Finishing the euchromatic sequence of the human genome. Nature.
2004;431(7011):931.

30.

Baric RS, Crosson S, Damania B, Miller SI, Rubin EJ. Next-generation high-throughput
functional annotation of microbial genomes. MBio. 2016;7(5):e01245-16.

31.

Zarrinpar A, Chaix A, Yooseph S, Panda S. Diet and feeding pattern affect the diurnal
dynamics of the gut microbiome. Cell metabolism. 2014;20(6):1006-17.

32.

Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al.
Human gut microbiome viewed across age and geography. nature. 2012;486(7402):222.

33.

Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, et al. Antibiotics, birth
mode, and diet shape microbiome maturation during early life. Science translational
medicine. 2016;8(343):343ra82-ra82.

34.

Yassour M, Vatanen T, Siljander H, Hämäläinen A-M, Härkönen T, Ryhänen SJ, et al.
Natural history of the infant gut microbiome and impact of antibiotic treatment on
bacterial strain diversity and stability. Science translational medicine.
2016;8(343):343ra81-ra81.

35.

Winter SE, Lopez CA, Bäumler AJ. The dynamics of gut‐associated microbial
communities during inflammation. EMBO reports. 2013;14(4):319-27.

36.

Gibbons R, Socransky S, Kapsimalis B. Establishment of human indigenous bacteria in
germ-free mice. Journal of bacteriology. 1964;88(5):1316-23.

37.

Syed SA, Abrams GD, Freter R. Efficiency of various intestinal bacteria in assuming
normal functions of enteric flora after association with germ-free mice. Infection and
Immunity. 1970;2(4):376-86.

38.

Friedman ES, Bittinger K, Esipova TV, Hou L, Chau L, Jiang J, et al. Microbes vs.
chemistry in the origin of the anaerobic gut lumen. Proceedings of the National Academy
of Sciences. 2018;115(16):4170-5.

39.

Ho NT, Li F, Lee-Sarwar KA, Tun HM, Brown BP, Pannaraj PS, et al. Meta-analysis of
effects of exclusive breastfeeding on infant gut microbiota across populations. Nature
communications. 2018;9(1):4169.

40.

123
Makino H, Kushiro A, Ishikawa E, Kubota H, Gawad A, Sakai T, et al. Mother-to-infant
transmission of intestinal bifidobacterial strains has an impact on the early development
of vaginally delivered infant's microbiota. PloS one. 2013;8(11):e78331.

41.

Makino H, Kushiro A, Ishikawa E, Muylaert D, Kubota H, Sakai T, et al. Transmission
of intestinal Bifidobacterium longum subsp. longum strains from mother to infant,
determined by multilocus sequencing typing and amplified fragment length
polymorphism. Appl Environ Microbiol. 2011;77(19):6788-93.

42.

Martín R, Jiménez E, Heilig H, Fernández L, Marín ML, Zoetendal EG, et al. Isolation of
bifidobacteria from breast milk and assessment of the bifidobacterial population by PCRdenaturing gradient gel electrophoresis and quantitative real-time PCR. Appl Environ
Microbiol. 2009;75(4):965-9.

43.

Milani C, Mancabelli L, Lugli GA, Duranti S, Turroni F, Ferrario C, et al. Exploring
vertical transmission of bifidobacteria from mother to child. Appl Environ Microbiol.
2015;81(20):7078-87.

44.

Jost T, Lacroix C, Braegger CP, Rochat F, Chassard C. Vertical mother–neonate transfer
of maternal gut bacteria via breastfeeding. Environmental microbiology.
2014;16(9):2891-904.

45.

Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB. In vitro fermentation of
breast milk oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. Appl
Environ Microbiol. 2006;72(6):4497-9.

46.

Ward RE, Niñonuevo M, Mills DA, Lebrilla CB, German JB. In vitro fermentability of
human milk oligosaccharides by several strains of bifidobacteria. Molecular nutrition &
food research. 2007;51(11):1398-405.

47.

Fallani M, Amarri S, Uusijarvi A, Adam R, Khanna S, Aguilera M, et al. Determinants of
the human infant intestinal microbiota after the introduction of first complementary foods
in infant samples from five European centres. Microbiology. 2011;157(5):1385-92.

48.

Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao J-z, et al. Age-related
changes in gut microbiota composition from newborn to centenarian: a cross-sectional
study. BMC microbiology. 2016;16(1):90.

49.

Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of
microbial consortia in the developing infant gut microbiome. Proceedings of the National
Academy of Sciences. 2011;108(Supplement 1):4578-85.

50.

Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics
and stabilization of the human gut microbiome during the first year of life. Cell host &
microbe. 2015;17(5):690-703.

51.

Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C, et al.
Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1
responses in infants delivered by caesarean section. Gut. 2014;63(4):559-66.

52.

124
Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al.
Delivery mode shapes the acquisition and structure of the initial microbiota across
multiple body habitats in newborns. Proceedings of the National Academy of Sciences.
2010;107(26):11971-5.

53.

Korpela K, Costea P, Coelho LP, Kandels-Lewis S, Willemsen G, Boomsma DI, et al.
Selective maternal seeding and environment shape the human gut microbiome. Genome
research. 2018;28(4):561-8.

54.

Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, Cox LM, Amir A, Gonzalez A, et
al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial
transfer. Nature medicine. 2016;22(3):250.

55.

Pannaraj PS, Li F, Cerini C, Bender JM, Yang S, Rollie A, et al. Association between
breast milk bacterial communities and establishment and development of the infant gut
microbiome. JAMA pediatrics. 2017;171(7):647-54.

56.

Nuttall GH, Thierfelder H. Thierisches Leben ohne Bakterien im Verdauungskanal.
Hoppe-Seylér s Zeitschrift für physiologische Chemie. 1896;21(2-3):109-21.

57.

Abrams GD, Bauer H, Sprinz H. Influence of the normal flora on mucosal morphology
and cellular renewal in the ileum. A comparison of germ-free and conventional mice.
MOUNT SINAI HOSPITAL NEW YORK; 1962.

58.

Thompson G, Trexler P. Gastrointestinal structure and function in germ-free or
gnotobiotic animals. Gut. 1971;12(3):230.

59.

Gordon HA. The germ-free animal. The American journal of digestive diseases.
1960;5(10):841-67.

60.

Bora SA, Kennett MJ, Smith PB, Patterson AD, Cantorna MT. The gut microbiota
regulates endocrine vitamin D metabolism through fibroblast growth factor 23. Frontiers
in immunology. 2018;9:408.

61.

Hirayama K, Uetsuka K, Kuwabara Y, Tamura M, Itoh K. Vitamin K deficiency of
germfree mice caused by feeding standard purified diet sterilized by γ-irradiation.
Experimental animals. 2007;56(4):273-8.

62.

Sumi Y, Miyakawa M, Kanzaki M, Kotake Y. Vitamin B-6 deficiency in germfree rats.
The Journal of nutrition. 1977;107(9):1707-14.

63.

Gustafsson BE. Vitamin K deficiency in germfree rats. Annals of the New York
Academy of Sciences. 1959;78(1):166-74.

64.

Hill M. Intestinal flora and endogenous vitamin synthesis. European journal of cancer
prevention: the official journal of the European Cancer Prevention Organisation (ECP).
1997;6:S43-5.

125
65.

Conly J, Stein K, Worobetz L, Rutledge-Harding S. The Contribution of Vitamin K 2
(Menaquinones) Produced by the Intestinal Microflora to Human Nutritional
Requirements for Vitamin K. American Journal of Gastroenterology. 1994;89(6).

66.

Pineo G, Gallus A, Hirsh J. Unexpected vitamin K deficiency in hospitalized patients.
Canadian Medical Association Journal. 1973;109(9):880.

67.

Resta SC. Effects of probiotics and commensals on intestinal epithelial physiology:
implications for nutrient handling. The Journal of physiology. 2009;587(17):4169-74.

68.

Strozzi GP, Mogna L. Quantification of folic acid in human feces after administration of
Bifidobacterium probiotic strains. Journal of clinical gastroenterology. 2008;42:S179S84.

69.

Pompei A, Cordisco L, Amaretti A, Zanoni S, Raimondi S, Matteuzzi D, et al.
Administration of folate-producing bifidobacteria enhances folate status in Wistar rats.
The Journal of nutrition. 2007;137(12):2742-6.

70.

Wostmann BS. The germfree animal in nutritional studies. Annual review of nutrition.
1981;1(1):257-79.

71.

Høverstad T, Midtvedt T. Short-chain fatty acids in germfree mice and rats. The Journal
of nutrition. 1986;116(9):1772-6.

72.

Donohoe DR, Wali A, Brylawski BP, Bultman SJ. Microbial regulation of glucose
metabolism and cell-cycle progression in mammalian colonocytes. PloS one.
2012;7(9):e46589.

73.

Roediger W. Utilization of nutrients by isolated epithelial cells of the rat colon.
Gastroenterology. 1982;83(2):424-9.

74.

Roediger W. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in
man. Gut. 1980;21(9):793-8.

75.

Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, et al. The
microbiome and butyrate regulate energy metabolism and autophagy in the mammalian
colon. Cell metabolism. 2011;13(5):517-26.

76.

Davie JR. Inhibition of histone deacetylase activity by butyrate. The Journal of nutrition.
2003;133(7):2485S-93S.

77.

Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate
regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings
of the National Academy of Sciences. 2014;111(6):2247-52.

78.

Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal
microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature.
2013;504(7480):446.

126
79.

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The
role of short-chain fatty acids in the interplay between diet, gut microbiota, and host
energy metabolism. Journal of lipid research. 2013;54(9):2325-40.

80.

Barcelo A, Claustre J, Moro F, Chayvialle J, Cuber J, Plaisancié P. Mucin secretion is
modulated by luminal factors in the isolated vascularly perfused rat colon. Gut.
2000;46(2):218-24.

81.

Burger-van Paassen N, Vincent A, Puiman PJ, Van Der Sluis M, Bouma J, Boehm G, et
al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids:
implications for epithelial protection. Biochemical Journal. 2009;420(2):211-9.

82.

Finnie I, Dwarakanath A, Taylor B, Rhodes J. Colonic mucin synthesis is increased by
sodium butyrate. Gut. 1995;36(1):93-9.

83.

Cobo ER, Kissoon-Singh V, Moreau F, Holani R, Chadee K. MUC2 mucin and butyrate
contribute to the synthesis of the antimicrobial peptide cathelicidin in response to
Entamoeba histolytica-and dextran sodium sulfate-induced colitis. Infection and
immunity. 2017;85(3):e00905-16.

84.

Gantois I, Ducatelle R, Pasmans F, Haesebrouck F, Hautefort I, Thompson A, et al.
Butyrate specifically down-regulates Salmonella pathogenicity island 1 gene expression.
Appl Environ Microbiol. 2006;72(1):946-9.

85.

Esquivel-Elizondo S, Ilhan Z, Garcia-Peña E, Krajmalnik-Brown R. Insights into butyrate
production in a controlled fermentation system via gene predictions. MSystems.
2017;2(4):e00051-17.

86.

Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, Preter V, et al. Systemic
availability and metabolism of colonic‐derived short‐chain fatty acids in healthy subjects:
a stable isotope study. The Journal of physiology. 2017;595(2):541-55.

87.

Cummings J, Pomare E, Branch W, Naylor C, Macfarlane G. Short chain fatty acids in
human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221-7.

88.

Waaij V. The ecology of the human intestine and its consequences for overgrowth by
pathogens such as Clostridium difficile. Annual review of microbiology. 1989;43(1):6987.

89.

Czuprynski CJ, Johnson W, Balish E, Wilkins T. Pseudomembranous colitis in
Clostridium difficile-monoassociated rats. Infection and immunity. 1983;39(3):1368-76.

90.

Wilson KH, Sheagren JN, Freter R, Weatherbee L, Lyerly D. Gnotobiotic models for
study of the microbial ecology of Clostridium difficile and Escherichia coli. Journal of
Infectious Diseases. 1986;153(3):547-51.

91.

Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal
bacteria. Journal of lipid research. 2006;47(2):241-59.

127
92.

Giel JL, Sorg JA, Sonenshein AL, Zhu J. Metabolism of bile salts in mice influences
spore germination in Clostridium difficile. PloS one. 2010;5(1):e8740.

93.

Theriot CM, Koenigsknecht MJ, Carlson Jr PE, Hatton GE, Nelson AM, Li B, et al.
Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase
susceptibility to Clostridium difficile infection. Nature communications. 2014;5:3114.

94.

Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease.
Gastroenterology. 2009;136(6):1899-912.

95.

Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating
Clostridium difficile infection with fecal microbiota transplantation. Clinical
Gastroenterology and Hepatology. 2011;9(12):1044-9.

96.

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium
difficile infection: systematic review and meta-analysis. The American journal of
gastroenterology. 2013;108(4):500.

97.

Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, et al. Microbiota
transplantation restores normal fecal bile acid composition in recurrent Clostridium
difficile infection. American Journal of Physiology-Gastrointestinal and Liver
Physiology. 2013;306(4):G310-G9.

98.

Velazquez EM, Nguyen H, Heasley KT, Saechao CH, Gil LM, Rogers AW, et al.
Endogenous Enterobacteriaceae underlie variation in susceptibility to Salmonella
infection. Nature microbiology. 2019:1.

99.

Litvak Y, Mon KK, Nguyen H, Chanthavixay G, Liou M, Velazquez EM, et al.
Commensal Enterobacteriaceae Protect against Salmonella Colonization through Oxygen
Competition. Cell host & microbe. 2019;25(1):128-39. e5.

100.

Lopez CA, Rivera-Chávez F, Byndloss MX, Bäumler AJ. The periplasmic nitrate
reductase NapABC supports luminal growth of Salmonella enterica serovar
Typhimurium during colitis. Infection and immunity. 2015;83(9):3470-8.

101.

Gillis CC, Winter MG, Chanin RB, Zhu W, Spiga L, Winter SE. Host-derived
metabolites modulate transcription of Salmonella genes involved in l-lactate utilization
during gut colonization. Infection and immunity. 2019;87(4):e00773-18.

102.

Yang J, Niu C, Guo X. Mixed culture models for predicting intestinal microbial
interactions between Escherichia coli and Lactobacillus in the presence of probiotic
Bacillus subtilis. Beneficial microbes. 2015;6(6):871-7.

103.

Fijan S, Šulc D, Steyer A. Study of the In Vitro Antagonistic Activity of Various SingleStrain and Multi-Strain Probiotics against Escherichia coli. International journal of
environmental research and public health. 2018;15(7):1539.

104.

128
Sreekumar O, Hosono A. Immediate effect of Lactobacillus acidophilus on the intestinal
flora and fecal enzymes of rats and the in vitro inhibition of Escherichia coli in coculture.
Journal of Dairy Science. 2000;83(5):931-9.

105.

Delley M, Bruttin A, Richard M, Affolter M, Rezzonico E, Brück WM. In vitro activity
of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli.
FEMS microbiology letters. 2015;362(13).

106.

Fooks LJ, Gibson GR. In vitro investigations of the effect of probiotics and prebiotics on
selected human intestinal pathogens. FEMS Microbiology Ecology. 2002;39(1):67-75.

107.

Kashket ER. Bioenergetics of lactic acid bacteria: cytoplasmic pH and osmotolerance.
FEMS Microbiology Reviews. 1987;3(3):233-44.

108.

Duncan SH, Louis P, Thomson JM, Flint HJ. The role of pH in determining the species
composition of the human colonic microbiota. Environmental microbiology.
2009;11(8):2112-22.

109.

Walker AW, Duncan SH, Leitch ECM, Child MW, Flint HJ. pH and peptide supply can
radically alter bacterial populations and short-chain fatty acid ratios within microbial
communities from the human colon. Appl Environ Microbiol. 2005;71(7):3692-700.

110.

Shin R, Suzuki M, Morishita Y. Influence of intestinal anaerobes and organic acids on
the growth of enterohaemorrhagic Escherichia coli O157: H7. Journal of medical
microbiology. 2002;51(3):201-6.

111.

Sorbara MT, Dubin K, Littmann ER, Moody TU, Fontana E, Seok R, et al. Inhibiting
antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification.
Journal of Experimental Medicine. 2019;216(1):84-98.

112.

Cherrington CA, Hinton M, Pearson G, Chopra I. Short‐chain organic acids at pH 5.0 kill
Escherichia coli and Salmonella spp. without causing membrane perturbation. Journal of
Applied Bacteriology. 1991;70(2):161-5.

113.

Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening–Baucke V, Ortner M, et
al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122(1):44-54.

114.

Schultsz C, van den Berg FM, Fiebo W, Tytgat GN, Dankert J. The intestinal mucus
layer from patients with inflammatory bowel disease harbors high numbers of bacteria
compared with controls. Gastroenterology. 1999;117(5):1089-97.

115.

Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli
belonging to the B2+ D phylogenetic group in inflammatory bowel disease. Gut.
2007;56(5):669-75.

116.

Frank DN, Amand ALS, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecularphylogenetic characterization of microbial community imbalances in human
inflammatory bowel diseases. Proceedings of the National Academy of Sciences.
2007;104(34):13780-5.

129
117.

Edwards PR, Ewing WH. Identification of enterobacteriaceae. Identification of
Enterobacteriaceae. 1972(Third edition).

118.

Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, et
al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal
cancer. The Journal of clinical investigation. 2013;123(2).

119.

Mondot S, Barreau F, Al Nabhani Z, Dussaillant M, Le Roux K, Doré J, et al. Altered gut
microbiota composition in immune-impaired Nod2−/− mice. Gut. 2012;61(4):634-5.

120.

Rehman A, Sina C, Gavrilova O, Häsler R, Ott S, Baines JF, et al. Nod2 is essential for
temporal development of intestinal microbial communities. Gut. 2011;60(10):1354-62.

121.

Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2dependent regulation of innate and adaptive immunity in the intestinal tract. Science.
2005;307(5710):731-4.

122.

Petnicki-Ocwieja T, Hrncir T, Liu Y-J, Biswas A, Hudcovic T, Tlaskalova-Hogenova H,
et al. Nod2 is required for the regulation of commensal microbiota in the intestine.
Proceedings of the National Academy of Sciences. 2009;106(37):15813-8.

123.

Robertson SJ, Zhou JY, Geddes K, Rubino SJ, Cho JH, Girardin SE, et al. Nod1 and
Nod2 signaling does not alter the composition of intestinal bacterial communities at
homeostasis. Gut microbes. 2013;4(3):222-31.

124.

Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, et al. Complex
host genetics influence the microbiome in inflammatory bowel disease. Genome
medicine. 2014;6(12):107.

125.

Roediger W. The colonic epithelium in ulcerative colitis: an energy-deficiency disease?
The Lancet. 1980;316(8197):712-5.

126.

Ahmad M, Krishnan S, Ramakrishna B, Mathan M, Pulimood A, Murthy S. Butyrate and
glucose metabolism by colonocytes in experimental colitis in mice. Gut. 2000;46(4):4939.

127.

Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, et al.
Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion.
Science. 2017;357(6351):570-5.

128.

Scheppach W, Sommer H, Kirchner T, Paganelli G-M, Bartram P, Christl S, et al. Effect
of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology.
1992;103(1):51-6.

129.

Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary
combination of germinated barley foodstuff plus Clostridium butyricum suppresses the
dextran sulfate sodium-induced experimental colitis in rats. Scandinavian journal of
gastroenterology. 2000;35(10):1060-7.

130
130.

Araki Y, Andoh A, Takizawa J, Takizawa W, Fujiyama Y. Clostridium butyricum, a
probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in
rats. International journal of molecular medicine. 2004;13(4):577-80.

131.

Rodríguez-Cabezas ME, Galvez J, Lorente MD, Concha A, Camuesco D, Azzouz S, et al.
Dietary fiber down-regulates colonic tumor necrosis factor α and nitric oxide production
in trinitrobenzenesulfonic acid-induced colitic rats. The Journal of nutrition.
2002;132(11):3263-71.

132.

Fabia R, Ar’Rajab A, Johansson M-L, Andersson R, Willén R, Jeppsson B, et al.
Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the
rat. Digestion. 1993;54(4):248-55.

133.

Zocco M, Dal Verme LZ, Cremonini F, Piscaglia A, Nista E, Candelli M, et al. Efficacy
of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary
pharmacology & therapeutics. 2006;23(11):1567-74.

134.

Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et al. Randomised clinical
trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with
active distal ulcerative colitis. Alimentary pharmacology & therapeutics. 2012;35(3):32734.

135.

Abdin AA, Saeid EM. An experimental study on ulcerative colitis as a potential target for
probiotic therapy by Lactobacillus acidophilus with or without “olsalazine”. Journal of
Crohn's and Colitis. 2008;2(4):296-303.

136.

Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on
the composition of the faecal flora by a new probiotic preparation: preliminary data on
maintenance treatment of patients with ulcerative colitis. Alimentary pharmacology &
therapeutics. 1999;13(8):1103-8.

137.

Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al.
VSL# 3 probiotic-mixture induces remission in patients with active ulcerative colitis. The
American journal of gastroenterology. 2005;100(7):1539.

138.

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nature
reviews Gastroenterology & hepatology. 2012;9(10):599.

139.

Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al.
Findings from a randomized controlled trial of fecal transplantation for patients with
ulcerative colitis. Gastroenterology. 2015;149(1):110-8. e4.

140.

Kump PK, Gröchenig H-P, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al.
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce
remission in patients with chronic active ulcerative colitis. Inflammatory bowel diseases.
2013;19(10):2155-65.

131
141.

Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal
microbiota transplantation induces remission in patients with active ulcerative colitis in a
randomized controlled trial. Gastroenterology. 2015;149(1):102-9. e6.

142.

Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al. Effect
of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis:
a randomized clinical trial. Jama. 2019;321(2):156-64.

143.

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et
al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a
randomised placebo-controlled trial. The Lancet. 2017;389(10075):1218-28.

144.

Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and
health. Nature Reviews Gastroenterology and Hepatology. 2012;9(10):577.

145.

Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, et al. Increased
oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel
disease. Digestive diseases and sciences. 1996;41(10):2078-86.

146.

McKenzie S, Baker M, Buffinton G, Doe W. Evidence of oxidant-induced injury to
epithelial cells during inflammatory bowel disease. The Journal of clinical investigation.
1996;98(1):136-41.

147.

Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, et al. Increases
in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients
with inflammatory bowel disease. Gut. 2003;52(5):720-8.

148.

Imlay JA. Pathways of oxidative damage. Annual Reviews in Microbiology.
2003;57(1):395-418.

149.

Rolfe RD, Hentges DJ, Campbell BJ, Barrett JT. Factors related to the oxygen tolerance
of anaerobic bacteria. Appl Environ Microbiol. 1978;36(2):306-13.

150.

Giuffrè A, Borisov VB, Arese M, Sarti P, Forte E. Cytochrome bd oxidase and bacterial
tolerance to oxidative and nitrosative stress. Biochimica et Biophysica Acta (BBA)Bioenergetics. 2014;1837(7):1178-87.

151.

Paauw A, Leverstein-van Hall MA, van Kessel KP, Verhoef J, Fluit AC. Yersiniabactin
reduces the respiratory oxidative stress response of innate immune cells. PLoS one.
2009;4(12):e8240.

152.

Achard ME, Chen KW, Sweet MJ, Watts RE, Schroder K, Schembri MA, et al. An
antioxidant role for catecholate siderophores in Salmonella. Biochemical Journal.
2013;454(3):543-9.

153.

Singh V, San Yeoh B, Xiao X, Kumar M, Bachman M, Borregaard N, et al. Interplay
between enterobactin, myeloperoxidase and lipocalin 2 regulates E. coli survival in the
inflamed gut. Nature communications. 2015;6:7113.

154.

132
Winter SE, Bäumler AJ. Why related bacterial species bloom simultaneously in the gut:
principles underlying the ‘Like will to like’concept. Cellular microbiology.
2014;16(2):179-84.

155.

Unden G, Bongaerts J. Alternative respiratory pathways of Escherichia coli: energetics
and transcriptional regulation in response to electron acceptors. Biochimica et Biophysica
Acta (BBA)-Bioenergetics. 1997;1320(3):217-34.

156.

Hawksworth GM, Hill M. Bacteria and the N-nitrosation of secondary amines. British
journal of cancer. 1971;25(3):520-6.

157.

Parham NJ, Gibson GR. Microbes involved in dissimilatory nitrate reduction in the
human large intestine. FEMS microbiology ecology. 2000;31(1):21-8.

158.

Stecher B, Denzler R, Maier L, Bernet F, Sanders MJ, Pickard DJ, et al. Gut
inflammation can boost horizontal gene transfer between pathogenic and commensal
Enterobacteriaceae. Proceedings of the National Academy of Sciences.
2012;109(4):1269-74.

159.

Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli
pathobionts associated with inflammatory bowel disease. Clinical microbiology reviews.
2019;32(2):e00060-18.

160.

Giaffer M, Holdsworth C, Duerden B. Virulence properties of Escherichia coli strains
isolated from patients with inflammatory bowel disease. Gut. 1992;33(5):646-50.

161.

Rigottier-Gois L. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. The
ISME journal. 2013;7(7):1256.

162.

Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, et al. Colonisation
by F aecalibacterium prausnitzii and maintenance of clinical remission in patients with
ulcerative colitis. Alimentary pharmacology & therapeutics. 2013;38(2):151-61.

163.

Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of
the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii
defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-83.

164.

Duncan SH, Barcenilla A, Stewart CS, Pryde SE, Flint HJ. Acetate utilization and butyryl
coenzyme A (CoA): acetate-CoA transferase in butyrate-producing bacteria from the
human large intestine. Appl Environ Microbiol. 2002;68(10):5186-90.

165.

Heinken A, Thiele I. Anoxic conditions promote species-specific mutualism between gut
microbes in silico. Appl Environ Microbiol. 2015;81(12):4049-61.

166.

Hansson GC. Role of mucus layers in gut infection and inflammation. Current opinion in
microbiology. 2012;15(1):57-62.

133
167.

Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM. High
throughput sequencing reveals distinct microbial populations within the mucosal and
luminal niches in healthy individuals. Gut microbes. 2015;6(3):173-81.

168.

Swidsinski A, Loening–Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure
of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea.
Gastroenterology. 2008;135(2):568-79. e2.

169.

Pullan R, Thomas G, Rhodes M, Newcombe R, Williams G, Allen A, et al. Thickness of
adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut.
1994;35(3):353-9.

170.

Larsson JMH, Karlsson H, Crespo JG, Johansson ME, Eklund L, Sjövall H, et al. Altered
O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is
associated with increased inflammation. Inflammatory bowel diseases.
2011;17(11):2299-307.

171.

van der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, et al. Structural
weakening of the colonic mucus barrier is an early event in ulcerative colitis
pathogenesis. Gut. 2019:gutjnl-2018-317571.

172.

Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, et al.
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis.
Differentiation. 2009;77(1):84-94.

173.

Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular
characterization of rectal mucosa-associated bacterial flora in inflammatory bowel
disease. Inflammatory bowel diseases. 2005;11(5):481-7.

174.

Johansson ME, Gustafsson JK, Sjöberg KE, Petersson J, Holm L, Sjövall H, et al.
Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis
model. PloS one. 2010;5(8):e12238.

175.

Johansson ME, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, et al.
Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine
colitis models and patients with ulcerative colitis. Gut. 2013:gutjnl-2012-303207.

176.

Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn’s disease
and ulcerative colitis. Expert review of gastroenterology & hepatology. 2011;5(3):41125.

177.

Swanson GR, Sedghi S, Farhadi A, Keshavarzian A. Pattern of alcohol consumption and
its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol.
2010;44(3):223-8.

178.

Jowett S, Seal C, Pearce M, Phillips E, Gregory W, Barton J, et al. Influence of dietary
factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut.
2004;53(10):1479-84.

179.

134
Hsu T-Y, Shih H-M, Wang Y-C, Lin L-C, He G-Y, Chen C-Y, et al. Effect of Alcoholic
Intoxication on the Risk of Inflammatory Bowel Disease: A Nationwide Retrospective
Cohort Study. PloS one. 2016;11(11):e0165411.

180.

Nakarnura Y, Labarthe DR. A case-control study of ulcerative colitis with relation to
smoking habits and alcohol consumption in Japan. American journal of epidemiology.
1994;140(10):902-11.

181.

Bergmann M, Hernandez V, Bernigau W, Boeing H, Chan S, Luben R, et al. No
association of alcohol use and the risk of ulcerative colitis or Crohn’s disease: data from a
European Prospective cohort study (EPIC). European journal of clinical nutrition.
2017;71(4):512.

182.

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from
the 2015 National Survey on Drug Use and Health: Detailed Tables [Table 2.41B—
Alcohol Use in Lifetime, Past Year, and Past Month among Persons Aged 12 or Older, by
Demographic Characteristics: Percentages, 2014 and 5]. Available from:
https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUHDetTabs-2015/NSDUH-DetTabs-2015.htm#tab2-41b.

183.

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from
the 2015 National Survey on Drug Use and Health: Detailed Tables [Table 2.46B—
Alcohol Use, Binge Alcohol Use, and Heavy Alcohol Use in Past Month among Persons
Aged 12 or Older, by Demographic Characteristics: Percentages, 2014 and 5.]. Available
from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUHDetTabs-2015/NSDUH-DetTabs-2015.htm#tab2-46b. .

184.

Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 national and state
costs of excessive alcohol consumption. American journal of preventive medicine.
2015;49(5):e73-e9.

185.

Zakhari S. Alcohol metabolism and epigenetics changes. Alcohol research: current
reviews. 2013;35(1):6.

186.

MacGregor RR. Alcohol and immune defense. Jama. 1986;256(11):1474-9.

187.

Bjarnason I, Ward K, Peters T. The leaky gut of alcoholism: possible route of entry for
toxic compounds. The Lancet. 1984;323(8370):179-82.

188.

Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum
endotoxin and bacterial DNA levels in healthy individuals. PloS one. 2014;9(5):e96864.

189.

Lowe PP, Gyongyosi B, Satishchandran A, Iracheta-Vellve A, Ambade A, Kodys K, et
al. Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration,
inflammation and steatosis in early alcoholic hepatitis in mice. PloS one.
2017;12(3):e0174544.

135
190.

Llopis M, Cassard A, Wrzosek L, Boschat L, Bruneau A, Ferrere G, et al. Intestinal
microbiota contributes to individual susceptibility to alcoholic liver disease. Gut.
2015:gutjnl-2015-310585.

191.

Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, et al. Metagenomic analyses
of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of
Lactobacillus rhamnosus GG treatment. PloS one. 2013;8(1):e53028.

192.

Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, et al. Colonic
microbiome is altered in alcoholism. American Journal of Physiology-Gastrointestinal
and Liver Physiology. 2012;302(9):G966-G78.

193.

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nature
Reviews Gastroenterology and Hepatology. 2012;9(10):599.

194.

Tsuruya A, Kuwahara A, Saito Y, Yamaguchi H, Tsubo T, Suga S, et al.
Ecophysiological consequences of alcoholism on human gut microbiota: implications for
ethanol-related pathogenesis of colon cancer. Scientific reports. 2016;6:27923.

195.

Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al.
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver
injury: a pilot study. Alcohol. 2008;42(8):675-82.

196.

Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, et al. Drinking
alcohol is associated with variation in the human oral microbiome in a large study of
American adults. Microbiome. 2018;6(1):59.

197.

Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG
culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver
injury. American Journal of Physiology-Gastrointestinal and Liver Physiology.
2012;303(1):G32-G41.

198.

Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease.
Liver research. 2017;1(4):197-207.

199.

Canesso MCC, Lacerda N, Ferreira C, Gonçalves J, Almeida D, Gamba C, et al.
Comparing the effects of acute alcohol consumption in germ-free and conventional mice:
the role of the gut microbiota. BMC microbiology. 2014;14(1):240.

200.

Yan AW, E. Fouts D, Brandl J, Stärkel P, Torralba M, Schott E, et al. Enteric dysbiosis
associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96105.

201.

Zhou C, Zhao J, Li J, Wang H, Tang C. Acute ethanol administration inhibits Toll-like
receptor 4 signaling pathway in rat intestinal epithelia. Alcohol. 2013;47(3):231-9.

202.

Halsted CH, Robles EA, Mezey E. Distribution of ethanol in the human gastrointestinal
tract. The American journal of clinical nutrition. 1973;26(8):831-4.

136
203.

Visapää J-P, Tillonen J, Salaspuro M. Microbes and mucosa in the regulation of
intracolonic acetaldehyde concentration during ethanol challenge. Alcohol and
Alcoholism. 2002;37(4):322-6.

204.

Tillonen J, Väkeväinen S, Salaspuro V, Zhang Y, Rautio M, Jousimies‐Somer H, et al.
Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic
ethanol‐treated rats. Alcoholism: Clinical and Experimental Research. 2000;24(4):570-5.

205.

Salaspuro V, Nyfors S, Heine R, Siitonen A, Salaspuro M, Jousimies-Somer H. Ethanol
oxidation and acetaldehyde production in vitro by human intestinal strains of Escherichia
coli under aerobic, microaerobic, and anaerobic conditions. Scandinavian journal of
gastroenterology. 1999;34(10):967-73.

206.

Das SK, Vasudevan D. Alcohol-induced oxidative stress. Life sciences. 2007;81(3):17787.

207.

Tuma J, Casey CA. Dangerous byproducts of alcohol breakdown-focus on adducts.
Alcohol Research and Health. 2003;27:285-90.

208.

Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Research & Health.
2007;30(1):38.

209.

Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer
development: role of genetics in ethanol metabolism. Genes & nutrition. 2010;5(2):121.

210.

Atkinson K, Rao R. Role of protein tyrosine phosphorylation in acetaldehyde-induced
disruption of epithelial tight junctions. American Journal of Physiology-Gastrointestinal
and Liver Physiology. 2001;280(6):G1280-G8.

211.

Sheth P, Seth A, Thangavel M, Basuroy S, Rao R. Epidermal growth factor prevents
acetaldehyde‐induced paracellular permeability in Caco‐2 cell monolayer. Alcoholism:
Clinical and Experimental Research. 2004;28(5):797-804.

212.

Seth A, Basuroy S, Sheth P, Rao R. L-Glutamine ameliorates acetaldehyde-induced
increase in paracellular permeability in Caco-2 cell monolayer. American Journal of
Physiology-Gastrointestinal and Liver Physiology. 2004;287(3):G510-G7.

213.

Cresci GA, Glueck B, McMullen MR, Xin W, Allende D, Nagy LE. Prophylactic
tributyrin treatment mitigates chronic‐binge ethanol‐induced intestinal barrier and liver
injury. Journal of gastroenterology and hepatology. 2017;32(9):1587-97.

214.

Enomoto N, Ikejima K, Bradford B, Rivera C, Kono H, Brenner DA, et al. Alcohol
causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on
endotoxin. Gastroenterology. 1998;115(2):443-51.

215.

Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World journal
of gastroenterology: WJG. 2007;13(37):4925.

216.

137
Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. The effect of alcohol
consumption on the prevalence of iron overload, iron deficiency, and iron deficiency
anemia. Gastroenterology. 2004;126(5):1293-301.

217.

Raymond KN, Dertz EA, Kim SS. Enterobactin: an archetype for microbial iron
transport. Proceedings of the National Academy of Sciences. 2003;100(7):3584-8.

218.

Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution
of inflammation. Nature medicine. 2015;21(7):698.

219.

Ferrier L, Bérard F, Debrauwer L, Chabo C, Langella P, Buéno L, et al. Impairment of
the intestinal barrier by ethanol involves enteric microflora and mast cell activation in
rodents. The American journal of pathology. 2006;168(4):1148-54.

220.

Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal
dysbiosis: a possible mechanism of alcohol‐induced endotoxemia and alcoholic
steatohepatitis in rats. Alcoholism: Clinical and Experimental Research.
2009;33(10):1836-46.

221.

Bode C, Bode JC. Effect of alcohol consumption on the gut. Best practice & research
Clinical gastroenterology. 2003;17(4):575-92.

222.

Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, et al. Dietary
patterns and self-reported associations of diet with symptoms of inflammatory bowel
disease. Digestive diseases and sciences. 2013;58(5):1322-8.

223.

Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ. 2000;320(7242):1119-23.

224.

Cannon AR, Kuprys PV, Cobb AN, Ding X, Kothari AN, Kuo PC, et al. Alcohol
enhances symptoms and propensity for infection in inflammatory bowel disease patients
and a murine model of DSS‐induced colitis. Journal of leukocyte biology.
2018;104(3):543-55.

225.

Reid C-A, Hillman K. The effects of retrogradation and amylose/amylopectin ratio of
starches on carbohydrate fermentation and microbial populations in the porcine colon.
Animal Science. 1999;68(3):503-10.

226.

Muralidhara K, Sheggeby G, Elliker P, England D, Sandine W. Effect of feeding
lactobacilli on the coliform and lactobacillus flora of intestinal tissue and feces from
piglets. Journal of Food Protection. 1977;40(5):288-95.

227.

Barman M, Unold D, Shifley K, Amir E, Hung K, Bos N, et al. Enteric salmonellosis
disrupts the microbial ecology of the murine gastrointestinal tract. Infection and
immunity. 2008;76(3):907-15.

228.

Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation and
subsequent analysis of murine lamina propria mononuclear cells from colonic tissue.
Nature protocols. 2007;2(10):2307.

229.

138
Earley ZM, Akhtar S, Green SJ, Naqib A, Khan O, Cannon AR, et al. Burn injury alters
the intestinal microbiome and increases gut permeability and bacterial translocation. PloS
one. 2015;10(7):e0129996.

230.

Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? The Journal of
clinical investigation. 1997;100(9):2146-52.

231.

Lowenstein CJ, Padalko E. iNOS (NOS2) at a glance. Journal of cell science.
2004;117(14):2865-7.

232.

Fukuto JM, Ignarro LJ. In vivo aspects of nitric oxide (NO) chemistry: does peroxynitrite
(-OONO) play a major role in cytotoxicity? Accounts of chemical research.
1997;30(4):149-52.

233.

Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, et al.
Peroxynitrite-induced rat colitis—a new model of colonic inflammation.
Gastroenterology. 1993;105(6):1681-8.

234.

Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al. Expression of
inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory
bowel disease. Gastroenterology. 1996;111(4):871-85.

235.

Tiedje JM. Ecology of denitrification and dissimilatory nitrate reduction to ammonium.
Biology of anaerobic microorganisms. 1988;717:179-244.

236.

Rivera-Chávez F, Lopez CA, Zhang LF, García-Pastor L, Chávez-Arroyo A, Lokken KL,
et al. Energy taxis toward host-derived nitrate supports a Salmonella pathogenicity island
1-independent mechanism of invasion. MBio. 2016;7(4):e00960-16.

237.

Collins L, Egan S, Stewart V. Mutational analysis reveals functional similarity between
NARX, a nitrate sensor in Escherichia coli K-12, and the methyl-accepting chemotaxis
proteins. Journal of bacteriology. 1992;174(11):3667-75.

238.

Pool MO, Bouma G, Visser J, Kolkman J, Tran D, Meuwissen S, et al. Serum nitrate
levels in ulcerative colitis and Crohn's disease. Scandinavian journal of gastroenterology.
1995;30(8):784-8.

239.

Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L.
Comparing histological activity indexes in UC. Gut. 2015;64(9):1412-8.

240.

Chassaing B, Aitken JD, Malleshappa M, Vijay‐Kumar M. Dextran sulfate sodium
(DSS)‐induced colitis in mice. Current protocols in immunology. 2014;104(1):15.25. 115.25. 14.

241.

Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal
messenger in an unsolved puzzle. Immunology. 2004;113(4):427-37.

242.

Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al. Hostderived nitrate boosts growth of E. coli in the inflamed gut. science. 2013;339(6120):70811.

243.

139
Jones SA, Gibson T, Maltby RC, Chowdhury FZ, Stewart V, Cohen PS, et al. Anaerobic
respiration of Escherichia coli in the mouse intestine. Infection and immunity.
2011;79(10):4218-26.

244.

Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al. Hostderived nitrate boosts growth of E. coli in the inflamed gut. Science.
2013;339(6120):708-11.

245.

Nicholas D, Nason A. Molybdenum and nitrate reductase II. Molybdenum as a
constituent of nitrate reductase. Journal of Biological Chemistry. 1954;207(1):353-60.

246.

Gates AJ, Hughes RO, Sharp SR, Millington PD, Nilavongse A, Cole JA, et al. Properties
of the periplasmic nitrate reductases from Paracoccus pantotrophus and Escherichia coli
after growth in tungsten-supplemented media. FEMS microbiology letters.
2003;220(2):261-9.

247.

Zhu W, Winter MG, Byndloss MX, Spiga L, Duerkop BA, Hughes ER, et al. Precision
editing of the gut microbiota ameliorates colitis. Nature. 2018.

248.

Naqib A, Poggi S, Wang W, Hyde M, Kunstman K, Green SJ. Making and sequencing
heavily multiplexed, high-throughput 16S ribosomal RNA gene amplicon libraries using
a flexible, two-stage PCR protocol. Gene expression analysis: Springer; 2018. p. 149-69.

249.

Bybee SM, Bracken-Grissom H, Haynes BD, Hermansen RA, Byers RL, Clement MJ, et
al. Targeted amplicon sequencing (TAS): a scalable next-gen approach to multilocus,
multitaxa phylogenetics. Genome biology and evolution. 2011;3:1312-23.

250.

Moonsamy P, Williams T, Bonella P, Holcomb C, Höglund B, Hillman G, et al. High
throughput HLA genotyping using 454 sequencing and the Fluidigm Access Array™
system for simplified amplicon library preparation. Tissue antigens. 2013;81(3):141-9.

251.

Green SJ, Venkatramanan R, Naqib A. Deconstructing the polymerase chain reaction:
understanding and correcting bias associated with primer degeneracies and primertemplate mismatches. PloS one. 2015;10(5):e0128122.

252.

Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative β diversity
measures lead to different insights into factors that structure microbial communities. Appl
Environ Microbiol. 2007;73(5):1576-85.

253.

Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, et al. NLRP6
protects Il10−/− mice from colitis by limiting colonization of Akkermansia muciniphila.
Cell reports. 2017;19(4):733-45.

254.

Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, et al. Recovery of
ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease.
Gut. 2018;67(5):891-901.

140
255.

Stanley D, Geier MS, Chen H, Hughes RJ, Moore RJ. Comparison of fecal and cecal
microbiotas reveals qualitative similarities but quantitative differences. BMC
microbiology. 2015;15(1):51.

256.

Ericsson AC, Gagliardi J, Bouhan D, Spollen WG, Givan SA, Franklin CL. The influence
of caging, bedding, and diet on the composition of the microbiota in different regions of
the mouse gut. Scientific reports. 2018;8(1):4065.

257.

Breton J, Massart S, Vandamme P, De Brandt E, Pot B, Foligné B. Ecotoxicology inside
the gut: impact of heavy metals on the mouse microbiome. BMC Pharmacology and
Toxicology. 2013;14(1):62.

258.

Bennion RS, Baron EJ, Thompson Jr JE, Downes J, Summanen P, Talan DA, et al. The
bacteriology of gangrenous and perforated appendicitis--revisited. Annals of surgery.
1990;211(2):165.

259.

Verweij W, Namavar F, Schouten W, Maclaren D. Early events after intra-abdominal
infection with Bacteroides fragilis and Escherichia coli. Journal of medical microbiology.
1991;35(1):18-22.

260.

Fujita H, Eishi Y, Ishige I, Saitoh K, Takizawa T, Arima T, et al. Quantitative analysis of
bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in
tissue samples from patients with inflammatory bowel diseases. Journal of
gastroenterology. 2002;37(7):509-16.

261.

Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of Bacteroides and Prevotella
spp. in ulcerative colitis. Journal of medical microbiology. 2006;55(5):617-24.

262.

Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
biomarker discovery and explanation. Genome biology. 2011;12(6):R60.

263.

Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and
portal hypertension. Clinical and molecular hepatology. 2012;18(4):337.

264.

Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease.
Liver International. 2006;26(10):1175-86.

265.

Rojo ÓP, Román ALS, Arbizu EA, de la Hera Martínez A, Sevillano ER, Martínez AA.
Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory
bowel disease. Inflammatory bowel diseases. 2006;13(3):269-77.

266.

Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, et al. Sonographic
prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel
disease: study of 511 subjects at a single center. Journal of clinical gastroenterology.
2003;36(5):417-20.

267.

Mendes FD, Levy C, Enders FB, Loftus Jr EV, Angulo P, Lindor KD. Abnormal hepatic
biochemistries in patients with inflammatory bowel disease. The American journal of
gastroenterology. 2007;102(2):344.

141
268.

Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al.
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United
States community. Gastroenterology. 2003;125(5):1364-9.

269.

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al.
Diagnosis and management of primary sclerosing cholangitis. Hepatology.
2010;51(2):660-78.

270.

Enomoto N, Ikejima K, Yamashina S, Hirose M, Shimizu H, Kitamura T, et al. Kupffer
cell sensitization by alcohol involves increased permeability to gut‐derived endotoxin.
Alcoholism: Clinical and Experimental Research. 2001;25:51S-4S.

271.

Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver
injury in rats following long-term exposure to ethanol. Gastroenterology.
1995;108(1):218-24.

272.

West MA, Heagy W. Endotoxin tolerance: a review. Critical care medicine.
2002;30(1):S64-S73.

273.

Vazquez DE, Niño DF, De Maio A, Cauvi DM. Sustained expression of lipocalin-2
during polymicrobial sepsis. Innate immunity. 2015;21(5):477-89.

274.

Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium
difficile infection: is there a relationship with inflammatory bowel disease? Therapeutic
advances in gastroenterology. 2013;6(1):53-68.

275.

Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile infection in
patients with alcoholic hepatitis. Clinical Gastroenterology and Hepatology.
2014;12(10):1745-52. e2.

276.

Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden
associated with Clostridium difficile in patients with inflammatory bowel disease. Gut.
2008;57(2):205-10.

277.

Sonnenburg ED, Sonnenburg JL. The ancestral and industrialized gut microbiota and
implications for human health. Nature Reviews Microbiology. 2019;17(6):383.

278.

Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of
12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United
States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on
Alcohol and Related Conditions. JAMA psychiatry. 2017;74(9):911-23.

279.

Williams NT. Probiotics. American Journal of Health-System Pharmacy.
2010;67(6):449-58.

280.

Hughes ER, Winter MG, Duerkop BA, Spiga L, de Carvalho TF, Zhu W, et al. Microbial
respiration and formate oxidation as metabolic signatures of inflammation-associated
dysbiosis. Cell host & microbe. 2017;21(2):208-19.

142
281.

Macfarlane GT, Gibson GR. Carbohydrate fermentation, energy transduction and gas
metabolism in the human large intestine. Gastrointestinal microbiology: Springer; 1997.
p. 269-318.

282.

Pedersen MB, Gaudu P, Lechardeur D, Petit M-A, Gruss A. Aerobic respiration
metabolism in lactic acid bacteria and uses in biotechnology. Annual review of food
science and technology. 2012;3:37-58.

283.

Whittenbury R. Hydrogen peroxide formation and catalase activity in the lactic acid
bacteria. Microbiology. 1964;35(1):13-26.

284.

Brioukhanov A, Netrusov A. Aerotolerance of strictly anaerobic microorganisms and
factors of defense against oxidative stress: a review. Applied Biochemistry and
Microbiology. 2007;43(6):567-82.

285.

Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Research.
2006;29(4):245.

286.

Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol
Research and Health. 2003;27:277-84.

287.

Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its
metabolites mediate ethanol-induced microtubule disruption and intestinal barrier
dysfunction. Journal of Pharmacology and Experimental Therapeutics. 2000;294(3):9971008.

288.

Deng X-S, Deitrich RA. Ethanol metabolism and effects: nitric oxide and its interaction.
Current clinical pharmacology. 2007;2(2):145-53.

289.

Deng X-S, Bludeau P, Deitrich RA. Formation of ethyl nitrite in vivo after ethanol
administration. Alcohol. 2004;34(2-3):217-23.

290.

Cederqvist B, Persson MG, Gustafsson LE. Direct demonstration of NO formation in
vivo from organic nitrites and nitrates, and correlation to effects on blood pressure and to
in vitro effects. Biochemical pharmacology. 1994;47(6):1047-53.

291.

Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases:
physiology and pathophysiology. Physiological reviews. 2007;87(1):245-313.

292.

Clark DP, Cronan JE. Acetaldehyde coenzyme A dehydrogenase of Escherichia coli.
Journal of bacteriology. 1980;144(1):179-84.

293.

Membrillo-Hernández J, Echave P, Cabiscol E, Tamarit J, Ros J, Lin EC. Evolution of
the adhE Gene Product ofEscherichia coli from a Functional Reductase to a
Dehydrogenase GENETIC AND BIOCHEMICAL STUDIES OF THE MUTANT
PROTEINS. Journal of Biological Chemistry. 2000;275(43):33869-75.

294.

Clark DP. The fermentation pathways of Escherichia coli. FEMS microbiology reviews.
1989;5(3):223-34.

295.

143
Lotz M, Gütle D, Walther S, Ménard S, Bogdan C, Hornef MW. Postnatal acquisition of
endotoxin tolerance in intestinal epithelial cells. Journal of Experimental Medicine.
2006;203(4):973-84.

296.

Harada K, Isse K, Sato Y, Ozaki S, Nakanuma Y. Endotoxin tolerance in human
intrahepatic biliary epithelial cells is induced by upregulation of IRAK‐M. Liver
International. 2006;26(8):935-42.

297.

Neagos J, Standiford TJ, Newstead MW, Zeng X, Huang SK, Ballinger MN. Epigenetic
regulation of tolerance to Toll-like receptor ligands in alveolar epithelial cells. American
journal of respiratory cell and molecular biology. 2015;53(6):872-81.

298.

Cerezo CS, Kulpa-Oliver V, Gruppuso PA, Morin MJ. Regulation of adolescent rat
intestinal epithelial inducible nitric oxide synthase expression in endotoxin tolerance:
modulation of signal transduction. Shock. 2004;21(5):476-83.

299.

O’Carroll C, Fagan A, Shanahan F, Carmody RJ. Identification of a unique hybrid
macrophage-polarization state following recovery from lipopolysaccharide tolerance. The
Journal of Immunology. 2014;192(1):427-36.

300.

Obermeier F, Kojouharoff G, Hans W, Schölmerich J, Gross V, Falk W. Interferongamma (IFN-γ)-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector
molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clinical and
experimental immunology. 1999;116(2):238.

301.

Varma TK, Toliver-Kinsky TE, Lin CY, Koutrouvelis AP, Nichols JE, Sherwood ER.
Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxintolerant mice. Infection and immunity. 2001;69(9):5249-63.

302.

Xie G, Zhong W, Zheng X, Li Q, Qiu Y, Li H, et al. Chronic ethanol consumption alters
mammalian gastrointestinal content metabolites. Journal of proteome research.
2013;12(7):3297-306.

303.

Roychowdhury S, Glueck B, Han Y, Mohammad M, Cresci G. A Designer Synbiotic
Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice. Nutrients.
2019;11(1):97.

304.

Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent
repression of the inducible nitric oxide synthase gene. Molecular and cellular biology.
2000;20(13):4699-707.

305.

Jacobson A, Lam L, Rajendram M, Tamburini F, Honeycutt J, Pham T, et al. A gut
commensal-produced metabolite mediates colonization resistance to salmonella infection.
Cell host & microbe. 2018;24(2):296-307. e7.

306.

Kobayashi K, Hernandez LD, Galán JE, Janeway Jr CA, Medzhitov R, Flavell RA.
IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110(2):191202.

307.

144
Glaros T, Fu Y, Xing J, Li L. Molecular mechanism underlying persistent induction of
LCN2 by lipopolysaccharide in kidney fibroblasts. PloS one. 2012;7(4):e34633.

308.

Mikami Y, Mizuno S, Nakamoto N, Hayashi A, Sujino T, Sato T, et al. Macrophages and
dendritic cells emerge in the liver during intestinal inflammation and predispose the liver
to inflammation. PLoS One. 2014;9(1):e84619.

309.

Karlsson A, Jägervall Å, Pettersson M, Andersson A-K, Gillberg P-G, Melgar S. Dextran
sulphate sodium induces acute colitis and alters hepatic function in hamsters.
International immunopharmacology. 2008;8(1):20-7.

310.

Dong F, Zhang L, Hao F, Tang H, Wang Y. Systemic responses of mice to dextran
sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. Journal of
proteome research. 2013;12(6):2958-66.

311.

Inoue H, Maeda-Yamamoto M, Nesumi A, Tanaka T, Murakami A. Low and medium but
not high doses of green tea polyphenols ameliorated dextran sodium sulfate-induced
hepatotoxicity and nephrotoxicity. Bioscience, biotechnology, and biochemistry.
2013;77(6):1223-8.

VITA
Paulius Kuprys was born in 1989 to Saulius and Roma Kuprys. He attended Lake Forest
College in Lake Forest, Illinois where he earned a Bachelor of Arts, cum laude, in Biology with
Honors in May 2012. In his undergraduate career, he researched trout red blood cell volume
regulation in Dr. Douglas Light’s laboratory and the telomerase RNA of filamentous fungi in Dr.
Karen Kirk’s laboratory. The latter became the topic of his undergraduate dissertation. After
graduation, Paulius worked for two years in the laboratory of Dr. Paul Knepper studying the
disease pathogenesis of glaucoma.
Paulius matriculated into the Loyola University Chicago Stritch School MD/PhD
Program in 2014. After two years of medical school, he began his graduate education in the
Integrative Cell Biology Program under the mentorship of Dr. Mashkoor Choudhry.
Paulius’ dissertation work on ethanol exacerbated intestinal dysbiosis in a mouse model
of colitis was initially supported by Loyola’s Alcohol Research Program Training Grant (T32)
funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National
Institutes of Health. Then in 2018, he was awarded a Predoctoral Ruth L. Kirschstein National
Research Service Award (F30) from the NIAAA. After completion of his doctoral studies,
Paulius will return to the Stritch School of Medicine in Maywood, Illinois to complete his final
two years of medical school.

145

